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General introduction
General introduction 9
intRoduCtion
For over 25 years, our research group and others have been investigating children born 
small for gestational age (SGA) with persistent short stature, and the efficacy and safety 
of biosynthetic growth hormone (GH) treatment in these children. The children that 
started treatment back then, are now young adults, and the knowledge about the long-
term effects of GH treatment has markedly increased.
One of the causes of short SGA is the Silver-Russell syndrome (SRS). Although overlap 
exists between the medical care for children born SGA and those with SRS, there are 
management issues that are specific to SRS, and the management of SRS requires a 
multidisciplinary approach. In the past years, the knowledge about SRS has improved, 
thanks to, among others, the discovery of new (epi)genetic alterations that cause SRS 
and a scoring system to facilitate clinicians in diagnosing SRS (1, 2). However, many 
knowledge gaps remained, some of which are addressed in this doctoral thesis.
Because being born with a lower birth weight leads to an increased risk for age-
associated diseases, health in later life has been a concern for those born SGA and/or 
preterm. One of the goals of this thesis was to investigate parameters associated with 
health in later life, such as telomere length and bone mineral density, and the effects of 
GH treatment on these parameters.
SmALL foR GeStAtionAL AGe
SGA refers to the size of an infant at birth, and is defined as a birth weight and/or birth 
length of at least two standard deviation scores (SDS) below the mean for gestational 
age (3, 4). SGA infants may be born either full-term or preterm. By definition, 2.3% of all 
infants are born SGA.
To determine whether a child is born SGA, it is important to have accurate information 
on gestational age, birth weight and birth length, as well as an appropriate reference 
population. The term intrauterine growth retardation (IUGR) is often used synonymously 
with the term SGA. However, IUGR does not mean that a child is born SGA (for example 
a child with IUGR in late gestation can have a normal size at birth), and SGA birth does 
not necessarily mean that IUGR occurred (for example when a short length was present 
from the beginning of gestation) (Figure 1).
The causes of SGA birth are heterogeneous: it can be caused by maternal, fetal or 
demographic factors (Table 1) (5). In a significant proportion of cases, the reason for SGA 
birth remains unclear.
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PoStnAtAL GRowth fAiLuRe And ShoRt StAtuRe
Most children born SGA show catch-up growth in the first two years of life, but 10-15% of 
SGA children fail to show sufficient catch-up growth and remain short, with a height <-2 
SDS (6, 7). Short stature is one of the most common medical concerns in childhood and SGA 
birth is a major risk factor for short stature, accounting for approximately 20% of all cases (8).
The causes of insufficient catch-up growth after SGA birth are not well understood. 
Several factors influence postnatal growth, such as (epi)genetics and physical, emotion-
al, and social environmental factors. Disturbances in the growth hormone/insulin-like 
growth factor (IGF)-axis (Figure 2) have also been postulated to play an important role in 
the insufficient catch-up growth after SGA birth (9-11).
Despite adult height (AH) being one of the most heritable human traits (12), the (epi)
genetic nature of short stature in SGA children is still largely unknown. Genome wide 
association studies have identified genes that contribute to the variation in height, but 
variations in these genes only have a small effect in the general population (13). Short 
stature can also be caused by mutations in one gene. Examples of this are IGF1-receptor 
mutations, 3M syndrome and SHOX deficiency. Also epigenetic changes (i.e. aberrations 
in regions that control the imprinting of genes) can lead to short stature, which is the 
case in SRS. Unravelling the (epi)genetic basis of short children born SGA is important 
for health prognosis, genetic counselling and treatment options.
figure 1. Fetal growth chart showing different intrauterine growth patterns
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SiLveR-RuSSeLL SyndRome
SRS is a rare disorder, with an estimated incidence of 1 in 30,000 to 1 in 100,000 life-born 
infants per year (15). Children with SRS are almost always born SGA, remain short and 
show various dysmorphic features, such as relative macrocephaly, a triangular shaped 
head with frontal bossing, clinodactyly, and asymmetry of face and/or body (Figure 3) 
(16-18). Severe feeding difficulties can be present, especially during infancy and early 
childhood. Untreated, mean AH is around -4 SDS (i.e. 155 cm for men and 145 cm for 
women) causing a significant handicap in adulthood (18). Growth charts of a girl with 
SRS during the first year of life are depicted in Figure 4.
SRS is primarily a clinical diagnosis. Children with SRS can be distinguished from 
non-syndromic SGA children, based on the presence of characteristic features. Over the 
years, several clinical scoring systems have been proposed to adequately diagnose SRS. 
table 1. Factors associated with reduced fetal growth (5)
maternal factors  
Medical conditions Pre-eclampsia
  Acute or chronic hypertension
  Abnormality of the uterus
  Severe chronic disease
  Therapeutic drugs
Social conditions Maternal nutrition
  Age at delivery <16 or >35 years
  Drug use (smoking, alcohol, illicit drugs)
Placental factors Single umbilical artery
  Bilobate placenta
fetal factors  
Chromosomal disorders Down syndrome
  Turner syndrome
(Epi)genetic disorders Silver-Russell syndrome
  3M-syndrome
Intrauterine infections Toxoplasmosis
  Rubella
  Cytomegalovirus
Inborn errors of metabolism  
Congenital defects  
demographic factors  
Ethnicity  
Maternal and paternal short stature  
Previous delivery of SGA infant  
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figure 2. Physiology of the GH-IGF-I axis (adapted from Kumar et al. (14))
GHRH = GH-releasing hormone; GH = Growth hormone; IGF-I = insulin-like growth factor 
A B C
figure 3. Dysmorphic features in SRS. A) Frontal bossing and triangular shaped head; B) Clinodactyly; C) 
Asymmetry
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The clinical scoring system with the highest sensitivity (98%) and negative predictive 
value (89%) is the Netchine-Harbison clinical scoring system (Table 2) (19). If at least four 
of the criteria of this scoring system are present, the clinical diagnosis SRS can be made. 
However, since the severity of symptoms varies significantly, and symptoms tend to get 
less severe as patients get older, the clinical diagnosis can be difficult. Therefore, in case 
of ≥3 symptoms, molecular testing is indicated (20).
The epigenetic aetiology of SRS is heterogeneous (Figure 5). Approximately 50% of 
the cases are caused by a loss of methylation in the 11p15 region (11p15 LOM) (1, 2, 
21). The 11p15 region contains two imprinting control regions and is important for pre- 
and postnatal growth (Figure 6). An additional 5-10% of the SRS cases are caused by a 
maternal uniparental disomy of chromosome 7 (mUPD7) (22). In approximately 40%, 
the genetic cause remains unknown, which is referred to as idiopathic or clinical SRS. 
Patients with 11p15 LOM show, on average, a more ‘classic’ SRS phenotype. Those with 
figure 4. Growth charts of a girl with SRS during the first year of life
 
figure 5. Epigenetic subtypes of SRS
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mUPD7 have a milder phenotype, but this subtype is associated with a higher incidence 
of behavioural problems (23).
Gh tReAtment in ShoRt ChiLdRen BoRn SGA And in SRS
Recombinant GH has been used since 1986 and has replaced GH extracted from human 
pituitaries. The indications for GH treatment have extended from replacement therapy 
in children with GH deficiency to a number of conditions. Since 2005, GH treatment is 
licensed for short SGA children. The aim of GH treatment is achieving an AH within the 
normal range and/or target height range of the child. Various clinical trials have shown 
that GH treatment with a dose of 1 mg/m2/day improves growth rate, and leads to a 
significant improvement of AH in children born SGA (24-26).
figure 6. The 11p15 region in healthy individuals (left) and in SRS patients with 11p15 LOM (right).
The telomeric imprinting control region (ICR) 1 domain regulates the expression of IGF-II and H19. IGF-II is a 
growth promotor and expressed exclusively from the methylated paternal allele. H19 is a growth inhibitor 
and expressed exclusively from the unmethylated maternal allele. Around 50% of the SRS patients have a 
loss of methylation at ICR1, causing reduction in IGF-II expression and biallelic expression of H19 (Adapted 
from Netchine et al. (2))
table 2. Netchine-Harbison clinical scoring system (19)
Clinical criteria definition
SGA Birth weight and/or birth length ≤-2 SDS for gestational age
Postnatal growth failure Height at 24±1 months ≤-2 SDS or height >2 SDS below mid-parental target 
height
Relative macrocephaly at birth Head circumference at birth ≥1.5 SDS above birth weight and/or length SDS
Protruding/prominent forehead Forehead projecting beyond the facial plane on a side view as a toddler (1-3 
years)
Body asymmetry Leg length discrepancy (LLD) of ≥0.5 cm or arm asymmetry or LLD<0.5 cm 
with at least two other asymmetrical body parts (one non-face)
Feeding difficulties and/or low 
BMI
BMI ≤-2 SDS at 24 months or current use of a feeding tube or 
cyproheptadine for appetite stimulation
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Gh in SRS
Because children with SRS are born SGA and remain short, GH treatment is also licensed 
for children with SRS. SRS was the only syndrome allowed in the clinical trials of GH in 
short children born SGA that led to indication of GH treatment for these children (20, 
27). However, it had never been investigated whether SRS patients benefited equally 
from GH treatment as non-SRS subjects born SGA. Moreover, it was unknown whether 
there were differences in GH response among the different genetic subtypes of SRS.
Besides the positive effects on linear growth, GH treatment has also several metabolic 
effects in children born SGA. An increase in lean body mass, a decline in fat mass, a 
decrease in blood pressure, and a more favourable lipid profile, but also a lower insulin 
sensitivity have been reported (28-30). We previously showed that GH treatment in short 
SGA children is safe on the long-term, and until five years after discontinuation of GH 
treatment (28, 29, 31). However, the long-term safety of GH treatment and metabolic 
effects after discontinuation of treatment after AH attainment, had never been investi-
gated in SRS patients.
PuBeRtAL deveLoPment And GonAdAL funCtion
Puberty is the period of transition from childhood to adolescence, marked by the 
development of secondary sexual characteristics, the pubertal growth spurt, epiphy-
seal maturation and behavioural changes (32). Pubertal changes are regulated by the 
hypothalamic-pituitary-gonadal axis (Figure 7). Due to an increase in frequency and 
amplitude of gonadotropin-releasing hormone (GnRH) pulses in the hypothalamus, 
the secretion of gonadotropins (i.e. luteinizing hormone (LH) and follicle stimulating 
hormone (FSH)) by the pituitary rises. In the Dutch population, median age of pubertal 
onset is 10.7 years for girls and 11.5 years for boys (33).
Data on puberty in children born SGA are limited and difficult to compare due to 
the various definitions of SGA and the various definitions used for the milestones of 
puberty. Most studies report that puberty in short SGA children starts at a normal age 
but relatively early for their short stature (34, 35). Moreover, subjects born SGA have a 
shorter duration of pubertal growth, resulting in a smaller pubertal growth spurt than 
appropriate for gestational age (AGA) born subjects.
male gonadal function
Inhibin B is produced by the Sertoli cells of the testis after stimulation of FSH and is a 
marker of spermatogenesis. Under the stimulation of LH, the Leydig cells of the testis 
produce testosterone, which is necessary for the development of male characteristics 
and to continue the process of spermatogenesis.
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Previous studies have shown that short SGA boys have a normal number of Sertoli cells 
and that serum inhibin B levels are the same in GH-treated SGA boys and age-matched 
AGA boys (37). SGA birth does not affect gonadal function in young men (38).
female gonadal function
The ovaries fulfil two main functions: the synthesis and secretion of sex hormones and 
the development and release of the mature oocyte. During fetal life and childhood, 
follicles develop through primordial and primary stages to preantral and small antral 
follicles (Figure 8) (39). The loss of primordial follicles already begins prior to birth and 
continues into childhood. At the time of menarche, approximately 500,000 follicles 
remain.
From onset of puberty, certain small antral follicles develop into antral follicles. When 
they reach the antral stage, most follicles undergo atresia, and only a few develop into a 
Graafian follicle and reach the (pre-)ovulatory stage (40).
Anti-Müllerian hormone (AMH) is produced by the preantral and small antral follicles. 
This way, serum AMH levels reflect the number of preantral and small antral follicles. 
Ovarian function can be difficult to evaluate in women because menstrual cycles do not 
always indicate ovulation. Since AMH is exclusively produced by the ovaries, indepen-
figure 7. Male and female hypothalamic-pituitary-gonadal axis (adapted from Kong et al. (36))
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dent of the gonadotropic status and menstrual cycle, AMH is an excellent marker of the 
ovarian follicle pool (41, 42).
Previous studies have shown that there are no adverse effects of SGA birth on AMH 
levels (43, 44). AMH levels in adolescent girls born SGA are comparable to those of AGA 
girls, indicating that SGA girls do not have a reduced size of the ovarian follicle pool (44).
Puberty and gonadal function in SRS
Since the majority of individuals with SRS are not routinely followed up, there is very 
little information in the literature regarding pubertal progression and potential repro-
ductive issues in SRS patients. Previous studies have shown that boys with SRS are at 
an increased risk of genital abnormalities such as cryptorchidism and hypospadias (22, 
46). In girls with SRS, an association has been described with Mayer-Rokitansky-Kuster-
Hauser syndrome, a disorder characterized by hypoplasia or aplasia of the uterus and 
upper part of the vagina (47, 48). However, pubertal development and gonadal function 
had never been evaluated in SRS patients.
heALth LAteR in Life in ChiLdRen BoRn SGA And/oR PReteRm
Several epidemiological studies have shown an association between small size at birth 
and subsequent catch-up in weight, and the risk for CVD and diabetes mellitus type 2 
(DM2) in later life (49-53). Both preterm birth and poor fetal growth can lead to small 
birth size.
The exact mechanisms underlying the associations between fetal and early life growth 
and health later in life are largely unknown. One of the hypotheses is the Fetal origin hy-
pothesis by Barker et al., which is based on the postulation that events during pregnancy 
figure 8. The normal ovarian follicle development (Adapted from Broekmans et al. (45))
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leading to fetal malnutrition could result in permanent metabolic changes in the foetus 
(i.e. reprogramming) (54). During fetal life, this is beneficial, but in the long-term, this 
reprogramming might result in diseases in adulthood.
In previous studies, our research group showed that accelerated weight gain during 
infancy is associated with determinants of adult diseases in early adulthood, such as 
an unfavourable body composition, an adverse lipid profile, higher blood pressure and 
lower insulin sensitivity (55-58).
The risk for adult-onset disorders had not been investigated in SRS. There were only 
two case reports addressing metabolic health in SRS. The first described three SRS pa-
tients (all with an 11p15 aberration, two received GH treatment for several years during 
childhood) who developed adult diseases such as obesity, hypertension, and DM2 in 
their early twenties (59). The second described the oldest SRS patient known so far, who 
has DM2, osteopenia, and hypercholesterolemia at the age of 69 years (60). Overall, adult 
follow-up data in SRS are lacking, which was also emphasized by the recently published 
consensus statement on diagnosis and management of SRS (20).
LeukoCyte teLomeRe LenGth: A BiomARkeR foR BioLoGiCAL AGe
Telomeres are noncoding repetitive DNA sequences at the end of each chromosome. 
Their primary function is to maintain genomic stability (61, 62). Due to the inability 
of DNA polymerase to fully replicate the end of the chromosome, telomeres shorten 
with each cell division. When telomeres are reduced to a critical length, the cell goes in 
senescence (Figure 9) (63, 64).
figure 9. Telomeres shorten with each cell division until a critical length (adapted from www.wholeheal-
thinsider.com (71))
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Population studies have shown that telomere length declines with increasing age, 
which makes it a usable index for biological age, rather than chronological age. Shorter 
telomere length is also associated with age-associated diseases (65, 66). The telomere 
hypothesis postulates that at least part of the inter-individual difference in susceptibility 
to CVD reflects variation in biological ageing. Telomere length can be measured in leuko-
cytes using a PCR-based technique (67) and acts as a valuable marker of this process (68).
Previous studies have highlighted that, next to genetic factors, gender and chronologi-
cal age, telomere length is also influenced by oxidative stress/chronic inflammation and 
replicative stress (Figure 10) (69, 70). Since pregnancies resulting in preterm and/or SGA 
birth are often accompanied by increased stress exposure, and postnatal catch-up growth 
might induce replicative stress, we postulated that reduced telomere length might be one 
of the underlying mechanisms of small size at birth and an increased risk for CVD at a 
relatively young age. However, data on whether preterm and SGA birth influence telomere 
length were scarce and contradictive. Furthermore, the effects of postnatal growth pat-
terns and possible effects of GH treatment on telomere length were unknown.
Bone mineRAL denSity in younG AduLtS AfteR CeSSAtion of Gh
Osteoporosis is a systemic skeletal disorder, characterized by low bone mass and de-
terioration of bone tissue, leading to bone fragility and susceptibility to fractures (72). 
Osteoporosis is a world-wide problem with high morbidity and increased mortality (73).
Bone mineral density of the total body (BMDTB) and bone mineral apparent density of 
the lumbar spine (BMADLS) are important determinants for fracture risk and osteoporo-
sis in later life (74, 75). Each standard deviation decrease in BMD has been shown to be 
associated with a doubling of fracture risk, in adults as well as in children (74, 75). During 
childhood, BMDTB and BMADLS increase, until peak bone mass is attained between the 
age of 18-20 years in girls and 18-23 years in boys (Figure 11) (76). Attained peak bone 
figure 10. Factors affecting telomere length and how these could explain variation in risk of CVD in differ-
ent individuals (adapted from Samani et al. (68))
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mass is an important factor determining later life bone health. Thus, maximizing peak 
bone mass in childhood is relevant to optimizing bone health in later life (77).
BMDTB and BMADLS are influenced by many factors, such as gender, age, body weight, 
body composition, calcium intake and physical activity (78-81). The GH-IGF-I axis is also 
an important factor in the regulation of BMDTB and BMADLS (82, 83).
BMDTB and BMADLS can be measured by Dual energy X-ray Absorptiometry (DXA) (Ap-
pendix C). DXA is the most widely used clinical tool for the assessment of bone status in 
children. Since DXA has low radiation dose, great precision and accuracy, it is a suitable 
technique to use in children and in research (84).
Short SGA children have a lower than average BMD, even after correction for their 
short stature (85). We have previously shown that GH treatment improves BMD on the 
short term (85, 86), but long-term studies were lacking, and the effects of discontinua-
tion of GH treatment on BMDTB and BMADLS were unknown.
figure 11. Bmd and peak bone mass (adapted from Compston et al. (87))
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Study deSiGn
Silver-Russell syndrome
In the past decades, our research group initiated three large GH trials (IUGR studies) to 
obtain more knowledge about the long-term effects of GH treatment in children born 
SGA with persistent short stature. The design and in- and exclusion criteria of these trials 
are described in Appendix A. SRS was the only syndrome allowed in these clinical trials, 
and there proved to be over 30 SRS patients included in our studies. Since the discovery 
of 11p15 LOM, we were able to confirm this diagnosis in a large part of the SRS patients. 
The IUGR trials therefore provided an excellent basis to study long-term effects of GH 
treatment in SRS patients, and to investigate whether there are differences between SRS 
patients and their non-syndromic SGA born counterparts regarding long-term response 
to GH treatment, metabolic health, pubertal development and gonadal function.
telomere length and bone mineral density
Evaluating the long-term effects of small size at birth and catch-up growth on health 
is challenging, since it is difficult to obtain large cohorts with enough variance in size 
at birth and childhood growth patterns. The PROgramming factors for Growth and 
Metabolism (PROGRAM) and Prematurity and Small for Gestational Age (PREMS) study 
cohorts consist of a large group of healthy young adults in which subjects with extreme 
variants of normal growth were oversampled. The design, in- and exclusion criteria are 
described in Appendix B. These cohorts made it possible to study the long-term effects 
of preterm birth, size at birth and early life growth patterns on LTL.
One of the problems with studying long-term effects of GH treatment is the lack of an 
adequate control group. Since most short SGA children are nowadays treated with GH, 
it is difficult to obtain a control group of untreated short SGA subjects. The PROGRAM 
study cohort can provide this control group, since subgroups were made by dividing 
the population into clinically relevant subgroups, consisting of subjects born SGA with 
and without catch-up growth and a subgroup of young adults born appropriate for 
gestational age.
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AimS of the Study
Silver-Russell syndrome
Response to GH treatment in Silver-Russell syndrome
Children with SRS are treated with GH to improve adult height, but there were limited 
data on response to GH treatment in SRS children and on differences in response among 
the (epi)genetic SRS subtypes. We therefore compared growth and adult height between 
GH-treated SGA children with and without SRS, and analyzed differences in GH response 
among SRS subtypes.
Metabolic health and long-term safety of GH treatment in Silver-Russell syndrome
Data on metabolic health and long-term safety of GH treatment in SRS were lacking. We 
therefore longitudinally investigated metabolic health in SRS patients during GH treat-
ment and until two years after cessation of GH treatment due to adult height attainment.
Pubertal development and gonadal function in Silver-Russell syndrome
Very little information existed on pubertal development and gonadal function in pa-
tients with SRS. We therefore assessed pubertal progression and gonadal function in 
children, adolescents and young adults with SRS.
telomere length
Telomere length in young adults born preterm
In this study, we investigated whether accelerated biological ageing might be one of the 
underlying mechanisms of the increased risk for CVD in those born preterm. We used LTL 
as an ageing biomarker to test this hypothesis, in a large cohort of young adults born 
either preterm or at term. We also assessed whether LTL was associated with putative 
cardiovascular risk factors at young adult age.
Effects of size at birth, childhood growth patterns and GH treatment on telomere length
In this study, we investigated whether LTL is influenced by size at birth, childhood 
growth and long-term GH treatment in a large cohort of young adults with differences 
in size at birth and childhood growth patterns.
Bone mineral density in early adulthood
Bone mineral density in GH treated young adults born SGA
We investigated BMD in young adults born SGA who were treated with GH during child-
hood, and had attained an age of 21 years. We also compared BMD at five years after 
cessation of treatment to age-matched untreated short young adults born SGA, and to 
AGA born controls with a normal stature.
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outLine of thiS theSiS
Chapter 1 gives an introduction on the topics described in this thesis.
Chapter 2 describes the response to GH treatment in children with SRS.
Chapter 3 shows metabolic health and long-term safety of GH treatment in SRS.
Chapter 4 demonstrates pubertal development and gonadal function in SRS.
Chapter 5 describes the effect of preterm birth on telomere length.
Chapter 6 demonstrates the effects of size at birth, childhood growth patterns and GH 
treatment on telomere length.
Chapter 7 shows bone mineral density in young adults born SGA, who were treated with 
GH during childhood.
Chapter 8 provides a general discussion of the results of the studies presented in this 
thesis.
Chapter 9 summarizes the findings described in this thesis in English and Dutch.
Chapter 10 contains a list of abbreviations, a list of publications, PhD portfolio, acknowl-
edgments and curriculum vitae.
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APPendix A
iuGR-2 and iuGR-3 studies
The second and third Dutch GH trials (IUGR-2 and -3 studies (88, 89)) included children 
born SGA with persistent short stature.
design
The IUGR-2 study started in 1996 and the IUGR-3 study in 2003. Both studies are open-
labelled, multicentre studies. Children were treated with a biosynthetic GH with a dose 
of 1 mg/m2/day. Three-monthly, the GH dose was adjusted to the calculated body 
surface area.
inclusion criteria
1) Birth length and/or birth weight SDS for gestational age <-2 SDS (90);
2) Uncomplicated neonatal period without signs of severe asphyxia (defined as Apgar 
score ≤3 after 5 minutes), sepsis or long-term complications of respiratory ventila-
tion such as bronchopulmonary dysplasia;
3) Chronological age between 3 and 8 years at start of the study;
4) Height SDS for age less than -2.5 SDS, according to Dutch references (33);
5) Height velocity SDS below 0 to exclude children with spontaneous catch-up growth;
6) Prepubertal, defined as Tanner stage I or testicular volume <4 ml in boys;
7) Normal liver, kidney and thyroid functions;
8) Well-documented growth data from birth to start of GH treatment;
9) Informed consent.
exclusion criteria
1) Endocrine metabolic disorders (i.e. diabetes mellitus, diabetes insipidus, hypothy-
roidism, or inborn errors of metabolism);
2) Celiac disease or other chronic diseases of the major organs;
3) Chromosomal abnormalities or dysmorphic features suggestive of a syndrome, 
except Silver-Russell syndrome;
4) Chondrodysplasia;
5) Serious suspicion of psychosocial dwarfism (emotional deprivation);
6) Active malignancy or increased risk of leukaemia;
7) Use of medication that might interfere with growth, such as corticosteroids and sex 
steroids;
8) Expected non-compliance.
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PRoGRAm and PRemS studies
The PROgramming factors for Growth and Metabolism (PROGRAM) study cohort and 
Prematurity and Small for Gestational Age (PREMS) study cohort consist of healthy 
young adults (38, 57). The difference between the two studies is that the subjects in the 
PROGRAM study were born term, whereas the subjects in the PREMS were born preterm 
(gestational age <36 weeks). In these participants, several parameters for metabolic 
health and CVD were determined.
design
To be able to investigate the influence of different growth patterns during childhood on 
determinants of adult diseases, subjects with extreme variants of normal growth, such 
as subjects born SGA with and without catch-up growth, were oversampled. This design 
created greater contrast in the study population, which contributed to more statistical 
power.
inclusion criteria
1) Chronological age at inclusion 18-24 years;
2) Neonatal period without signs of severe asphyxia (defined as Apgar score ≤3 after 
5 minutes), no serious diseases such as long-term artificial ventilation and oxygen 
supply, broncho-pulmonary dysplasia or other chronic lung disease;
3) Well-documented growth data;
4) Caucasian;
5) Born singleton;
6) Signed informed consent;
7) PROGRAM study: gestational age ≥36 weeks;
8) PREMS study: gestational age <36 weeks.
exclusion criteria
1) Chromosomal abnormalities or dysmorphic features suggestive of a syndrome, 
except Silver-Russell syndrome;
2) Any disease, endocrine or metabolic disorder that could have interfered with growth 
(such as diabetes, growth hormone deficiency, malignancies, severe chronic disease);
3) Treatment that could have interfered with growth (such as radiotherapy or growth 
hormone treatment);
4) Serious suspicion of psychosocial dwarfism (emotional deprivation) during child-
hood.
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Body composition by dual energy x-ray Absorptiometry (dxA)
DXA can be used to measure bone mineral density and body composition (i.e. fat mass 
and lean body mass) (84). The participant lies still for approximately 15 minutes while 
a scanner slides over the participant. DXA uses X-ray to assess these measures, but the 
radiation dose is low (approximately 1/10th of a chest X-ray).
frequently Sampled intravenous Glucose tolerance (fSiGt) test
Glucose homeostasis can be assessed by means of an FSIGT test with Tolbutamide (91, 
92). The FSIGT test provides the following values regarding glucose homeostasis:
– Insulin sensitivity: The ability of insulin to increase glucose disposal;
– Glucose effectiveness: The capacity of glucose to mediate its own disposal;
– Acute insulin response: An estimate of insulin secretory capacity;
– Disposition index: A measure of ß-cell function.
These indicators of glucose regulation were determined by the Bergman’s minimal 
model, calculating paired glucose and insulin data obtained by frequent measurements 
during an FSIGT test with Tolbutamide. This way, early changes in glucose metabolism 
can be assessed, many years before the first symptoms of DM2.
Adult treatment Panel iii (AtP-iii) score
The 10-year risk for coronary heart disease and DM2 can be assessed using the ATP-III 
score (93). This score includes the following factors: 1) waist circumference in men >102 
cm, and in women >88 cm; 2) triglyceride >1.7 mmol/L; 3) high-density lipoprotein 
in men <1.03, in women <1.3 mmol/L; 4) blood pressure ≥130/≥85 mmHg; 5) fasting 
glucose >5.6 mmol/L. Metabolic syndrome is defined as having 3 or more of these risk 
factors.
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ABStRACt
Context: Silver-Russell syndrome (SRS) is a genetically heterogeneous syndrome char-
acterized by low birth weight, severe short stature and variable dysmorphic features. 
Growth hormone (GH) treatment is a registered growth-promoting therapy for short 
children born small for gestational age, including SRS, but there are limited data on the 
GH response in SRS children and on differences in response among the (epi)genetic SRS 
subtypes (11p15 aberrations, maternal uniparental disomy of chromosome 7 (mUPD7) 
and idiopathic SRS).
Objectives: To compare growth and adult height between GH-treated small for gesta-
tional age children with and without SRS (non-SRS) and to analyze the difference in GH 
response among SRS genotypes.
Design and setting: A longitudinal study.
Participants: Sixty-two SRS and 227 non-SRS subjects.
Intervention: All subjects received GH treatment (1 mg/m2/day).
Main outcome measures: Adult height and total height gain.
Results: The SRS group consisted of 31 children with 11p15 aberrations, 11 children with 
mUPD7 and 20 children with idiopathic SRS. At the start of GH treatment, mean (SD) 
height standard deviation score (SDS) was significantly lower in SRS (-3.67 (1.0)) than 
in non-SRS (-2.92 (0.6), p<0.001). Adult height SDS was lower in SRS (-2.17 (0.8)) than 
in non-SRS (-1.65 (0.8), p=0.002), but the total height gain SDS was similar. There was a 
trend toward a greater height gain in mUPD7 than in 11p15 (p=0.12).
Conclusion: Children with SRS have a similar height gain during GH treatment as non-
SRS subjects. All (epi)genetic SRS subtypes benefit from GH treatment, with a trend 
toward mUPD7 and idiopathic SRS having the greatest height gain.
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intRoduCtion
Silver-Russell syndrome (SRS) is characterized by intrauterine growth retardation lead-
ing to small size at birth, feeding difficulties during infancy and early childhood, severe 
short stature, body asymmetry, triangular face with prominent forehead and several 
other minor anomalies (1-3). Incidence is estimated as 1 in 30000 to 100000 life-born 
infants per year (4). Without treatment, mean adult height (AH) is around -4.2 standard 
deviation score (SDS), causing a significant handicap in adulthood (3).
The (epi)genetic etiology of SRS is heterogeneous. In most cases, the 11p15 region, 
important for controlling growth, is involved (5). The 11p15 region contains two im-
printing control regions, ICR1 and ICR2. More than 50% of SRS cases are caused by a 
hypomethylation of the paternal allele of the ICR1 (6). Maternal duplications of the ICR2 
region have also been described (7,8). Recently, mutations in the CDKN1C and IGF-2 
genes, also located in the 11p15 region, were discovered as a cause of SRS (9,10). An 
additional 5-10% of the SRS cases are caused by a maternal uniparental disomy of chro-
mosome 7 (mUPD7) (11). Furthermore, it has been suggested that uniparental disomy 
events outside chromosome 7 and widespread DNA methylation changes are present 
in many SRS patients (12). In approximately 40%, the genetic cause remains unknown, 
which is referred to as idiopathic SRS.
GH treatment is a registered growth-promoting therapy for short children born small 
for gestational age (SGA), including children with SRS (13). However, there are few data 
on the growth response to and safety of GH in SRS patients, especially on the long-
term. Toumba et al. (14) described AH after GH treatment in a small group (n=26) of SRS 
patients. None of these patients were tested for aberrations in the 11p15 region and the 
clinical scoring system used to diagnose SRS has been updated since then (15). Binder et 
al. (16) described AH after GH treatment in a group of 37 SRS patients, but most patients 
measured AH themselves, which might give less reliable results.
Data on genotype-phenotype correlations (ie, differences in phenotype among the 
different (epi)genetic alterations seen in SRS) are scarce. It has been stated that the 11p15 
alterations lead to a more severe SRS phenotype (17), but it is unknown whether there 
are differences in GH response among the different (epi)genetic aberrations seen in SRS.
In the present study, we compared response to GH treatment between 62 SRS sub-
jects and 227 non-SRS subjects born SGA. Based on previous literature and our clinical 
experience, we hypothesized that SRS patients have a similar height gain from the start 
of treatment until AH as non-SRS subjects born SGA. We also compared growth data of 
subjects with different (epi)genetic causes of SRS, hypothesizing that SRS subjects with 
mUPD7 or idiopathic SRS attain a larger AH compared to subjects with aberrations in the 
11p15 region, since the 11p15 alterations cause the most severe SRS phenotype.
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SuBJeCtS And methodS
Subjects
For the present study, we included 62 SRS and 227 non-SRS subjects. All subjects were 
born SGA (birth length and/or birth weight SDS below -2.0 for gestational age) (18) and 
received GH treatment because of short stature (height below -2.5 SDS) (19). Excluded 
were subjects with chromosomal abnormalities or signs of a syndrome except SRS, 
subjects who received less than three years of GH treatment and non-SRS subjects who 
were also treated with a GnRH analog (GnRHa).
Subjects were diagnosed with clinical SRS based on the Netchine-Harbison clinical 
scoring system (15). This recently developed scoring system includes the following six 
factors: 1) prenatal growth retardation (birth weight and/or length ≤ -2 SDS for gesta-
tional age); 2) postnatal growth retardation (height SDS for calendar age below -2.0 ac-
cording to national reference (19); 3) relative macrocephaly at birth (head circumference 
at birth at least 1.5 SDS above birth weight and/or length SDS according to Usher and 
McLean (18); 4) prominent forehead (defined as forehead that projects beyond the facial 
plane on a side view as a toddler); 5) body asymmetry (defined as leg length discrepancy 
of ≥ 0.5 cm or arm asymmetry or leg length discrepancy <0.5 cm with at least two other 
asymmetrical body parts (with one being a non-face part)); 6) feeding difficulties dur-
ing early childhood. Patients were classified as clinical SRS if at least four of these six 
factors were present. All clinical SRS subjects were tested for methylation aberrations in 
the 11p15 region (ICR1 and ICR2) and for methylation of chromosome 7. Furthermore, 
14 out of the 20 clinical SRS patients who tested negative for 11p15 aberrations and 
mUPD7 were also tested for CDKN1C and IGF-2 mutations. Six patients could not be 
tested for CKDN1C and IGF-2 mutations because there was no DNA available anymore, 
and they did not want to revisit the hospital after attainment of AH. Patients with clinical 
SRS without a genetic alteration were classified as idiopathic SRS.
This study was performed according to the Helsinki Declaration and approved by the 
Medical Ethics Committee of all participating centres. Written informed consent was 
obtained from all participants and/or their parents.
design
In this prospective study, all participants were treated with biosynthetic GH at a dose 
of 1 mg/m2/d (0.035 mg/kg/d). GH was administered sc once daily at bedtime. Height, 
weight and Tanner stage were determined three-monthly, and GH dose adjusted to the 
calculated body surface area.
GH treatment was discontinued at AH. AH was defined as the condition when height 
velocity dropped below 0.5 cm during the previous 6 months and a bone age ≥ 15 years 
for girls and ≥ 16.5 years for boys.
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measurements
Birth data were obtained from records of hospitals and primary health care centres. 
Height was measured to the nearest 0.1 cm (Harpenden stadiometer), weight to the 
nearest 0.1 kg (Servo Balance KA-20-150S). Anthropometric measurements were per-
formed twice according to standardised methods, after which the mean was calculated. 
Target height (TH) was calculated as TH=[(maternal height + paternal height + 13) / 2 + 
4.5] for boys and TH= [(maternal height + paternal height - 13) / 2 + 4.5] for girls (20). On-
set of puberty was defined as breast stage 2 according to Tanner for girls and testicular 
volume ≥ 4 ml for boys (21). Bone age was determined once a year according to Tanner 
and Whitehouse RUS (22). Bone age delay was calculated as calendar age minus bone 
age in years.
dnA analysis
DNA analysis for 11p15 methylation aberrations, CDKN1C and IGF-2 mutations, and 
mUPD7 was performed in clinical SRS patients. Genomic DNA was extracted from pe-
ripheral blood leucocytes. DNA methylation testing of the 11p15 region (ICR1 (H19) and 
ICR2 (KCNQ1OT1)) was performed using Methylation-specific multiplex ligation-mediat-
ed Probe amplification (MS-MLPA). The SALSA MS-MLPA kit ME-030 (MRC Holland) was 
used according to manufacturer’s instructions. Testing for mUPD7 was also performed 
by MS-MLPA. The SALSA MS-MLPA kit Me-032 (MRC Holland) was used according to 
manufacturer’s instructions. To identify CDKN1C mutations (c.836G>T (pArg279Leu)) 
(10) or IGF2 mutations (IGF2c.191C>A (p.Ser64Ter)) (9), genomic DNA extracted from 
peripheral blood leucocytes was diluted to a concentration of 5 ng/µl. Target regions 
were amplified by PCR with Taq polymerase (Qiagen). The forward primer
IGF2exR3 5’-CTCGGCATTATGACCTGTGT-‘3 and reverse primer
IGF2ex3R 5’-AGGCGTGTGATGGGAAAG-‘3 were used in order to amplify the target 
including the IGF-2 mutation. The CDKN1C target region containing the mutation was 
amplified using primers described previously (10).
Calculations and statistical analysis
SDS values for birth length and birth weight were calculated to correct for gestational 
age and gender (18), SDS for weight and blood pressure to correct for height and gender 
and SDS for height, IGF-I and IGF binding protein-3 (IGFBP-3) levels to correct for gender 
and age (19,23). SDS values for birth length, birth weight, height, and weight were 
calculated using the Growth Analyzer software (http://www.growthanalyser.org). Total 
height gain was defined as AH SDS minus height SDS at start of GH. Prepubertal height 
gain was defined as height SDS at onset of puberty minus height SDS at start of GH, and 
pubertal height gain as AH SDS minus height SDS at onset of puberty. Distance to TH 
SDS at AH was determined as TH SDS minus AH SDS.
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Differences in characteristics between SRS and non-SRS were determined using an 
independent-sample t test (continuous data) or X2 test (categorical data). Using one-way 
ANOVA, we compared characteristics and response to GH treatment among the differ-
ent genetic causes of SRS.
Because follow-up was not complete until AH (AH data were available for 26 SRS sub-
jects (42%) and 159 non-SRS subjects (70%)), in addition to the uncensored cases analy-
sis, we also performed a linear mixed model analysis to compare longitudinal changes 
in height between SRS and non-SRS, adjusting for missing values. In this analysis, factors 
were SRS (1 = SRS; 0 = non-SRS) and time (0 = baseline; 1 = 1 year GH, 2 = onset puberty, 
3= AH). An unstructured repeated covariance type was used, correcting for total treat-
ment duration and age at start of treatment.
To evaluate which variables associate with total height gain SDS in the total group 
and in subjects with SRS, we used multiple regression (MR) analyses. We included TH 
SDS, age at start of treatment, height at start of treatment, and duration of treatment. To 
analyze whether SRS negatively influenced total height gain, we included the variable 
SRS (1 = yes, 0 = no) as a dummy variable in the total group analysis. Consecutively, 
we added 11p15 alteration (1 = yes, 0 = mUPD7 or idiopathic SRS) to the MR analysis 
for the SRS subjects to test the influence of 11p15 on total height gain in SRS subjects 
compared to mUPD7 and idiopathic SRS.
Results were considered statistically significant if the P value was <.05. All analyses 
were performed with SPSS for Windows (version 21.0; SPSS Inc).
ReSuLtS
Clinical characteristics of the SRS and non-SRS subjects born SGA are listed in Table 1. 
Of the 62 SRS patients, 31 had a methylation defect in the 11p15 region (n = 24 ICR1 
hypomethylation, six duplication of the maternal 11p15 allele, one deletion of the 
paternal allele) and 11 patients an mUPD7. There were no patients with an IGF-2 or 
CDKN1C mutation in the 14 out of 20 idiopathic SRS patients who were tested for these 
mutations. Twenty clinical SRS patients tested negative for the (epi)genetic alterations 
causing SRS and were thus assigned to the idiopathic SRS group.
The ratio males/females was similar between SRS and non-SRS and among the three 
SRS groups. SRS patients had a significantly lower birth weight and birth length (P < 
.005). Those with mUPD7 had the greatest birth length SDS of the three SRS groups 
(-1.92 SDS, vs -4.37 in 11p15 and -4.55 in idiopathic SRS, P = .002), and there was a trend 
toward the greatest birth weight (P = .10). TH was 0.30 SDS higher in SRS than in non-SRS 
(P = .01). There was a trend toward a higher TH in 11p15 and mUPD7 than in idiopathic 
SRS (P = .08).
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Growth during Gh treatment in SRS vs non-SRS
Table 2 and Figure 1A show height SDS in SRS and non-SRS from the start of GH treat-
ment until AH. At the start of GH treatment, mean (SD) age was 4.9 (2.2) years in SRS 
and 6.7 (2.2) years in non-SRS (P < .001). Mean height (SD) at the start of GH treatment 
was -3.67 (1.0) SDS in SRS vs. -2.92 (0.6) SDS in non-SRS (P < .001). Weight for height 
at start was 1.36 SDS lower in SRS subjects than in non-SRS subjects (P < .001). Serum 
IGF-I and IGFBP-3 SDS at start were comparably low in both groups (P = .96 and P = .31, 
respectively).
During the first year of GH treatment, height gain was 0.96 (0.5) SDS in SRS vs 0.84 (0.3) 
SDS in non-SRS (P = .08). Serum IGF-I SDS increased to 1.51 (1.3) SDS in SRS vs 0.63 (1.3) 
SDS in non-SRS (P < .001).
SRS subjects, both girls and boys, were significantly younger at the onset of puberty 
than non-SRS (P < .001). Height SDS at onset of puberty was similar in SRS and non-SRS 
(P = .81).
SRS and non-SRS attained AH at a similar age (P = .17). From onset of puberty until AH, 
height SDS declined in both groups: with 0.75 (0.7) SDS in SRS and with 0.44 (0.7) SDS 
in non-SRS (P = .051), resulting in an mean AH SDS of -2.17 (0.8) in SRS and -1.65 (0.8) in 
non-SRS (P = .002) and a larger distance to TH in SRS subjects (P < .001). Total height gain 
SDS from start of treatment until AH was, however, similar in SRS (1.30 (1.0) SDS) and 
non-SRS (1.26 (0.8) SDS (P = .81)). At near AH, IGF-I SDS was similar in SRS and non-SRS 
(P = .47).
The estimated mean AH from the mixed-model analysis (accounting for missing 
values) was -2.21 (95% confidence interval (CI) -2.50 to -1.92) SDS in SRS and -1.66 (95% 
CI -1.78 to -1.54) SDS in non-SRS and thus similar to the AH of the uncensored cases 
analysis.
table 1. Baseline characteristics
total group SRS
SRS non-SRS P valuea 11p15 muPd7 idiopathic P valueb
n 62 227   31 11 20  
No. of males/females 34/28 139/88 .36 19/12 4/7 11/9 .36
Gestational age, wk 37.6 (2.7) 36.4 (3.5) .005 38.0 (2.4) 38.8 (1.5) 36.4 (3.4) .06
Birth length SDS -3.99 (1.7) -3.04 (1.6) .001 -4.37 (1.4) -1.92 (1.5) -4.55 (1.3) .002
Birth weight SDS -2.79 (1.2) -2.28 (1.2) .004 -2.98 (0.9) -2.03 (1.2) -2.86 (1.4) .10
Birth head circumference SDS -0.62 (0.6) -1.02 (0.9) .29 -1.08 (0.9) n.a. -0.70 (1.5) .63
TH SDS -0.20 (0.8) -0.50 (0.8) .01 -0.11 (0.8) 0.10 (0.8) -0.52 (0.7) .08
Abbreviations: 11p15, alteration in 11p15 region; n.a., no data available; TH, target height. Values are ex-
pressed as mean (SD) unless otherwise specified. Boldface indicates P values below .05.
a Represents P values of SRS vs non-SRS.
b Represents P values of 11p15 vs mUPD7 vs idiopathic.
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differences among 11p15, muPd7, and idiopathic SRS
We evaluated whether the growth response to GH differed among the three SRS groups 
(Table 2 and Figure 1B). Height SDS and weight for height at start of GH treatment were 
similar in the three groups. During the first year of GH treatment, height gain was also 
similar in the three groups (P = .57). IGF-I SDS was highest in those with an 11p15 altera-
tion (2.10 (1.0) SDS vs. 0.65 (1.4) in mUPD7 and 0.92 (1.1) in idiopathic SRS; P = .001).
Boys with mUPD7 were the youngest at onset of puberty (P = .04). There was a trend 
toward the greatest height SDS at onset of puberty in 11p15 SRS and the lowest in 
idiopathic SRS (P = .12).
The three SRS subgroups attained their AH at a comparable age (P = .44). AH SDS was 
-2.42 (1.0) in 11p15, -2.00 (0.7) in mUPD7 and -1.96 in idiopathic SRS (P = .39). There was 
a trend toward a lower total height gain from the start of GH to AH in 11p15 compared 
to mUPD7 and idiopathic SRS (P = .12). At near AH, IGF-I levels were similar among the 
three SRS subgroups (P = .82).
factors associated with total height gain
The MR analysis in the total group (SRS and non-SRS; Table 3, left column) showed that 
TH SDS (ß = 0.33, P < .001), and total treatment duration (ß = 0.14, P = .001) positively 
influenced total height gain. Height SDS at the start of GH treatment (ß = -0.49; P < .001) 
was negatively associated with total height gain. SRS patients negatively influenced 
total height gain of the total group (ß = -0.44, P = .013). This model explained 35% of the 
variance in total height gain until AH (P < .001).
In the non-SRS group, the variables influencing total height gain were similar to those 
of the total group (SRS and non-SRS) (Table 3, middle column).
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figure 1. height SdS during Gh treatment in SRS and non-SRS (A) and SRS (B).
Data are expressed as estimated marginal means with 95% CI. *, P value <.05 SRS vs non-SRS.
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table 2. First year growth, pubertal growth and AH in SRS vs non-SRS
total group SRS
SRS non-SRS P valuea 11p15 muPd7 idiopathic P valueb
n 62 227   31 11 20  
At start of Gh              
Age, y 4.9 (2.2) 6.7 (2.2) <.001 4.6 (2.1) 4.8 (2.2) 5.3 (2.3) .51
BA delay (age – BA) 1.2 (1.4) 1.2 (1.0) .41 0.90 (1.6) 1.49 (0.4) 1.58 (1.2) .84
Height SDS -3.67 (1.0) -2.92 (0.6) <.001 -3.69 (1.2) -3.73 (0.8) -3.60 (0.9) .93
Weight/height SDS -2.64 (1.3) -1.28 (1.2) <.001 -2.71 (1.4) -2.33 (1.3) -2.70 (1.1) .68
IGF-I SDS -1.17 (1.7) -1.16 (1.3) .96 -0.57 (1.2) -1.95 (1.4) -1.36 (2.1) .61
IGFBP-3 SDS -1.98 (0.8) -1.54 (1.3) .31 -2.54 (0.3) -2.26 (0.8) -1.36 (0.8) .13
After 1 yr GH              
Height SDS -2.71 (1.0) -2.08 (0.6) <.001 -2.79 (1.1) -2.65 (0.6) -2.62 (0.9) .80
Height gain SDS 0.96 (0.5) 0.84 (0.3) .08 0.90 (0.6) 1.08 (0.4) 0.98 (0.3) .57
Weight/height SDS -2.15 (1.3) -0.95 (1.1) <.001 -2.38 (1.5) -1.61 (0.8) -2.09 (1.0) .22
IGF-I SDS 1.51 (1.3) 0.63 (1.3) <.001 2.10 (1.0) 0.65 (1.4) 0.92 (1.1) .001
At onset puberty              
Age, y        
•      Total  10.8 (1.3) 11.7 (1.1) <.001 10.9 (1.3) 9.8 (1.0) 11.4 (1.3) .02 
•      Boys  11.4 (1.1) 12.0 (1.1) .02 11.5 (0.9) 10.3 (1.0) 12.0 (1.0) .04 
•      Girls  10.2 (1.3) 11.2 (1.0) .003 10.3 (1.4) 9.2 (0.4) 10.7 (1.3) .16 
Duration of GH, y 5.6 (2.5) 5.0 (2.2) .13 6.1 (2.4) 4.1 (2.3) 5.8 (2.7) .18
Height SDS -1.12 (1.1) -1.17 (0.8) .81 -0.74 (0.8) -1.09 (1.3) -1.64 (1.2) .12
At Ah              
No. that achieved AH 26 159   11 5 10  
Age, y        
•      Total  15.6 (1.3) 16.0 (1.1) .17 15.4 (0.7) 16.3 (1.6) 15.6 (1.7) .44 
•      Boys  16.8 (1.5) 16.6 (0.9) .56 15.8 (0.9) 17.8 (1.2) 17.5 ( 1.8) .20 
•      Girls  15.0 (0.7) 15.3 (0.9) .34 15.0 (0.5) 15.4 (1.1) 14.8 (0.8) .51 
Duration of GH, y 9.6 (2.5) 8.8 (2.0) .02 9.5 (2.7) 10.7 (2.3) 9.7 (3.0) .73
Pubertal height gain -0.75 (0.7) -0.44 (0.7) .051 -1.27 (0.4) -0.52 (0.7) -0.35 (0.7) .01
AH SDS -2.17 (0.8) -1.65 (0.8) .002 -2.42 (1.0) -2.00 (0.7) -1.96 (0.2) .39
Total height gain SDS 1.30 (1.0) 1.26 (0.8) .81 0.91 (1.0) 2.04 (0.8) 1.37 (1.0) .12
Distance to TH SDS 2.14 (1.0) 1.11 (0.7) <.001 2.37 (1.4) 2.03 (0.4) 1.97 (0.9) .69
IGF-I SDS (near AH) 1.31 (1.2) 1.16 (0.7) .47 1.45 (0.8) 1.38 (1.0) 1.11 (1.6) .82
Abbreviations: 11p15, alteration in 11p15 region; BA, bone age Greulich & Pyle. Values are expressed as 
mean (SD), unless specified otherwise. Boldface P values are < .05.
a Represents P values of SRS vs non-SRS.
b Represents P values of 11p15 vs mUPD7 vs idiopathic.
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Subsequently, we analyzed which variables influenced total height gain in the SRS 
subjects (Table 3, right column). TH SDS (P = .84) and total duration of GH (P = .58) did 
not significantly influence total height gain in this model. Height SDS at start (ß = -0.67, 
P = .02) negatively influenced total height gain. There was a trend toward a negative 
influence of subjects with an 11p15 aberration on total height gain of the SRS subjects 
(ß = -0.52, P = .13). This model explained 45% of the variance in total height gain in SRS 
subjects (P = .007).
GnRha treatment in SRS
In 17 SRS subjects (five 11p15; five mUPD7 and seven idiopathic SRS), puberty was 
postponed for two years due to a low predicted AH using GnRHa (leuprolide acetate 
depot, 3.75 mg sc every 4 weeks) in addition to GH treatment. Five patients were male 
and 12 were female.
Mean (SD) age at start of puberty was significantly lower (9.4 (0.9) years) in the SRS 
girls treated with additional GnRHa than in those without (11.0 (1.2) years; P = .004). 
Height at the onset of puberty was 132.1 (8.8) cm in SRS girls with GnRHa vs 139.4 (9.9) 
cm in SRS girls without (P = .15). Height gain from the onset of puberty until AH was 
greater in SRS girls with additional GnRHa (26.3 (6.1) cm) than in SRS girls without GnRHa 
(15.5 (5.5) cm) (P = .004), leading to a similar AH (155.0 (4.6) cm with GnRHa and 156.9 
(4.9) cm without GnRHa) (P = .41).
SRS boys treated with additional GnRHa were also younger at start of puberty than 
those without (10.7 (1.1) years vs 11.7 (0.9) years, respectively, P = .052). Height at the 
onset of puberty was 142.5 (6.9) cm in SRS boys with GnRHa and 145.2 (6.2) cm in those 
table 3. Multiple regression analysis with independent variable total height gain
total height gain SdS
 
variables
total group non-SRS SRS
ß P value ß P value ß P value
TH SDS 0.33 <.001 0.36 0.001 0.05 .84
Age at start GH 0.03 .48 0.02 .62 -0.06 .69
Height SDS at start GH -0.49 <.001 -0.43 0.001 -0.67 .02
Total duration of GH, y 0.14 .001 0.11 .008 0.09 .58
SRS -0.44 .013 NA NA NA NA
11p15 NA NA NA NA -0.52 .13
Overall P value <.001 <.001 .007
R2 adjusted 0.35 0.32 0.45
Abbreviations: NA, not applicable; SRS, subjects with Silver-Russell syndrome (non-SRS subjects are the 
reference group). 11p15 indicates SRS subjects with an alteration of the 11p15 region (mUPD7 and idio-
pathic SRS are the reference group). Total group columns represent SRS and non-SRS subjects. SRS columns 
represent SRS subjects only. Boldface P values are <.05.
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without (P = .44). Height gain from onset of puberty until AH was greater in SRS boys 
with GnRHa than in those without (33.1 (2.8) cm vs. 22.3 (1.9) cm, respectively, P = .03), 
leading to a similar AH (P = .55).
Safety
GH treatment was well tolerated in SRS and non-SRS. No adverse events considered to 
be drug-related were observed. After 1 year of treatment, 38.6% of the SRS patients had 
IGF-I levels above +2 SDS vs. 11.1% of the non-SRS subjects (P < .001). At near AH, 24.0% 
of the SRS patients and 9.1% of the non-SRS subjects had IGF-I levels above +2 SDS (P 
= .15).
Two female SRS patients with an ICR1 hypomethylation were diagnosed with a slipped 
capital femoral epiphysis (SCFE) during GH treatment at 11 and 10 years of age. Both girls 
underwent surgical fixation of the hip joint. Because these events were not considered 
related to GH by the treating physicians, after fixation, GH treatment was continued.
diSCuSSion
In this study, the growth response to GH treatment was compared between 62 SRS 
patients and 227 short, non-syndromic subjects born SGA. Mean total height gain was 
similar in SRS and non-SRS subjects born SGA. Although SRS subjects did not attain the 
same AH, GH treatment is similarly effective in SRS as in non-SRS SGA subjects. All SRS 
subtypes benefit from GH treatment, with a trend toward mUPD7 and idiopathic SRS 
having the greatest height gain.
Our study represents a large study describing growth during GH treatment in a cohort 
of SRS subjects treated for a long time. We found that SRS patients attained a mean AH 
of -2.17 SDS and that total height gain was 1.30 SDS, compared to a mean AH of -1.65 
SDS and a total height gain of 1.26 SDS in non-SRS patients. The effectiveness of GH 
treatment in short children born SGA had been reported (24-26), but long-term effects 
of GH in SRS patients were very scarce. Rakover et al. (27) described 33 SRS patients 
treated with GH. There was a significant improvement in growth during three years of 
GH therapy but AH data were missing. To our knowledge, there are only two studies 
describing AH after GH therapy in SRS patients (14,16). Binder et al. (16) described 37 
patients with a mean height at start of -3.34 SDS. Overall height gain was 1.18 SDS in 
males and 1.47 SDS in females, which is comparable with the height gain in our cohort. 
Unfortunately, in that study a large number of patients measured their height them-
selves, which might lead to unreliable results. Also, only data at start of treatment and at 
AH were analyzed, and height data around puberty were lacking. In the study of Toumba 
et al. (14), 26 SRS patients with a median height at start of -2.7 SDS were described. 
In that study, boys attained a higher AH (-1.0 SDS) than girls (-2.3 SDS), and median 
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height gain was 1.4 SDS. However, no patients were tested for methylation aberrations 
on 11p15 and the scoring system to diagnose clinical SRS has been updated since then. 
In both studies, a control group of short SGA children without SRS was lacking.
Although total height gain in SRS and non-SRS subjects was similar in our study, SRS 
patients did not attain the same AH because they were significantly shorter at start of 
GH. Also, puberty started earlier in SRS patients leading to earlier closure of the growth 
plates and a lower AH at a younger age. Indeed, there was a steeper decline in height 
SDS from onset of puberty until AH in SRS. A decline in height SDS during puberty is a 
known phenomenon in short SGA children who are treated with GH (26). Puberty was 
delayed with GnRHa in 17 SRS patients. Because pubertal height gain was greater in 
those treated with GnRHa in addition to GH, adding GnRHa treatment can be beneficial 
in those who start puberty at a young age with a short height. However, our study was 
not designed to give a definite answer on this matter.
Our study has two important strengths: the application of strict criteria to diagnose 
clinical SRS (15) and the performance of additional DNA analysis in all clinical SRS pa-
tients, including the recently discovered CDKN1C and IGF-2 mutations in a majority of 
the patients (9,10). Previous studies describing GH treatment in SRS patients did not per-
form extensive genetic testing (14,27). In our cohort, we did not detect IGF-2 or CDKN1C 
mutations in 14 out of 20 idiopathic SRS patients who were tested for these mutations. 
Our findings are in line with those of Muller et al. (28) who did not find IGF-2 mutations 
in 72 patients with a clinical SRS phenotype. Until now, CDKN1C mutations have been 
described in just one family (10,30). Our study shows that IGF-2 and CDKN1C mutations 
are not a major molecular cause of SRS and that only in familial cases with paternal 
inheritance of the SRS phenotype, IGF-2 mutations need to be considered (9,28,30).
To analyze genotype-phenotype correlations, we compared GH response among 
patients with an 11p15 methylation defect, mUPD7 and idiopathic SRS. Height SDS was 
similar at start but there was a trend toward a greater height gain in the patients with 
mUPD7 and idiopathic SRS compared to patients with an 11p15 methylation defect. This 
is in line with a previous study reporting that the 11p15 alterations cause a more severe 
phenotype of SRS (17). Patients with mUPD7 or idiopathic SRS thus respond better to GH 
treatment than those with 11p15. Because those with an 11p15 alteration also increase 
their height with almost 1 SDS, we also consider GH treatment beneficial for SRS patients 
with an 11p15 alteration.
The number of patients in the SRS subgroup analysis for AH was relatively small due 
to the fact that SRS is a rare disorder and not all patients attained AH yet. Thus, definite 
conclusions should await findings in a larger cohort. Despite applying the most recent 
genetic assessments regarding SRS, there was still an idiopathic SRS group. We, there-
fore, suggest that future studies aim at elucidating the genetic causes of idiopathic SRS.
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IGF-I levels were similar at the start of GH treatment in SRS and non-SRS groups. How-
ever, after 1 year of GH treatment, IGF-I levels were higher in the SRS group due to high 
IGF-I levels in the SRS patients with an 11p15 alteration. This finding is in concordance 
with a previous study, suggesting reduced IGF-I sensitivity in SRS patients with an 11p15 
epimutation (31). However, the mechanism behind the reduced IGF-I sensitivity remains 
to be elucidated. At near AH, IGF-I levels were not significantly different anymore 
between SRS and non-SRS or among the different SRS subgroups, which is reassur-
ing. Based on the higher IGF-I levels in the SRS group after 1 year of GH treatment, we 
suggest careful monitoring of IGF-I levels in these children, especially in those with an 
11p15 alteration. Our findings highlight the importance of attaining more knowledge 
about the degree of IGF-I insensitivity in SRS children and whether higher IGF-I levels, 
even within the normal range, have long-term consequences.
GH treatment was well tolerated in SRS and non-SRS groups. Two SRS patients were 
diagnosed with SCFE during GH treatment. Whether GH-treated SRS subjects are at 
increased risk for SCFE cannot be concluded from these two events. Besides this, there 
were no adverse events observed that were considered to be drug-related over a long 
period of time. We therefore conclude that, besides a possible increased risk for SCFE, 
there is no safety concern about GH treatment in children with SRS.
In conclusion, we showed that SRS patients respond well to GH treatment and that 
total height gain is similar in SRS and non-SRS subjects born SGA. There was a trend 
toward a better response to GH treatment in SRS patients with mUPD7 and idiopathic 
SRS compared to patients with an 11p15 methylation defect, but GH treatment is also 
beneficial for those with 11p15. Since no adverse events occurred over a long treatment 
period, there is no safety concern about GH in children with SRS. Future studies should 
aim at elucidating the genetic causes of idiopathic SRS and the long-term consequences 
of short SGA in general and SRS in particular. Children with clinical signs of SRS should 
be tested for 11p15 methylation aberrations and mUPD7.
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ABStRACt
Context: Children with Silver-Russell syndrome (SRS) are born small for gestational age 
(SGA) and remain short. Growth hormone (GH) treatment improves height in short SGA 
children, including those with SRS. Data on metabolic health and long-term safety of GH 
treatment in SRS are lacking.
Objective: To investigate metabolic health in SRS patients during and until 2 years after 
discontinuation of GH treatment.
Design: Metabolic health was assessed longitudinally at GH-start, GH-stop, 6 months 
and 2 years thereafter.
Patients: Twenty-nine SRS patients vs 171 non-SRS subjects born SGA.
Main outcome measures: Lean body mass (LBM) and fat mass percentage (FM%), insulin 
sensitivity (Si) and β-cell function, blood pressure and serum lipids.
Results: At GH-start (mean age (standard deviation) 5.4 (2.1) years in SRS and 6.7 (2.0) in 
non-SRS (P = 0.003)), blood pressure, serum lipids, glucose and insulin levels were similar 
and within normal ranges in SRS and non-SRS. LBM SDS and FM% SDS were lower than 
average in both groups. During treatment, LBM SDS remained stable while FM% SDS 
increased in both groups. During the 2 years after GH-stop, LBM decreased and FM% 
increased, while Si and β-cell function improved. At 2 years after GH-stop (mean age 18 
years), all parameters were similar and within normal ranges in SRS and non-SRS. None 
of the SRS patients developed metabolic syndrome, diabetes mellitus type 2, or adverse 
events.
Conclusion: GH-treated SRS patients have a similar metabolic health and safety profile as 
non-SRS subjects born SGA, both during and until 2 years after GH-stop.
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intRoduCtion
Silver-Russell syndrome (SRS) is characterized by small for gestational age (SGA) birth, 
postnatal growth retardation, feeding difficulties, and several dysmorphic features (1-
3). Approximately 60% of cases are caused by an aberration in the imprinting control 
region of the 11p15 region (4) and 5% to 10% by a maternal uniparental disomy of 
chromosome 7 (mUPD7) (5). In 30% to 40%, the genetic cause is unknown, which is 
referred to as clinical SRS (6).
Children born with a low birth weight are at increased risk to develop adult-onset 
disorders such as diabetes mellitus type 2 (DM2), hypertension, and hyperlipidemia at a 
relatively young age (7). Epigenetic changes could be one of the underlying mechanisms 
behind this increased risk (8), but the risk for adult-onset disorders has not been investi-
gated in SRS. Overall, adult follow-up data in SRS are lacking, which was also emphasized 
by the recently published consensus statement on diagnosis and management of SRS (6).
Growth hormone (GH) treatment is a registered growth promoting therapy for short 
children born SGA (9), including children with SRS. It has been shown that GH treatment 
is effective at increasing adult height (AH) in SRS (10, 11). GH treatment has also several 
metabolic effects in children born SGA, namely an increase in lean body mass (LBM), a 
decline in fat mass (FM), a decrease in blood pressure (BP), and a more favorable lipid 
profile, but also a lower insulin sensitivity (Si) (12-14). Data on whether these effects also 
occur in GH-treated SRS patients are lacking.
In the present study, we assessed longitudinal changes in metabolic health (i.e. BP, fast-
ing lipid levels, body composition, Si, and occurrence of DM2 and metabolic syndrome) 
in patients with SRS, from start of GH treatment until 2 years after discontinuation of 
GH due to AH attainment. We compared these data with GH-treated non-SRS subjects 
born SGA, hypothesizing that SRS patients have a less favorable metabolic health profile 
due to their epigenetic changes, but that the metabolic changes during and after GH 
treatment are similar in SRS and non-SRS subjects.
methodS
Subjects
The study group comprised 29 SRS and 171 non-SRS subjects who participated in a 
large, multicenter GH trial (13-15) and had attained AH. All subjects were born SGA (birth 
length (BL) and/or birth weight (BW) ≤ -2 standard deviation score (SDS) for gestational 
age (16)) and received biosynthetic GH at a dose of 1 mg/m2/d (~0.035 mg/kg/d) be-
cause of short stature (height ≤ -2.5 SDS (17)), until they attained AH (i.e. height velocity 
<0.5 cm in 6 months and bone age ≥15 years for girls and ≥16.5 years for boys). Excluded 
were subjects with chromosomal abnormalities or signs of a syndrome except SRS.
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From start of GH until 2 years after discontinuation of treatment, parameters of vas-
cular and metabolic health were investigated at 4 time points: 1) at GH-start; 2) when 
subjects reached AH (i.e. GH-stop); 3) at 6 months after GH-stop; and 4) at 2 years after 
GH-stop. Owing to the time-consuming aspect of the study and the fact that not all 
patients had already discontinued GH for 2 years, data were available of 18 SRS patients 
and 165 non-SRS subjects at 6 months after GH-stop and 13 SRS patients and 109 non-
SRS subjects at 2 years after GH-stop.
Subjects were diagnosed with SRS based on the Netchine-Harbison clinical scoring sys-
tem (18), which includes the following 6 factors: 1) prenatal growth retardation (BL and/
or BW ≤ -2 SDS for gestational age); 2) postnatal growth retardation (height SDS < -2.0 ac-
cording to national reference (17); 3) relative macrocephaly at birth (head circumference at 
birth ≥1.5 SDS above BL and/or BW SDS according to Usher and McLean (16); 4) prominent 
forehead; 5) body asymmetry (leg length discrepancy of ≥0.5 cm or arm asymmetry or leg 
length discrepancy <0.5 cm with ≥2 other asymmetrical body parts (one being a non-face 
part)); and 6) feeding difficulties during early childhood. Patients were classified as SRS if 
at least 4 factors were present. SRS patients were tested for methylation aberrations of the 
11p15 region and mUPD7, and when negative, also for CDKN1C and insulin-like growth 
factor (IGF)2 mutations. Patients with SRS based on the Netchine-Harbison clinical scoring 
system but without a known genetic aberration were classified as clinical SRS.
This study was performed according to the Helsinki Declaration and approved by the 
Medical Ethics Committee of all participating centers. Written informed consent was 
obtained from all participants and/or their parents.
measurements
Birth data were obtained from records of hospitals and primary health care centers. 
Anthropometric measurements were performed twice according to standardized 
methods, after which the mean was calculated. Height was measured to the nearest 0.1 
cm (Harpenden stadiometer), weight to the nearest 0.1 kg (Servo Balance KA-20-150S). 
Waist circumference was measured midway between the lower margin of the lowest rib 
and the upper margin of the iliac crest at the end of a normal expiration.
Diastolic BP (DBP) and systolic BP (SBP) were measured after 10 minutes of rest, in 
sitting position, using the non-dominant arm, with an automatic device (Accutorr Plus, 
Datascope, Montvale NJ) at every 5 minutes for 1 hour; the mean value was taken to 
reflect resting BP.
LBM and FM were measured on a dual-energy X-ray absorptiometry (DXA) machine 
(Lunar Prodigy; GE Healthcare, Chalfont St. Giles, UK). FM was measured as a percentage 
of total body weight (FM%). Quality control was performed daily.
Glucose homeostasis was assessed at GH-stop and 6 months and 2 years thereafter, 
by frequently sampled intravenous glucose tolerance (FSIGT) tests with Tolbutamide 
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after an overnight fast (19). Si, glucose effectiveness (Sg), acute insulin response (AIRg), 
and disposition index (DI) were calculated using R.N. Bergman’s minimal model software 
(MINMOD 6.01). Si quantifies the capacity of insulin to promote glucose disposal, and Sg 
reflects the capacity of glucose to mediate its own disposal. AIRg is an estimate of insulin 
secretory capacity and was measured as the area under the curve from 0 to 10 minutes 
corrected for baseline insulin levels. DI equals AIRg times Si (DI = AIRg X Si) and indicates 
the ß-cell function.
Revised criteria of the National Cholesterol Education Program (adult treatment panel 
III (ATP-III)) were used to determine components of metabolic syndrome (20). Metabolic 
syndrome was defined as having ≥3 of the following risk factors: 1) waist circumference 
in men >102 cm, and in women >88 cm; 2) triglycerides (Tg) >1.7 mmol/L; 3) high-density 
lipoprotein cholesterol (HDLc) in men <1.03, in women <1.3 mmol/L; 4) BP ≥130/≥85 
mm Hg; 5) fasting glucose >5.6 mmol/L.
Behavioral problems were defined as attention deficit hyperactivity disorder, perva-
sive developmental disorder, or autism spectrum disorder, diagnosed by an experienced 
psychologist.
Laboratory measurements
After centrifugation, all samples were kept frozen until assayed (-80°C). Fasting levels of total 
cholesterol (TC), Tg and high-density lipoprotein (HDLc) were measured using the CHOD-
PAP and the GPO-PAP reagent kits (Roche Diagnostics, Mannheim, Germany) (TC and Tg), 
and using a homogeneous enzymatic colorimetric assay (Roche Diagnostics) (HDLc). Low-
density lipoprotein cholesterol (LDLc) was calculated using the Friedewald formula: LDLc 
(mmol/L) = TC – HDLc – 0.45 X level of Tg. Fasting glucose levels were determined on an 
Architect ci8200 system (Abbott Laboratories, Abbott Park, IL). Fasting insulin levels were 
measured by immunoradiometric assay (Medgenix, Biosource Europe, Nivelles, Belgium). 
Calculated glomerular filtration rate (GFR) was calculated using the Schwartz equation: GFR 
(mL/min/1.73 m2) = (0.41 X Height (cm))/serum creatinine (mg/dL) (21).
dnA analyses
DNA methylation testing of the 11p15 region (ICR1 (H19) and ICR2 (KCNQ1OT1)) and 
mUPD7 was performed using methylation-specific multiplex ligation-mediated probe 
amplification (MS-MLPA), as previously described (11). To identify CDKN1C mutations 
(c.836G>T (pArg279Leu)) (22) or IGF2 mutations (IGF2c.191C>A (p.Ser64Ter) (23), ge-
nomic DNA extracted from peripheral blood leucocytes was diluted to a concentration 
of 5 ng/µl and target regions of CDKN1C and IGF2 were amplified by PCR using primers. 
The IGF2 region containing the mutation was amplified using the forward primer IG-
F2exR3 5’-CTCGGCATTATGACCTGTGT-’3 and reverse primer IGF2ex3R 5’-AGGCGTGTGAT-
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GGGAAAG-’3, and the CKDN1C target region containing the mutation using the primers 
described previously (22).
Calculations and statistics
SD scores for BL and BW were calculated in order to correct for gestational age and sex 
(16), SD scores for height, serum IGF-I, and IGF binding protein-3 (IGFBP3) to correct for 
sex and age (17, 24) and SD scores for weight and BP to correct for height and sex (25). 
SD scores for BL, BW, height, and weight were calculated using the Growth Analyzer 
software (http://www.growthanalyser.org). FM% SDS was calculated according to age- 
and sex-matched Dutch reference values (26). Because LBM is strongly related to height, 
LBM was expressed as SDS for height and sex (26).
Distribution of variables was determined by Shapiro-Wilk tests and normal Q-Q-plots. Be-
cause of a skewed distribution, Si, Sg, AIR and DI were log transformed. Differences between 
SRS and non-SRS were analyzed using independent-sample t tests. To analyze differences in 
longitudinal changes during GH treatment between SRS and non-SRS, linear mixed model-
ling for repeated measurements was used with SRS and time as factors. An unstructured 
repeated covariance type was used, adjusting for missing values. A P value of <0.05 was 
considered statistically significant. Analyses were performed with SPSS version 21.0.
ReSuLtS
Clinical characteristics
Clinical characteristics of the SRS and non-SRS subjects are listed in Table 1. Fourteen 
SRS patients had an 11p15 aberration and 6 patients an mUPD7. There were no patients 
with an IGF2 or CDKN1C mutation. Nine SRS patients tested negative for all known 
aberrations causing SRS and were assigned to the clinical SRS group. SRS patients had 
a lower BL and BW SDS than the non-SRS subjects (P = 0.005 and P = 0.04, respectively). 
Head circumference SDS was similar in SRS and non-SRS (P = 0.56), but the discrepancy 
between head circumference and BL was larger in SRS (P = 0.009).
At GH-start, SRS patients were significantly younger than non-SRS subjects (mean age 
(SD) 5.4 (2.1) years vs 6.7 (2.0) years, respectively, P = 0.003), and had a lower height SDS 
(P < 0.001) and weight for height SDS (P < 0.001). SRS patients attained AH at a younger 
age (15.7 (1.5) years vs 16.4 (1.3) years, respectively; P = 0.01). Mean AH SDS (SD) was -1.63 
(0.8) in SRS and -1.43 (0.8) in non-SRS (P = 0.26). SRS patients had a lower weight for height 
SDS at AH (P < 0.001). At 2 years after GH-stop, age was similar in the 2 groups (P = 0.72).
BP and fasting lipid levels
At GH-start, SRS patients had a lower mean SBP SDS than did non-SRS subjects (P = 
0.04), whereas DBP SDS was similar in both groups (Table 2). At the end of treatment, 
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SBP and DBP SDS had remained similar in SRS whereas they had decreased in non-SRS 
(P < 0.001). At GH-stop, SRS patients had a similar SBP and DBP SDS as did non-SRS (P = 
0.44 and P = 0.07, respectively). In the 2 years after GH-stop, SBP and DBP SDS remained 
stable in SRS, whereas DBP and SBP SDS increased in the 6 months after GH-stop in 
non-SRS and decreased again in the 18 months thereafter. At 2 years after GH-stop, SBP 
and DBP SDS were similar and within normal ranges in SRS and non-SRS.
At GH-start, fasting serum levels of TC, LDLc, HDLc and Tg were similar in SRS and non-
SRS (Table 2). During treatment, serum lipids remained similar and within normal ranges 
in SRS. In non-SRS, there was a significant decrease of TC and LDLc during treatment, 
followed by an increase in the 2 years after GH-stop, whereas HDLc and Tg remained 
similar during and after GH-stop.
table 1. Clinical characteristics
  SRS (n=29) non-SRS (n=171) P
Male/Female 13/16 82/89 0.76
11p15/mUPD7/clinical 14/6/9 N/A N/A
Gestational age, wk 37.6 (2.8) 35.7 (3.9) 0.003
Birth length SDS -4.26 (1.6) -3.02 (1.5) 0.005
Birth weight SDS -2.76 (1.4) -2.21 (1.2) 0.04
Birth head circumference SDS -1.73 (1.5) -2.02 (1.1) 0.56
Target height SDS -0.09 (0.7) -0.48 (0.8) 0.02
At Gh-start      
Age, y 5.4 (2.1) 6.7 (2.0) 0.003
Height SDS -3.60 (0.8) -2.96 (0.5) <0.001
Weight/height SDS -2.76 (1.1) -1.26 (1.2) <0.001
Head circumference SDS -0.64 (1.1) -1.23 (0.9) 0.003
IGF-I SDS -0.33 (1.4) -0.55 (1.2) 0.49
IGFBP3 SDS -1.51 (1.2) -1.38 (1.2) 0.69
At Ah (Gh-stop)      
Age, y 15.7 (1.5) 16.4 (1.3) 0.01
Height SDS -1.63 (0.8) -1.43 (0.8) 0.26
Weight/height SDS -0.30 (1.1) 0.48 (1.0) <0.001
Head circumference SDS -0.47 (1.0) -0.82 (0.9) 0.24
IGF-I SDS 1.27 (0.9) 1.25 (0.8) 0.95
IGFBP3 SDS -0.12 (0.5) -0.32 (0.6) 0.35
At 2yrs after Gh-stop      
Age, y 18.3 (1.6) 18.4 (1.3) 0.72
Values expressed as mean (SD). Boldface P values are <0.05.
Abbreviation: N/A, not applicable.
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Body Composition
Figure 1 shows the longitudinal changes in LBM and FM%, during and after GH-stop 
in SRS and non-SRS. At GH-start, estimated mean (SE) LBM SDS was -1.63 (0.9) in SRS 
vs. -0.53 (0.3) in non-SRS (P = 0.12). During treatment, LBM remained similar in both 
groups, and SRS patients had a lower LBM at GH-stop (P = 0.007). In the 6 months after 
GH-stop, LBM SDS deteriorated in both groups, but remained stable in the 18 months 
thereafter. At 2 years after GH-stop, there was still a trend toward a lower LBM in SRS 
than in non-SRS (P = 0.10).
At GH-start, FM% SDS was similar in both groups (estimated mean (SE) -0.51 (0.3) in 
SRS vs -0.65 (0.2) in non-SRS; P = 0.72). During GH treatment, FM% SDS increased in both 
groups. During the 6 months after GH-stop, FM% SDS increased further in SRS, but re-
mained stable in the 18 months thereafter. In non-SRS, FM% SDS increased persistently 
until 2 years after GH-stop. At 2 years after GH-stop, FM% SDS was similar in SRS and 
non-SRS (P = 0.97).
insulin sensitivity and ß-cell function
At GH-start, fasting glucose levels were lower in SRS than in non-SRS (P = 0.047), while 
fasting insulin levels were similar in the 2 groups (Table 2). During treatment, fasting 
glucose levels increased, whereas insulin levels remained stable in both groups. After 
GH-stop, glucose levels remained stable in SRS, whereas they decreased in the 6 months 
after GH-stop in non-SRS. Insulin levels decreased in the 6 months after GH-stop, and 
remained stable in the 18 months thereafter in both groups.
Figure 2 shows the longitudinal changes in Si, Sg, AIR, and DI from GH-stop until 2 
years thereafter. At GH-stop, Si, Sg, AIR, and DI were similar in SRS and non-SRS. During 
the 6 months after GH-stop, Si and DI increased significantly in both groups and re-
mained stable in the 18 months thereafter. Sg only increased in non-SRS in the 6 months 
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figure 1. Longitudinal changes in body composition at GH-start, GH-stop and 6 months and 2 years there-
after in SRS (black lines) and non-SRS (gray dotted lines). Data are expressed as estimated marginal means 
± standard error of the mean. *P < 0.05 SRS vs non-SRS; # P < 0.05 compared with previous time point (in 
black for SRS and gray for non-SRS).
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after GH-stop, and remained stable in both groups in the 18 months thereafter. At 2 
years after GH-stop, SRS patients had a lower AIR than did non-SRS subjects (P = 0.009), 
while Si, Sg and DI were similar in both groups. Until 2 years after GH-stop, none of the 
SRS and non-SRS patients had developed DM2.
metabolic syndrome
ATP-III score was similar and overall low in SRS and non-SRS at GH-start, GH-stop and 
6 months and 2 years thereafter (Table 2). There were no SRS patients with an ATP-III 
score ≥3 at any time point. One girl of 15.4 years and one boy of 15.9 years in the non-
SRS group had an ATP-III score of 3, and thus met the criteria for metabolic syndrome. 
Two SRS patients had an ATP-III score of 2 at GH-start due to an adverse lipid profile. In 
both patients, this improved during treatment, resulting in an ATP-III score of 1 and 0 
at GH-stop. Three other SRS patients, all girls, had an ATP-III score of 2 at GH-stop due 
to adverse lipid levels and high BP. At 2 years after GH-stop, the lipid levels of 1 girl had 
improved, probably due to dietary changes, resulting in an ATP-III score of 1. Of the 
other 2 girls, there were no follow-up data available.
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figure 2. Longitudinal changes in FSIGT-results at GH-stop and 6 months and 2 years thereafter in SRS 
(black lines) and non-SRS (gray dotted lines).
Data expressed as estimated marginal means ± standard error of the mean. *P < 0.05 SRS vs non-SRS; # P < 
0.05 compared with previous time point (in black for SRS and gray for non-SRS).
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Renal function
At GH-start, mean (SD) serum creatinine was significantly lower in SRS than in non-SRS 
(P = 0.02), probably due to the younger age and the trend toward a lower LBM in SRS 
patients at GH-start (Table 2). Consequently, calculated GFR was higher in SRS than in 
non-SRS at GH-start. At GH-stop, serum creatinine was lower in SRS (P = 0.04), while 
calculated GFR was similar in the 2 groups. There were no differences in serum creatinine 
and calculated GFR 6 months and 2 years after GH-stop. Serum creatinine and calculated 
GFR fell within the normal ranges for age at all time points.
follow-up of congenital malformations in SRS
Table 3 shows the congenital malformations, anomalies, and developmental problems 
in the total group of SRS patients and per subgroup based on the underlying epigenetic 
alteration. Multiple patients had craniofacial and musculoskeletal anomalies such as 
micrognathia and retrognathia, as well as asymmetry of face or limbs. A congenital 
heart defect was seen in 1 patient with an 11p15 aberration and in 1 patient with clinical 
SRS. Genital anomalies were only seen in SRS males, of which 1 patient with an 11p15 
aberration had a hypospadias, and 2 patients (1 with an 11p15 aberration and 1 with 
clinical SRS) had cryptorchidism. Developmental impairments were seen in 33.3% of the 
mUPD7 patients and in 14.3% of the 11p15 patients, but not in the clinical SRS patients. 
Behavioral problems were present in half of the mUPD7 patients, vs in <15% of the 
11p15 and clinical SRS patients. Besides these known malformations and developmental 
problems, there were also patients with various other anomalies, such as hearing loss (in 
1 patient with mUPD7), strabismus (in 1 patient with an 11p15 aberration) and epilepsy 
(in 1 patient with clinical SRS).
Safety of Gh treatment
At GH-start, SRS and non-SRS subjects had similar mean (SD) serum IGF-I SDS (-0.33 
(1.4) in SRS and -0.55 (1.2) in non-SRS; P = 0.49), (Table 1). At GH-stop, IGF-I SDS had 
significantly increased in both groups, but was still similar and within normal ranges in 
SRS and non-SRS (1.27 (0.9) in SRS and 1.25 (0.8) in non-SRS; P = 0.95).
Two female SRS patients with an 11p15 aberration were diagnosed with a slipped 
capital femoral epiphysis during GH treatment at the ages of 10 and 11 years, after 6 
and 7 years, respectively, of GH treatment. Both girls were simultaneously treated with 
a gonadotropin-releasing hormone analog, for 1 month and 1 year, respectively, when 
their capital femoral epiphyses slipped. Both girls underwent surgical fixation of the hip 
joint. After this, GH treatment was continued and they both attained an AH around -1 
SDS (-0.95 SDS and -1.04 SDS).
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diSCuSSion
This study shows long-term data on metabolic health, safety of GH treatment, and 
phenotype in SRS patients compared to non-SRS short SGA subjects treated with GH. 
We found that SRS and non-SRS patients have a very similar metabolic health profile at 
start of treatment, and that, apart from minor variations, the metabolic profile of SRS 
and non-SRS patients responds similarly to GH treatment. At the age of 18 years, there is 
no difference in risk for metabolic syndrome between SRS and non-SRS.
This longitudinal study describes extensive metabolic health data in a cohort of 
GH-treated SRS patients that was followed from childhood into early adulthood. We 
table 3. Congenital malformations, anomalies and developmental problems in the total group of SRS pa-
tients and per subgroup.
  Anomaly total SRS 
(n=29)
11p15 
(n=14)
muPd7 
(n=6)
Clinical 
(n=9)
Craniofacial Micro/retrognathia 4 (13.8) 2 (14.3) 2 (33.3) -
  Face asymmetry 3 (10.3) 3 (21.4) - -
musculoskeletal Limb asymmetry 7 (24.1) 6 (42.9) 1 (16.7) 1 (11.1)
  Scoliosis 2 (6.9) 1 (7.1) 1 (16.7) -
  Bilateral club feet 1 (3.5) 1 (7.1) - -
  Hip dysplasia 1 (3.5) 1 (7.1) - -
  Slipped femoral epiphysis 2 (6.9) 2 (14.3) - -
  Joint contractures 1 (3.5) 1 (7.1) - -
  Inguinal hernia 1 (3.5) - - 1 (11.1)
  Exostosis 1 (3.5) - - 1 (11.1)
heart Atrial septal defect 1 (3.5) 1 (7.1) - -
  Ventricular septal defect 1 (3.5) - - 1 (11.1)
Genital Hypospadias 1 (3.5) 1 (7.1) - -
  Cryptorchidism 2 (6.9) 1 (7.1) - 1 (11.1)
development Mild impairment 2 (6.9) - 2 (33.3) -
  Speech delay 1 (3.5) 1 (7.1) - -
  Delayed motor milestones 2 (6.9) 1 (7.1) 1 (16.7) -
  Behavioral problems 4 (13.8) 1 (7.1) 3 (50.0) 1 (11.1)
other Hearing loss 1 (3.3) - 1 (16.7) -
  Strabismus 1 (3.5) 1 (7.1) - -
  Thrombocytopenia 1 (3.5) - 1 (16.7) -
  Lung hypoplasia 1 (3.5) 1 (7.1) - -
  Hashimoto thyroiditis 1 (3.5) - - 1 (11.1)
  Epilepsy 1 (3.5) - - 1 (11.1)
Values are n (%).
-, no anomaly.
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used gold standard tests such as dual-energy X-ray absorptiometry to measure body 
composition, and FSIGT tests with Tolbutamide to assess Si and ß-cell function, making 
our data unique (27). All major determinants of cardiovascular disease risk were similar 
in SRS and non-SRS at start of treatment, and SBP and fasting glucose levels were even 
lower in SRS than in non-SRS. LBM was low in both groups, especially in SRS patients, 
but this difference did not reach statistical significance. We found some differences 
between the 2 groups regarding the response to GH treatment. In SRS, BP and lipid 
levels did not change during treatment, although the lack of difference could be caused 
by the relatively small number of patients in the SRS group. BP, TC and LDLc significantly 
decreased in non-SRS, but the actual differences were small, and thus most likely not 
clinically relevant. Both groups responded similarly to GH with respect to the changes 
in body composition, but LBM remained lower in SRS patients. During the 2 years after 
GH-stop, we found several changes related to the loss of pharmacologic effects of GH in 
SRS patients, such as a decrease in LBM and an increase in FM%, but this was similar as 
in non-SRS patients. Si and ß-cell function improved after GH-stop. Most importantly, at 
2 years after GH-stop, at a mean age of approximately 18 years, there were no significant 
differences between the groups, and none of the SRS patients had developed DM2 or 
metabolic syndrome.
To our knowledge, there are only 2 case reports addressing metabolic health in SRS. 
The first described 3 SRS patients (all with an 11p15 aberration, 2 received GH treatment 
for several years during childhood) who developed adult diseases such as obesity, hy-
pertension, and DM2 in their early 20s (28). The second described the oldest SRS patient 
known so far, who has DM2, osteopenia, and hypercholesterolemia at the age of 69 
years (29). However, these studies were very small and did not compare the data of SRS 
patients with those of non-SRS subjects who were similarly treated with GH.
We found multiple malformations, anomalies, and developmental problems in the SRS 
patients, with differences between the 11p15, mUPD7 and clinical patients. In particular, 
behavioral problems and mild developmental impairments were very common in the 
mUPD7 patients. However, most SRS patients went to a normal school and had a similar 
educational level as their non-SRS peers born SGA. These findings are in contrast with a 
previous study, that found an impairment of cognitive abilities in half of the SRS patients 
(30). That study was, however, conducted before genetic testing for SRS was available 
and patients were compared with healthy controls, instead of short children born SGA. 
In our cohort of SRS patients, there were 2 patients with a congenital heart defect: one 
11p15 patient with an atrial septal defect and 1 clinical SRS patient with a ventricular 
septal defect. Previous literature showed that the prevalence of congenital heart defects 
is increased to 5.5% in SRS patients with an 11p15 aberration, compared with 1% in the 
general population (31). We also found malformations that have not been described in 
association with SRS, such as hearing loss and epilepsy. Renal anomalies in SRS have 
64 Chapter 3
been described (32, 33), but were not present in our study group, and kidney function 
was similar in SRS and non-SRS. Future studies are needed to decide whether there 
is an increased risk for these anomalies in SRS. Overall, although we did not perform 
statistical tests due to the low number of patients in the subgroups, our findings seem 
in concordance with the study of Wakeling et al. (34), who found that 11p15 aberrations 
are associated with more typical SRS features and congenital defects, and mUPD7 with 
an increased prevalence of developmental delay.
Considering that SRS is a rare disorder, our study cohort comprises a relatively large 
group. However, to be able to draw definitive conclusions, larger cohorts are needed. 
Unfortunately, due to the heterogeneous phenotype and the fact that approximately 
40% of the patients remain even nowadays without a genetically confirmed diagnosis, 
underdiagnosis is still a problem. Therefore, developments in finding new (epi)genetic 
causes of SRS (4, 22, 23, 35), advanced molecular testing, and guidelines on how to diag-
nose SRS (6, 18, 36) are valuable to improve awareness and identification of SRS patients.
In conclusion, we showed that there are no metabolic differences between SRS and 
non-SRS subjects born SGA, before, during and after GH treatment. However, a longer 
follow-up of SGA born adults, and SRS patients specifically, is needed to see whether this 
will be maintained over the years when patients reach their 30s and 40s.
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ABStRACt
Context: Silver-Russell syndrome (SRS) is characterized by small for gestational age 
(SGA) birth, postnatal growth failure and several dysmorphic features. Data on puberty 
and gonadal function in SRS are lacking.
Objective: To evaluate pubertal progression and gonadal function in SRS.
Design: A longitudinal study.
Patients: 31 SRS patients (14 males) and 123 non-SRS patients born SGA (65 males). 
All received growth hormone and 27.3% received additional gonadotropin-releasing 
hormone analogue treatment (GnRHa).
Main outcome measures: Pubertal progression, serum levels of inhibin-B, follicle stimu-
lating hormone (FSH), luteinizing hormone (LH), testosterone, anti-Müllerian hormone 
(AMH).
Results: Mean age at onset of puberty was 11.5yrs in SRS males vs. 11.6yrs in non-SRS 
males (p=0.51), and 10.5yrs in SRS females vs. 10.7yrs in non-SRS females (p=0.50). 
Pubertal duration to Tanner stage 5 was similar in SRS and non-SRS. Pubertal height 
gain was better in SRS patients who additionally received GnRHa (p<0.01). Mean age 
at menarche was 13.1yrs in SRS vs. 13.3yrs in non-SRS (p=0.62). One SRS female had 
primary amenorrhea due to Müllerian agenesis. Four of 14 SRS males had a postpubertal 
inhibin-B level below the 5th percentile compared to healthy controls, and two an FSH 
above the 95th percentile, indicating Sertoli cell dysfunction. One of them had a history 
of bilateral cryptorchidism and orchiopexy. All SRS females had AMH, LH and FSH levels 
within the reference range.
Conclusion: Age at onset of puberty and pubertal progression is similar in SRS and non-
SRS subjects born SGA. Sertoli cell dysfunction is more common in SRS males. In SRS 
females, gonadal function does not seem impaired.
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intRoduCtion
Silver-Russell syndrome (SRS) is characterized by small for gestational age (SGA) birth, 
postnatal growth failure, feeding difficulties, and several dysmorphic features (i.e. body 
asymmetry, a triangular face with a prominent forehead and several other minor anoma-
lies) (1-3). Without treatment, mean adult height (AH) is around -4.2 standard deviation 
score (SDS), causing a significant handicap in adulthood. Incidence is estimated as 1 in 
30 000 to 100 000 life-born infants per year. Overall, SRS is probably more common than 
some estimates have suggested, but the exact incidence remains unknown (4). Of all 
SRS cases, 60% are caused by a loss of methylation in the 11p15 region (11p15 LOM) (5), 
and 5-10% by a maternal uniparental disomy of chromosome 7 (mUPD7) (6). In 30-40%, 
the genetic cause is unknown, which is referred to as clinical SRS (4). Nowadays, most 
SRS patients are treated with growth hormone (GH), which is an effective treatment to 
improve AH (7, 8).
Since the majority of adults with SRS are not routinely followed up, there is very little 
information in the literature regarding the natural history of SRS (4, 9). Previous studies 
have found that onset of puberty is usually within the normal range, but at the younger 
end of the spectrum, and that adrenarche can be early and aggressive in comparison 
with children born SGA without SRS (4). However, there are not many data on pubertal 
progression in SRS. Another unresolved issue is whether SRS patients have reproduc-
tive difficulties. Males with SRS have an increased risk for genital abnormalities such as 
cryptorchidism and hypospadias (10-12), which could be associated with reproductive 
problems in later life. In SRS females, an association has been described with Mayer-
Rokitansky-Küster-Hauser syndrome (MRKH), a disorder characterized by hypoplasia or 
aplasia of the uterus and upper part of the vagina (13, 14). However, data on gonadal 
function in SRS are lacking.
In this longitudinal study, we analyzed progression of puberty and gonadal function 
(i.e. serum levels of inhibin B, follicle stimulating hormone (FSH), luteinizing hormone 
(LH), anti-Müllerian hormone (AMH) and testosterone) in SRS patients from childhood 
until early adulthood. AMH is a marker of immature Sertoli cells in males, and of the 
follicle pool size in females (15-17), and inhibin B is a marker of the Sertoli cell function in 
males (18). We compared these data to those of subjects born SGA without SRS, and to 
age-appropriate reference data. We hypothesized that SRS patients would be younger 
at onset of puberty and have a faster pubertal progression than their non-SRS SGA 
counterparts and the healthy reference population. We also hypothesized that gonadal 
function would not be altered in SRS patients without congenital genital anomalies.
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SuBJeCtS And methodS
Subjects
For the present study, we included 31 SRS and 123 non-SRS subjects who participated in 
a large, multicenter GH trial (19, 20). All subjects were born SGA (birth length and/or birth 
weight standard deviation score (SDS) <-2.0 for gestational age (21)), received treatment 
1 mg GH/m2/day (0.035 mg/kg/day) because of persistent short stature (height <-2.5 
SDS (22)), and were prepubertal at onset of GH treatment. Subjects were excluded when 
they had not yet completed puberty, when blood samples were not available, or when 
they had chromosomal abnormalities or signs of a syndrome except SRS.
The diagnosis SRS was based on the Netchine-Harbison clinical scoring system (23), 
which comprises the following six factors: 1) prenatal growth retardation (birth length 
and/or birth weight ≤-2 SDS for gestational age); 2) postnatal growth retardation (height 
<-2.0 SDS according to national reference (22); 3) relative macrocephaly at birth (head 
circumference at birth ≥1.5 SDS above birth length and/or birth weight SDS accord-
ing to Usher and McLean (21); 4) prominent forehead; 5) body asymmetry (leg length 
discrepancy of ≥0.5 cm or arm asymmetry or leg length discrepancy <0.5 cm with ≥2 
other asymmetrical body parts (one being a non-face part)); and 6) feeding difficulties 
during early childhood. Patients were classified as SRS if at least four factors were pres-
ent. SRS patients were tested for 11p15 LOM and mUPD7, and when negative, also for 
CDKN1C and IGF2 mutations as previously described (7). Patients with SRS based on the 
Netchine-Harbison clinical scoring system but without a known genetic aberration were 
classified as clinical SRS.
This study was performed according to the Helsinki Declaration and approved by the 
Medical Ethics Committee of all participating centers. Written informed consent was 
obtained from all participants and/or their parents.
design
From onset of GH treatment until AH attainment, all subjects visited the hospital every 
three months. At each visit, pubertal stage was examined. Blood samples were obtained 
yearly, always between 8.30 and 9.30 a.m..
Serum levels of inhibin B (males) and AMH (males and females) were measured in 
the SRS subjects at three time-points: 1) Prepubertal stage; 2) the first blood sample 
after onset of puberty and 3) postpubertal stage (i.e. a testicular volume (TV) ≥15 ml in 
males and ≥one year post menarche in females). At time-point two and three, we also 
measured serum levels of LH, FSH (males and females) and testosterone (males). For the 
postpubertal blood sample in females, we only used samples that were drawn before 
start of oral contraceptives. All results were compared to those of healthy children and 
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adolescents of the same pubertal stage (17, 18, 24, 25) and with postpubertal results of 
GH-treated age-matched non-SRS subjects born SGA, collected at similar time points.
measurements
Pubertal stage was assessed by an experienced investigator (C.C.J.S and J.S.R) accord-
ing to the method of Tanner (26), at each three-monthly visit. This allowed adequate 
determination of pubertal onset, which was defined as persistent breast development 
stage II according to Tanner for females (M2), and a TV ≥4 ml for males as determined 
by means of the Prader orchidometer. Precocious puberty was defined as pubertal signs 
before age of 8 years in females and 9 years in males (27).
SRS and non-SRS subjects with an AH expectation of less than -2.5 SDS at onset of 
puberty additionally received gonadotropin-releasing hormone analogue treatment 
(GnRHa, leuprolide acetate depots, 3.75 mg sc every four weeks) for two years to post-
pone puberty. A height of less than 140 cm at onset of puberty was used to identify 
children with an AH expectation of less than -2.5 SDS, based on Dutch reference values 
(22). To be certain of central puberty, a GnRHa test was performed before commence-
ment of GnRHa treatment.
AH was defined as the condition when height velocity dropped below 0.5 cm during 
the previous six months and a bone age ≥15 years for females and ≥16.5 years for males. 
Details regarding genital malformations and surgery before the start of GH treatment 
were retrieved from medical records.
Laboratory measurements
After centrifugation, all samples were kept frozen (-80°C) until assayed. All hormone 
concentrations were determined in the Endocrine Laboratory, Dept. of Clinical Chem-
istry, Erasmus UMC. Both serum AMH and inhibin B levels were measured by the Gen II 
ELISA (Beckman Coulter, Inc. Brea, CA, USA). Serum LH and FSH levels were measured by 
immunometric assays (Immulite 2000XPi, Siemens, Los Angeles, CA, USA). Total serum 
testosterone was measured using the liquid chromatography-tandem mass spectrom-
etry (LC-MS-MS) method with the CHS™ MSMS Steroids Kit (Perkin Elmer, Turku, Finland). 
Chromatographic separation and quantification was performed using a Waters® XEVO-
TQ-S system equipped with an electrospray ionization (ESI) source. Inter-assay coef-
ficients of variation were 15.1% for AMH, 11.4% for inhibin B, 6.4% for LH, 5.2% for FSH 
and 6.8% for testosterone, respectively.
Statistics
Analyses were performed with SPSS version 21.0. Shapiro Wilk tests and Normal Q-Q-
plots were used to determine distribution of variables. Differences between SRS and 
non-SRS were analyzed by independent-sample t tests (continuous data) or chi-squared 
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tests (categorical data). Subjects who had also received GnRHa treatment were analyzed 
separately. One-sided t tests were used to compare data with those of healthy refer-
ences. P-values <0.05 were considered statistically significant.
ReSuLtS
Clinical characteristics
Table 1 shows the clinical characteristics of the 31 SRS and 123 non-SRS subjects. Fifteen 
SRS patients had an 11p15 aberration, seven patients an mUPD7 and no patients had 
an IGF2 or CDKN1C mutation. In nine SRS patients, no genetic aberration was found, 
and these subjects were assigned to the clinical SRS group. Four SRS males had crypt-
orchidism during infancy, for which two males underwent orchiopexy. In the other two 
males, the testes descended spontaneously during early childhood.
In SRS males, mean (SD) age at first blood sampling was 5.7 (2.0) years. Age at onset 
of puberty was 11.5 years in SRS vs. 11.6 years in non-SRS males (p=0.51). In 28.6% of 
the SRS males, puberty was postponed by means of two years of GnRHa treatment, vs. 
table 1. Clinical characteristics
  SRS
(n=31)
non-SRS
(n=123)
p-value
males (n, %) 14 (45.2) 65 (52.8)  
Age at first blood sampling (yrs) 5.7 (2.0)    
Molecular diagnosis (n, %)  
      •      11p15 LOM  8 (57.1)     
      •      mUPD7 4 (28.6)    
      •      Clinical 2 (14.3)    
Age at onset of puberty (yrs) 11.5 (0.8) 11.6 (0.8) 0.51
GnRHa (n, %) 4 (28.6) 8 (12.5) 0.13
females (n, %) 17 (54.8) 58 (47.2)  
Age at first blood sampling (yrs) 6.8 (2.8)    
Molecular diagnosis (n, %)   
      •      11p15 LOM  7 (41.2)    
      •      mUPD7 3 (17.6)    
      •      Clinical 7 (41.2)    
Age at onset of puberty (yrs) 10.5 (1.2) 10.7 (1.1) 0.50
GnRHa (n, %) 9 (52.9) 21 (36.2) 0.22
Data expressed as mean (SD) or number (%)
Abbreviations: 11p15 LOM, loss of methylation in 11p15 region; mUPD7, maternal uniparental disomy of 
chromosome 7
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in 12.5% of the non-SRS males (p=0.13). In SRS females, mean (SD) age at first blood 
sampling was 6.8 (2.8) years. Age at onset of puberty was 10.5 years in SRS and 10.7 years 
in non-SRS females (p=0.50). In 52.9% of the SRS females, puberty was postponed by 
means of two years of GnRHa treatment, vs. in 36.2% of the non-SRS females (p=0.22).
Puberty in SRS vs. non-SRS, treated with Gh only
Figure 1 depicts onset and progression of puberty in SRS and non-SRS males and fe-
males. In males treated with GH only, mean (SD) age at onset of puberty was 11.8 (0.8) 
years in both SRS and non-SRS. None of the males had precocious puberty. Progression 
of puberty from TV 4 ml to TV 15 ml lasted 2.5 (0.7) years in SRS, vs. 2.1 (0.8) years in 
non-SRS (p=0.66). The period from TV 15 to AH attainment lasted 2.2 (1.1) years in SRS, 
vs. 2.9 (0.9) years in non-SRS (p=0.07).
In females treated with GH only, mean age at onset of puberty was 11.2 (1.0) years 
in both SRS and non-SRS. Mean age at menarche was 13.1 (1.1) years in SRS, vs. 13.3 
(1.1) years in non-SRS (p=0.62). There was one SRS female with primary amenorrhea due 
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figure 1. duration of puberty in SRS and non-SRS.
Abbreviations: GH, growth hormone; GnRHa, gonadotropin-releasing hormone analogue; M2, breast de-
velopment stage II according to Tanner; TV, testicular volume in ml
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to MRKH. The period from menarche to AH lasted 1.8 (1.1) years in SRS vs. 2.0 (0.8) in 
non-SRS (p=0.61).
Puberty in SRS vs. non-SRS, treated with Gh and two years of GnRha
In males who additionally received two years of GnRHa, mean age at onset of puberty 
was 10.6 (0.6) years in both SRS and non-SRS (Figure 1). The period from restart of pu-
berty after two years of GnRHa to TV 15 ml lasted 2.3 (0.9) years in SRS vs. 1.5 (0.4) years 
in non-SRS (p=0.19). The period from TV 15 to AH attainment lasted 2.6 (1.0) years in SRS 
vs. 2.1 (0.2) years in non-SRS (p=0.53).
In females who were additionally treated with two years of GnRHa, mean (SD) age at 
onset of puberty was 9.8 (0.9) years in SRS, vs. 9.9 (1.0) years in non-SRS (p=0.85). There 
were two SRS females with Tanner stage M2 before the age of eight years. Underlying 
pathology was not found. The period from cessation of GnRHa to menarche lasted 1.3 
(0.6) years in SRS, vs. 1.5 (0.4) years in non-SRS (p=0.29). Mean age at menarche was 13.2 
(1.1) years in SRS, vs. 13.7 (1.1) years in non-SRS (p=0.33). The period from menarche to 
AH attainment lasted 2.1 (0.9) years in SRS, vs. 1.8 (0.6) years in non-SRS (p=0.29).
Pubertal growth in SRS vs. non-SRS, with and without additional GnRha
In males and females who were treated with GH only, pubertal height gain was similar in 
SRS and non-SRS (p=0.12 and p=0.89, respectively (Table 2)). In males and females who 
additionally received two years of GnRHa, total pubertal height gain was similar in SRS 
and non-SRS (p=0.48 and p=0.44 resp.).
table 2. Pubertal growth in SRS and non-SRS
  height at onset of 
puberty (cm)
Ah (cm) Pubertal height 
gain (cm)*
p-value
males        
SRS GH 146.6 (5.1) 169.0 (7.3) 22.4 (5.3) 0.12
non-SRS GH 147.8 (5.1) 172.9 (5.5) 25.2 (5.0)  
SRS GH/GnRHa 135.8 (1.2) 169.5 (3.1) 33.0 (2.0) 0.48
non-SRS GH/GnRHa 139.7 (3.5) 171.6 (6.1) 31.4 (3.4)  
females        
SRS GH 140.4 (7.8) 156.8 (4.6) 16.4 (5.6) 0.89
non-SRS GH 143.2 (5.1) 159.6 (5.2) 16.6 (4.5)  
SRS GH/GnRHa 129.0 (4.7) 156.9 (1.8) 27.8 (5.3) 0.44
non-SRS GH/GnRHa 132.4 (4.7) 158.2 (3.5) 26.1 (4.3)  
Data expressed as mean (SD). p-values represent pubertal height gain in SRS vs. non-SRS.
*Pubertal height gain in GH/GnRHa subjects includes two years of GnRHa treatment.
Abbreviations: GH, growth hormone; GnRHa, gonadotropin-releasing hormone analogue
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In SRS males who were treated with GH only, pubertal height gain was 22.4 cm vs. 33.0 
cm in SRS males who additionally received two years of GnRHa (p=0.008). In SRS females 
who were treated with GH only, pubertal height gain was 16.4 cm, vs. 27.8 cm in SRS 
females who additionally received two years of GnRHa (p=0.004).
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figure 2. Serum levels of inhibin B, fSh, Lh, testosterone and Amh in SRS and non-SRS males
Each black line represents the longitudinal measurements of each SRS male, based on Tanner stage (G1-5) 
at the moment of the measurement. The shaded area with the blue line indicates the median and 5-95th 
percentile per Tanner stage of the healthy population. The red lines indicate the patients with suspected 
Sertoli cell dysfunction. The vertical bar represents the median and 5-95th percentile of the postpubertal 
non-SRS subjects born SGA.
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Longitudinal serum levels of reproductive hormones
Longitudinal serum levels of reproductive hormones in SRS males and females are 
depicted in Figure 2 and 3, respectively. Postpubertal mean levels were similar in SRS 
and non-SRS, except for LH levels of females, which were lower in SRS (Table 3). Four of 
the 14 SRS males (28.6%) had an inhibin B level below the 5th percentile (patients 1-4 in 
Figure 2), indicating Sertoli cell dysfunction. This was a significantly higher proportion 
than in the non-SRS males (7.1%, p=0.02). Two of the SRS males with a low inhibin B 
had also an FSH level above the 95th percentile (patient 1 and 3). One of them, with an 
11p15 LOM, had a history of cryptorchidism, hypospadias and orchiopexy, and had AMH 
levels below the 5th percentile, already from a prepubertal age (patient 3). There was 
also one SRS patient with a low inhibin B level who had a testosterone level below the 
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figure 3. Serum levels of Amh, fSh and 
Lh in SRS and non-SRS females
Each black line represents the longitudinal 
measurements of each SRS female, based 
on Tanner stage (M1-5) at the moment of 
the measurement. The shaded area with the 
pink line indicates the median and 2.5-97.5th 
percentile per Tanner stage of the healthy 
population. The red line indicates the pa-
tient with AMH levels <2.5th percentile. The 
vertical bar represents the median and 5-95th 
percentile of the postpubertal non-SRS sub-
jects born SGA.
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5th percentile (patient 4), but FSH and LH levels were within the normal range. All SRS 
females had AMH, LH and FSH levels within the reference range, with the exception of 
one SRS female, who had a postpubertal AMH level below the 2.5th percentile (patient 
1, Figure 3).
diSCuSSion
This study shows longitudinal data on pubertal progression and gonadal function in 
SRS patients, compared to a large group of non-SRS patients born SGA and to healthy 
controls. We found that onset and progression of puberty are similar in SRS and non-SRS 
subjects born SGA. Sertoli cell dysfunction is more common in males with SRS than non-
SRS. Gonadal function does not seem to be impaired in females with SRS.
The age at onset of puberty was similar in SRS compared to non-SRS subjects born 
SGA. In the recently published consensus statement, it was mentioned that onset of 
puberty in SRS is usually within the normal range, although mostly in the younger age 
of the spectrum (4), which has disadvantages for the eventual AH. In our cohort, the 
proportion of patients treated with GnRHa to postpone puberty was larger in SRS than 
in non-SRS, due to the fact that SRS patients were shorter at onset of puberty. We found 
that SRS patients have the same benefit from additional two years of GnRHa treatment 
as non-SRS patients, with improved height gain from onset of puberty until AH (28). We, 
therefore, suggest to consider additional treatment with two years of GnRHa when SRS 
children have an expected AH below -2.5 SDS at onset of puberty.
table 3. Postpubertal gonadal function in SRS and non-SRS
  SRS
(n=31)
non-SRS
(n=123)
p-value normal 
postpubertal range
males        
Age at blood sampling (yrs) 16.5 (2.5) 16.8 (1.3) 0.74  
Inhibin B (ng/L) 193.5 (140) 218.0 (101.5) 0.25 95-323
FSH (U/L) 4.1 (3.2) 4.9 (3.9) 0.25 1.4-7.5
LH (U/L) 3.6 (1.3) 4.1 (2.1) 0.18 1.5-6.3
Testosterone (nmol/L) 14.4 (14.7) 16.1 (4.4) 0.35 11.3-32.3
AMH (ug/L) 8.5 (6.5) 9.0 (6.3) 0.47 3.2-17.9
females        
Age at blood sampling 15.1 (1.3) 15.4 (1.4) 0.36  
AMH (ug/L) 3.4 (3.5) 3.2 (3.5) 0.64 0.7-8.4
FSH (U/L) 4.4 (4.1) 5.0 (3.0) 0.15 0.2-9.2
LH (U/L) 2.6 (2.2) 3.9 (3.5) <0.001 0.0-20
Data expressed as median (interquartile range). P<0.05 in bold.
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Overall, puberty progressed similarly in SRS and non-SRS. There were two SRS females 
with Tanner stage M2 before the age of eight years. Underlying pathology was not 
found, and after two years of GnRHa treatment, their puberty progressed normally. All 
SRS patients attained an adult Tanner stage. To our knowledge, progression of puberty 
had never been investigated in SRS patients. Our study shows that there seems to be no 
concern for an abnormal pubertal progression in SRS patients. However, we emphasize 
that more research is warranted.
We longitudinally assessed gonadal function from childhood to early adulthood in 
SRS patients and compared these data to those of non-SRS subjects born SGA and to 
those of healthy controls. To our knowledge, our study is the first study that assesses go-
nadal function in SRS patients. More than a quarter of the SRS males had a postpubertal 
inhibin B level below the 5th percentile for healthy references, and two males also had an 
FSH level above the 95th percentile. Our results imply that Sertoli cell dysfunction is more 
common in SRS males. One of the SRS males in our cohort had both Sertoli- and Leydig 
cell dysfunction. He was born with hypospadias and bilateral cryptorchidism, for which 
he underwent orchiopexy. Previous literature has shown that both cryptorchidism and 
orchiopexy are associated with decreased gonadal function (29, 30). In our cohort, four 
of the 14 SRS males had cryptorchidism, for which two underwent orchiopexy. Although 
the exact incidence of genital anomalies in SRS males is unknown, our results are in 
concordance with previous studies, reporting an incidence of cryptorchidism in 19-59% 
of the SRS males (10-12). Interestingly, there were SRS males with a normal gonadal 
function who had a history of cryptorchidism, and on the other hand, three males with 
Sertoli cell dysfunction without a history of cryptorchidism. Thus, more research is war-
ranted to investigate the aetiology of Sertoli cell dysfunction in SRS males. Moreover, 
our data show that Sertoli cell dysfunction should also be evaluated in absence of 
genital anomalies. Larger cohorts with a long follow-up period are needed to confirm 
our findings.
To study gonadal function in females, we only used blood samples that were drawn 
before the start of oral contraceptives. In SRS females, we found that LH levels were 
lower in SRS than in non-SRS. This could be due to the fact that not all blood samples 
were drawn at the same moment during the menstrual cycle. Unfortunately, data on 
menstrual cycle length and possible irregularities were lacking. However, all females 
with SRS had LH, FSH and AMH levels within the reference range. Thus, the follicle 
pool and gonadal function do not seem to be impaired in SRS females, although there 
was one female with clinical SRS with primary amenorrhea due to Müllerian agenesis. 
Previous case-reports have shown an association between SRS and MRKH (12-14, 31). 
In three of these case-reports, the patients had SRS based on 11p15 LOM. In one study, 
describing two SRS patients with MRKH, an association was found between MRKH and 
the severity of H19 hypomethylation (12). However, our patient with MRKH had clinical 
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SRS, similar as the patient in the case-report of Abraham et al. (13). More research is thus 
warranted to establish the aetiology of the association between SRS and MRKH, and to 
investigate whether it is more common in certain SRS subtypes. Since the ovaries are 
unaffected in MRKH, pubertal development and gonadal function are normal in these 
females, and the diagnosis is usually not made before the age of 16 years, after work-
up for primary amenorrhea. Awareness of the association between SRS and MRKH can 
facilitate timely diagnosis. One female in our study had a postpubertal AMH level below 
the 2.5th percentile indicating a low follicle reserve. All other SRS females had an AMH 
level within the normal range. Apart from the association with MRKH and this low AMH 
level in our patient, our results are reassuring regarding gonadal function in females 
with SRS. However, to draw definite conclusions, larger cohorts are needed.
In conclusion, we show that SRS patients have a similar age at onset of puberty and 
pubertal progression as non-SRS subjects born SGA. Although gonadal function is on 
average similar in SRS and non-SRS subjects born SGA and within the normal range, 
disturbances in Sertoli cell function are more common in SRS males. Gonadal function 
does not seem to be impaired in SRS females with normal puberty. There is an associa-
tion with Müllerian agenesis, but larger cohorts are needed to assess the incidence of 
Müllerian agenesis in SRS. Based on our results, we advise clinicians to assess gonadal 
function in SRS patients, also when Tanner stage 5 is achieved, particularly in males.
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ABStRACt
Background: Subjects born preterm have an increased risk for age-associated diseases, 
such as cardiovascular disease in later life, but the underlying causes are largely un-
known. Shorter leukocyte telomere length (LTL), a marker of biological age, is associated 
with increased risk of cardiovascular disease.
Objectives: To compare LTL between subjects born preterm and at term and to assess if 
LTL is associated with other putative cardiovascular risk factors at young adult age.
Methods: We measured mean LTL in 470 young adults. LTL was measured using a quanti-
tative PCR assay and expressed as T/S ratio. We analyzed the influence of gestational age 
on LTL and compared LTL between subjects born preterm (n=186) and at term (n=284). 
Additionally, we analyzed the correlation between LTL and potential risk factors of 
cardiovascular disease.
Results: Gestational age was positively associated with LTL (r = 0.11, p=0.02). Subjects 
born preterm had shorter LTL (mean (SD) T/S ratio = 3.12 (0.44)) than subjects born at 
term (mean (SD) T/S ratio = 3.25 (0.46)), p=0.003). The difference remained significant 
after adjustment for gender and size at birth (p=0.001). There was no association of LTL 
with any one of the putative risk factors analyzed.
Conclusions: Young adults born preterm have shorter LTL than young adults born at 
term. Although we found no correlation between LTL and risk for CVD at this young 
adult age, this biological ageing indicator might contribute to CVD and other adult 
onset diseases at a later age in those born preterm.
Telomere length in young adults born preterm 87
intRoduCtion
Nowadays, 5-13% of all newborns in developed countries are born preterm (i.e. gesta-
tional age <37 weeks) (1). Next to respiratory morbidity and neurodevelopmental im-
pairment, the ex-preterm infant phenotype is also characterized by adverse metabolic 
health in later life (2): Already at a young adult age, ex-preterms have a higher risk for 
age-associated diseases, such as cardiovascular disease (CVD) (3-7) and have increased 
cardiovascular mortality (8). The fetal origin hypothesis states that this increased risk is 
programmed during fetal life and that adverse events during pregnancy lead to repro-
gramming, causing diseases in later adulthood (9). This way, subjects born preterm, who 
have a low birth weight and more stress during early life, could be programmed to a dif-
ferent health outcome in later life (10), but the exact underlying mechanism is unknown. 
Because risk for CVD is age-associated, we hypothesized that accelerated ageing might 
be one of the mechanisms linking preterm birth and higher risk for CVD.
Telomeres are noncoding repetitive DNA sequences at the end of each chromosome. 
Their primary function is to maintain genomic stability (11,12). Due to the inability of 
DNA polymerase to fully replicate the end of the chromosome, telomeres shorten with 
each cell division. When telomeres are reduced to a critical length, the cell enters a state 
of arrest (i.e. cell senescence) (13,14). In population studies, telomere length declines 
with increasing age, which makes leukocyte telomere length (LTL) a usable index for 
biological ageing (13). Also, several studies found correlations between shorter LTL and 
age-associated diseases (15-18).
Studies reporting on the relation between telomere length and preterm birth are scarce 
and contradictive. A small study (n=26) measured LTL in umbilical cords of neonates and 
found no difference between LTL in preterm and full-term controls (19). Henckel et al. 
(20) found shorter telomere length in ex-preterms with bronchopulmonary dysplasia 
at the age of 10 years, suggesting a faster telomere attrition rate in these children. Two 
studies measuring telomere length at an adult age found no differences between ex-
preterms and controls (21,22). Because of the large methodologic differences between 
these studies (i.e. salivary vs. leukocyte telomere length; neonates vs. children vs. adults, 
TRF vs. PCR-based measurements) many gaps remain in the current literature on the 
relation between preterm birth and telomere length. This was also emphasized by a 
recent review on telomere length and preterm birth (2).
We hypothesized that accelerated biological ageing may at least partly explain the 
increased risk of CVD in subjects born preterm and used LTL as an ageing biomarker to 
test this hypothesis. We therefore investigated the correlation between gestational age 
and LTL and analyzed differences in LTL between subjects born preterm and at term. 
Additionally, we assessed if, at the age of 21 years, putative risk factors for later CVD (i.e. 
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body composition, blood pressure, lipid levels, insulin sensitivity and the inflammatory 
biomarker high sensitivity C-reactive protein) correlate with shorter LTL.
mAteRiALS And methodS
Subjects
The study population consisted of 470 healthy individuals, aged 18-24 years (23,24). 
Subjects born preterm (gestational age <37 weeks, n=186) had been admitted to the 
neonatal intensive care unit of the Erasmus University Medical Centre shortly after birth. 
Subjects born at term were randomly selected from hospitals and schools in The Nether-
lands. All participants fulfilled the same inclusion criteria: 1) age 18-24 yr; 2) born single-
ton; 3) Caucasian; 4) uncomplicated neonatal period without signs of severe asphyxia 
(defined as an Apgar score <3 after 5 min), without sepsis or long-term complications 
of respiratory ventilation and/or oxygen supply of 2 weeks during the neonatal period. 
Subjects were excluded if they had been suffering from any serious complication or con-
dition (including necrotizing enterocolitis, intraventricular hemorrhage with a degree of 
three or more, spastic hemiplegia, or quadriplegia), from any disease or if they had an 
endocrine or metabolic disorder, chromosomal defect, syndrome, or serious dysmorphic 
symptoms suggestive for a yet unknown syndrome.
The Medical Ethics Committee of Erasmus Medical Centre approved the study. Written 
informed consent was obtained from all participants.
measurements
Participants were invited to visit the Erasmus University Medical Centre. Prior to the visit, 
participants fasted for at least 12 hours and abstained from smoking and alcohol for at 
least 16 hours. Birth data regarding gestational age and birth size were obtained from 
hospital records, primary health care records and general practitioner records. Informa-
tion regarding socioeconomic status (SES) and smoking of the participants was obtained 
using questionnaires. Education level of the participants was used as socioeconomic 
indicator to determine SES (25). Height was measured to the nearest 0.1 cm (Harpenden 
stadiometer), weight to the nearest 0.1 kg (Servo Balance KA-20-150S). Lean body mass 
and fat mass were measured on one Dual-energy X-ray Absorptiometry (DXA) machine 
(Lunar Prodigy, GE Healthcare, Chalfont St Giles, England). Systolic and diastolic blood 
pressure (SBP and DBP) were measured after 10 minutes at rest, in the sitting position, 
using the non-dominant arm with an automatic device (Accutorr Plus, Datascope Corp, 
Montvale, New Jersey) (26) every five minutes for one hour and the mean value was 
taken to reflect the resting blood pressure. To measure insulin sensitivity (Si), which plays 
an important role in the pathogenesis of Diabetes Mellitus type 2 (DM2), a frequent 
sampled intravenous glucose tolerance (FSIGT) test with Tolbutamide was performed 
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(27). Si quantifies the capacity of insulin to promote glucose disposal and was calculated 
using Bergman’s minimal model (MINMOD 6.01, copyright R.N. Bergman).
Laboratory methods
After centrifugation, all blood samples were kept frozen until assayed (-80°C). For mea-
surement of hsCRP, an important predictor of future atherosclerotic events, an in-house-
high-sensitivity ELISA with polyclonal rat CRP antibodies for catching and tagging 
(DAKO, Denmark) was used. Total cholesterol level was measured using the CHOD-PAP 
and the GPO-PAP reagent kit (Roche Diagnostics, Mannheim, Germany). High-density 
lipoprotein (HDL) cholesterol level was measured using a homogeneous enzymatic 
colorimetric assay (Roche Diagnostics). Low-density lipoprotein (LDL) cholesterol was 
calculated using the Friedewald formula: LDL cholesterol level in mmol/L = total choles-
terol – HDL cholesterol level – 0.45 x level of triglycerides.
LtL assessment
Genomic DNA was isolated from peripheral leukocytes using standard procedures. All 
LTL measurements were made in the same laboratory at the University of Leicester, 
without knowledge of birth status. Mean LTL was measured by the quantitative PCR-
based technique as previously described (28,29). Telomere sequence copy number (T) 
was compared with a single copy gene number in the genome 36B4 (S) and telomere 
length expressed as a T/S ratio. All T and S values were calculated relative to a calibrator 
DNA (genomic DNA from the K562 cell line) that was included on every plate. This al-
lows correction for inter-run variation. For quality control, all samples were checked for 
concordance between duplicate values. Samples showing a difference of greater than 
0.2 cycles in the take-off value or amplifying outside of the linear range of the assay were 
excluded and re-run. Reproducibility of the assay was tested by re-running samples on 
separate days. The mean inter-run CV for the T/S ratio was 3.13%.
Statistical analysis
Standard deviation (SD)-scores for birth length and birth weight were calculated in order 
to correct for gestational age and gender (30). SD-scores for adult height and weight were 
calculated to correct for gender and age (31). SD-scores for blood pressure, fat mass per-
centage and lean body mass were calculated to correct for gender and height. SD-scores 
were calculated using growth analyzer software (http://www.growthanalyser.org).
Baseline characteristics of normally distributed data are presented as mean (SD) and 
of non-normally distributed data as median (interquartile range (IQR)). ANOVA (continu-
ous data) and Chi square tests (categorical data) were used to determine differences be-
tween participants born either preterm or at term. The association between gestational 
age and LTL was determined using multiple linear regression analysis. After assessing 
90 Chapter 5
the linear correlation (Model A), adjustments were made for age, gender, birth length 
SDS, birth weight SDS and adult height SDS (Model B). The interaction term birth length 
SDS * adult height SDS was added to the analysis because the study group had been 
selected on birth length and adult height, in order to ensure that the effect of these 
variables was modeled correctly. Additionally, we adjusted for smoking and SES (Model 
C). Difference in LTL between subjects born preterm and at term was analyzed with an 
independent samples t-test. In an ANCOVA model, we additionally corrected for gender, 
birth length SDS and birth weight SDS. The association between LTL and risk factors of 
CVD was assessed with linear regression, with LTL as dependent variable and the differ-
table 1. Clinical characteristics and risk factors for CVD of the total study population and the subjects born 
preterm and at term
  Total group
(n=470)
Preterm
(n=186)
At Term
(n=284)
p-value
Male/Female 204/266 90/96 114/170 0.08
Age (yrs)1 20.9 (1.7) 20.9 (1.7) 20.9 (1.7) 0.61
Gestational age (wks)1 36.7 (3.9) 32.5 (2.4) 39.4 (1.5) <0.001
Birth weight (SDS)1 -0.97 (1.6) -0.57 (1.9) -1.22 (1.3) <0.001
Birth length (SDS)1 -1.44 (1.6) -1.36 (1.9) -1.49 (1.4) 0.41
Height SDS1 -0.85 (1.3) -0.39 (1.0) -1.13 (1.3) <0.001
Weight SDS1 -0.48 (1.3) -0.23 (1.2) -0.66 (1.4) 0.001
BMI SDS1 0.00 (1.2) 0.01 (1.2) -0.00 (1.1) 0.94
Fat mass % SDS1 0.00 (1.0) 0.30 (1.7) -0.02 (0.9) 0.19
Lean body mass SDS1 -0.48 (1.0) -0.42 (1.1) -0.49 (1.0) 0.76
SBP SDS1 -0.08 (0.7) -0.03 (0.7) -0.12 (0.8) 0.24
DBP SDS1 0.21 (0.5) 0.12 (0.5) 0.29 (0.5) 0.002
TC (mmol/L)1 4.4 (0.9) 4.3 (0.8) 4.5 (1.0) 0.005
HDLc (mmol/L)1 1.4 (0.4) 1.4 (0.3) 1.4 (0.4) 0.49
LDLc (mmol/L)1 2.6 (0.8) 2.5 (0.7) 2.7 (0.9) 0.12
Tg (mmol/L)1 1.0 (0.5) 1.0 (0.5) 1.0 (0.5) 0.47
hsCRP (mg/l)2 1.12 (3.1) 1.24 (3.7) 0.75 (1.6) 0.78
Si * 10-4/min (μU/ml)2 6.32 (6.2) 6.41 (6.4) 5.59 (6.7) 0.13
Smoking (%) 26.8 26.7 27.9 0.53
SES (%) 1 12.4 14.1 11.5  
       2 26.6 30.2 24.5 0.70 
       3 60.9 55.7 64.0   
1Values are given as mean (sd).
2Values are given as median (IQR).
p-values below 0.05 are shown in bold type. Preterm = gestational age <37 wks, at term = gestational age 
>37 wks. BMI = Body mass index; DBP = diastolic blood pressure; HDLc = high-density lipoprotein choles-
terol; hsCRP = C-reactive protein; LDLc =low-density lipoprotein cholesterol; SBP = systolic blood pressure; 
SES = Socioeconomic status; Si = Insulin sensitivity; TC = Total cholesterol; Tg = triglycerides.
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ent risk factors as independent variables. Finally, we assessed if there were differences 
in these risk factors between subjects in the bottom quartile for LTL and subjects in 
the upper quartile for LTL, using independent samples t-tests. Results were considered 
statistically significant if the p-value was <0.05. Statistical package SPSS version 21.0 
(SPSS, Inc., Chicago, IL) was used for all analyses.
ReSuLtS
Characteristics of the study population are shown in Table 1. The total population con-
sisted of 470 subjects with a mean (SD) T/S of 3.20 (0.46). Gestational age varied between 
27 and 43 weeks, with 186 subjects born preterm (gestational age <37 weeks) and 284 
subjects born at term (gestational age >37 weeks). Birth weight SDS, adult height SDS 
and weight SDS were significantly higher in subjects born preterm. Diastolic blood pres-
sure SDS and total cholesterol were significantly lower in subjects born preterm.
variables at birth and at young adult age influencing telomere length
We evaluated the relative contribution of several variables at birth and at young adult 
age to LTL in a multiple regression analysis (Table 2). There was a significant positive 
correlation between gestational age and LTL (Model A, R2 = 0.01, p=0.02). Adding age, 
gender, height SDS, birth weight SDS, birth length and the interaction term birth length 
SDS * adult height SDS to the model (Model B, R2 = 0.04), improved the model and the 
table 2. Multiple regression analysis for variables influencing telomere length in the total study popula-
tion
variables
model A model B model C
ß p ß p ß p
GA (wks) 0.01 0.02 0.02 0.03 0.02 0.04
Age (yrs)     0.02 0.30 0.01 0.46
Female gender     0.16 0.002 0.16 0.003
Adult height SDS     -0.02 0.48 -0.03 0.27
Birth weight SDS     0.01 0.64 0.00 0.95
Birth length SDS     0.01 0.81 0.02 0.50
BL*AH (SDS)     0.00 0.86 0.01 0.56
Smoking         -0.07 0.26
SES         -0.01 0.83
Overall p-value 0.02 0.006 0.008
R² adjusted 0.01 0.04 0.05
p-values below 0.05 are shown in bold type. GA = Gestational age; BL*AH = Interaction term birth length 
* adult height. SES = Socioeconomic status (Low and middle socioeconomic status are used as reference 
for SES analyses).
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correlation between gestational age and LTL remained significant (p=0.03). Also, a posi-
tive association was found between female gender and LTL (p=0.002). Gestational age 
and gender both remained significant after adding smoking and socioeconomic status 
(Model C, R2 = 0.05) to the analysis (p=0.04 and p=0.003, respectively).
telomere length in subjects born preterm versus at term
Figure 1 shows the difference in LTL between subjects born preterm and at term. Un-
adjusted for possible confounders, subjects born preterm had significantly shorter LTL 
than subjects born at term (mean (SD) T/S of 3.12 (0.44) and 3.25 (0.46), respectively, 
p=0.003). This difference remained significant after correction for gender, birth length 
SDS and birth weight SDS (Table 3, p=0.001).
Relationship between telomere length and Cvd and dm2 risk factors
We assessed the relation between LTL and several putative CVD risk factors, including 
insulin sensitivity (Si), at 21 years of age (Table 3). There were no significant associations 
between LTL and these variables. Moreover, these risk factors did not significantly differ 
between subjects in the bottom and upper quartile for LTL (S1 Table).
diSCuSSion
In this study, we analyzed the association between gestational age and LTL in 470 young 
adults and compared LTL between subjects born preterm and at term. We found that 
gestational age is positively associated with LTL and that subjects born preterm have 
shorter LTL than subjects born at term. This difference remained significant after correc-
tion for birth length and birth weight, indicating an independent effect of gestational 
age on LTL, not confounded by birth size. We also found that females had longer telo-
meres than males, which is in concordance with earlier studies (29). At this young age, 
no relation between LTL and other putative risk factors for CVD was found.
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figure 1. Distributions of mean telomere 
lengths in subjects born preterm and at 
term.
T/S ratio = Telomere to single-gene copy ra-
tio; Preterm = gestational age < 37 wks; The 
horizontal bars represent the mean values.
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Thus far, there is limited literature on the association between preterm birth and 
LTL and the results are contradictive. Friedrich et al. (19) measured telomere length in 
umbilical cords of neonates and found no relation between preterm birth and telomere 
table 3. Relation of telomere length with preterm birth and cardiovascular risk factors
 
 
telomere length
ß p
Preterm -0.13 0.003
Preterm adjusted1 -0.15 0.001
SBP SDS -0.01 0.79
DBP SDS -0.00 0.99
Fat mass % SDS 0.02 0.58
Lean body mass SDS -0.04 0.13
TC (mmol/l) 0.04 0.09
LDLc (mmol/l) 0.04 0.26
HDLc (mmol/l) -0.01 0.90
Tg (mmol/l) 0.05 0.31
hsCRP (mg/l) 0.00 0.95
Si * 10-4/min (μU/ml) 0.00 0.54
p-values below 0.05 are shown in bold type. ß coefficients equate to the difference in telomere length per 
unit change in the variable. DBP = diastolic blood pressure; HDLc =high-density lipoprotein cholesterol; 
hsCRP = C-reactive protein; LDLc = low-density lipoprotein cholesterol; SBP = systolic blood pressure; Si = 
Insulin sensitivity; TC = Total cholesterol; Tg = triglycerides. The variable preterm equates to the difference 
between subjects born preterm and the reference group subjects born at term. 1 = Adjusted for gender, 
birth weight SDS and birth length SDS.
S1 table. Difference in cardiovascular risk factors between highest and lowest quartile telomere length
  Lowest quartile LtL highest quartile LtL p-value
SBP SDS -0.02 (0.7) -0.08 (0.8) 0.58
DBP SDS 0.20 (0.5) 0.21 (0.6) 0.93
Fat mass % SDS 0.10 (1.1) 0.19 (1.1) 0.63
Lean body mass SDS -0.61 (1.0) -0.82 (0.9) 0.17
TC (mmol/l) 4.38 (0.9) 4.57 (0.9) 0.12
LDLc (mmol/l) 2.55 (0.7) 2.64 (0.7) 0.37
HDLc (mmol/l) 1.38 (0.4) 1.38 (0.4) 0.96
Tg (mmol/l) 0.99 (0.6) 1.06 (0.5) 0.33
hsCRP (mg/l) 5.11 (7.4) 4.43 (7.2) 0.53
Si * 10-4/min (μU/ml) 6.72 (3.8) 7.72 (6.1) 0.28
Values are given as mean (sd). DBP = diastolic blood pressure; HDLc = high-density lipoprotein cholesterol; 
hsCRP = C-reactive protein; LDLc = low-density lipoprotein cholesterol; SBP = systolic blood pressure; Si = 
Insulin sensitivity; TC = Total cholesterol; Tg = triglycerides.
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length. Although this study provides valuable insights on telomere length at birth, it 
lacks data on telomere length at a later age and had a very small sample size (n=26). 
Henckel et al. (20) measured telomere length in children at the age of 10 and found 
that ex-preterm children with bronchopulmonary dysplasia had shorter telomeres than 
at term children with asthma, suggesting a faster telomere attrition in preterm infants, 
already present at the age of 10 years old. However, these results are difficult to com-
pare to ours as children with asthma or bronchopulmonary dysplasia comprise a very 
different study population. A recent study of Hadchouel et al. (21) found a correlation 
between telomere length and abnormal airflow in adolescents born extremely preterm. 
However, there was no association found between telomere length and gestational age 
or perinatal events, suggesting that preterm birth per se is not a risk factor for shortening 
of telomeres. In contrast to our study, telomere length was measured in saliva in that 
study, which questions the comparability of their results to our findings. Kajantie et al. 
(22) described the relation between several birth factors and adult LTL. In contrast to our 
study, no correlation was found between preterm birth and LTL. One of the reasons for 
the different results could be that the percentage of preterms was very low compared to 
those born at term (5.9%).
Previous studies have highlighted oxidative stress as an important determinant of LTL 
(32,33) and showed that intrauterine stress causes shorter LTL (34-36). Since pregnancies 
resulting in preterm birth are often accompanied by increased stress exposure (37) and 
preterm born infants are frequently exposed to stressful events, we think it is plausible 
that oxidative stress is one of the explanations for the difference in LTL between those 
born preterm and at term. Other determinants of LTL are replicative stress and genetic 
factors (38). Most preterm born infants go through a phase of slow postnatal growth due 
to feeding problems, followed by a phase of accelerated growth (i.e. catch-up growth) 
mostly from term age onwards. Since catch-up growth can induce replicative stress, 
preterms could be exposed to increased replicative stress, causing shorter telomeres. 
To analyze this, we added both birth length SDS and adult height SDS to the multiple 
regression analysis, indicating the change in height SDS during childhood. If catch-up 
growth influences LTL, we would have expected a significant association between the 
change in height SDS during childhood and LTL. Because we did not find this, we think 
that replicative stress does not explain the findings in our study. This is in concordance 
with previous studies (22,39). To our knowledge, there is no reason to believe that par-
ents of preterm infants have shorter LTL than those of term infants and we thus do not 
consider genetic factors to be the cause for the difference in LTL between preterms and 
terms. A future study that measures LTL and oxidative stress biomarkers during fetal and 
early postnatal life and, subsequently at a later age, would be a good way to evaluate if 
increased perinatal oxidative stress is indeed the mechanism behind shorter LTL in those 
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born preterm. Ideally, LTL would be measured in parents too, to analyze the influence of 
genetic factors.
To provide a more meaningful context in terms of kilobases for the observed differ-
ence in T/S ratio between those born preterm and those born at term, we used data 
from a previous study from the same laboratory where a comparison had been made 
between LTL measured by PCR and in kilobases by Southern blotting (40,41). On this 
basis, a difference in T/S ratio of 0.13 equates to approximately 180 base pairs. Since age-
related decline in LTL has been reported to be between 15 and 35 base pairs per year 
(15,18,41,42) the difference of 180 base pairs equates to approximately 5 to 12 years. 
This might suggest that young adults born preterm are 5-12 biological years older than 
young adults born at term with a comparable calendar age. However, since this conver-
sion is based on data of a previous study, we have to be cautious with drawing definitive 
conclusions from this calculation. Because longitudinal telomere length measurements 
were lacking and all participants had the same age, we were unable to calculate the 
mean telomere attrition rate per year in our cohort. Therefore, we cannot take inter-
individual telomere attrition rates into account. Previous studies showed that telomere 
attrition rates vary at different ages, with the most rapid loss early in life, followed by a 
plateau between age 3-4 and young adulthood, and gradual attrition later in life (43-45). 
Since the participants of our study had a comparable calendar age, the conversion from 
base pairs to years was not influenced by this.
Previously, we have shown that several putative risk factors for CVD are already 
increased at a young age in subjects born preterm (3,4). We therefore investigated 
whether there was an association between LTL and these risk factors. However, in these 
young adults, correlations between LTL and risk factors for CVD were not found. This is 
in concordance with earlier studies, indicating that the association between LTL and 
CVD is independent of risk factors for CVD, including markers of inflammation (15,40,41). 
Although we found no correlation between LTL and risk for CVD at this young adult 
age, we think that this biological ageing indicator may contribute to CVD and other 
adult onset diseases at a later age in those born preterm. It would therefore be very 
interesting to analyze how LTL and CVD progress over time when these young adults 
reach their 30s and 40s.
In conclusion, our data show that gestational age is positively correlated with LTL and 
that young adults born preterm have shorter LTL than young adults born at term. This 
could reflect pre- and postnatal oxidative stress and in turn could partly explain the 
association between preterm birth and later life risk of CVD. Since the prevalence of 
preterm birth and survival is rapidly increasing, our results are of clinical relevance for a 
large and increasing number of subjects worldwide.
96 Chapter 5
RefeRenCeS
 1. Goldenberg RL, Culhane JF, Iams JD, Romero R (2008) Preterm birth 1 - Epidemiology and causes 
of preterm birth. Lancet 371: 75-84.
 2. Turner KJ, Vasu V, Greenall J, Griffin DK (2014) Telomere length analysis and preterm infant health: 
the importance of assay design in the search for novel biomarkers. Biomarkers in Medicine 8: 
485-498.
 3. Kerkhof GF, Breukhoven PE, Leunissen RWJ, Willemsen RH, Hokken-Koelega ACS (2012) Does 
Preterm Birth Influence Cardiovascular Risk in Early Adulthood? Journal of Pediatrics 161: 390-+.
 4. Breukhoven PE, Kerkhof GF, Willemsen RH, Hokken-Koelega ACS (2012) Fat Mass and Lipid Profile 
in Young Adults Born Preterm. Journal of Clinical Endocrinology & Metabolism 97: 1294-1302.
 5. Tinnion R, Gillone J, Cheetham T, Embleton N (2014) Preterm birth and subsequent insulin sensi-
tivity: a systematic review. Archives of Disease in Childhood 99: 362-368.
 6. Evensen KAI, Steinshamn S, Tjonna AE, Stolen T, Hoydal MA, et al. (2009) Effects of preterm birth 
and fetal growth retardation on cardiovascular risk factors in young adulthood. Early Human 
Development 85: 239-245.
 7. Sipola-Leppanen M, Vaarasmaki M, Tikanmaki M, Hovi P, Miettola S, et al. (2014) Cardiovascular 
Risk Factors in Adolescents Born Preterm. Pediatrics 134: E1072-E1081.
 8. Crump C, Sundquist K, Sundquist J, Winkleby MA (2011) Gestational Age at Birth and Mortality in 
Young Adulthood. Jama-Journal of the American Medical Association 306: 1233-1240.
 9. Barker DJP (1995) Fetal Origins of Coronary Heart-Disease. British Medical Journal 311: 171-174.
 10. Nilsson PM, Lurbe E, Laurent S (2008) The early life origins of vascular ageing and cardiovascular 
risk: the EVA syndrome. Journal of Hypertension 26: 1049-1057.
 11. Chan SRWL, Blackburn EH (2004) Telomeres and telomerase. Philosophical Transactions of the 
Royal Society of London Series B-Biological Sciences 359: 109-121.
 12. Blasco MA (2005) Telomeres and human disease: Ageing, cancer and beyond. Nature Reviews 
Genetics 6: 611-622.
 13. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, et al. (1994) Evidence for a Mitotic 
Clock in Human Hematopoietic Stem-Cells - Loss of Telomeric DNA with Age. Proceedings of the 
National Academy of Sciences of the United States of America 91: 9857-9860.
 14. Allsopp RC, Harley CB (1995) Evidence for a Critical Telomere Length in Senescent Human Fibro-
blasts. Experimental Cell Research 219: 130-136.
 15. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ (2003) White cell telomere length 
and risk of premature myocardial infarction. European Heart Journal 24: 121-121.
 16. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA (2003) Association between telomere 
length in blood and mortality in people aged 60 years or older. Lancet 361: 393-395.
 17. Minamino T, Komuro I (2002) Role of telomere in endothelial dysfunction in atherosclerosis. Cur-
rent Opinion in Lipidology 13: 537-543.
 18. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH (2001) Telomere shortening in athero-
sclerosis. Lancet 358: 472-473.
 19. Friedrich U, Schwab M, Griese EU, Fritz P, Klotz U (2001) Telomeres in neonates: new insights in 
fetal hematopoiesis. Pediatr Res 49: 252-256.
 20. Henckel E, Brostrom EB, Hedlin G, Roos G, Bohlin K (2011) Prematurity and Lung Function in 
Relation to Telomere Length and Inflammation in 10-Year Old Children. Pediatric Research 70: 
136-136.
Telomere length in young adults born preterm 97
 21. Hadchouel A, Marchand-Martin L, Franco-Montoya ML, Peaudecerf L, Ancel PY, et al. (2015) 
Salivary Telomere Length and Lung Function in Adolescents Born Very Preterm: A Prospective 
Multicenter Study. PLoS One 10.
 22. Kajantie E, Pietilainen KH, Wehkalampi K, Kananen L, Raikkonen K, et al. (2012) No association 
between body size at birth and leucocyte telomere length in adult life--evidence from three 
cohort studies. Int J Epidemiol 41: 1400-1408.
 23. Kerkhof GF, Leunissen RWJ, Willemsen RH, de Jong FH, Stijnen T, et al. (2009) Influence of Preterm 
Birth and Birth Size on Gonadal Function in Young Men. Journal of Clinical Endocrinology & 
Metabolism 94: 4243-4250.
 24. Leunissen RWJ, Kerkhof GF, Stijnen T, Hokken-Koelega A (2009) Timing and Tempo of First-Year 
Rapid Growth in Relation to Cardiovascular and Metabolic Risk Profile in Early Adulthood. Jama-
Journal of the American Medical Association 301: 2234-2242.
 25. CentraalBureauStatistiek (2006) Dutch standard classification of education. In: Statistiek CBvd, 
editor. Heerlen, the Netherlands.
 26. Anwar YA, Tendler BE, McCabe EJ, Mansoor GA, White WB (1997) Evaluation of the Datascope 
Accutorr Plus according to the recommendations of the Association for the Advancement of 
Medical Instrumentation. Blood Press Monit 2: 105-110.
 27. Pacini G, Bergman RN (1986) Minmod - a Computer-Program to Calculate Insulin Sensitivity 
and Pancreatic Responsivity from the Frequently Sampled Intravenous Glucose-Tolerance Test. 
Computer Methods and Programs in Biomedicine 23: 113-122.
 28. Cawthon RM (2002) Telomere measurement by quantitative PCR. Nucleic Acids Research 30.
 29. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, et al. (2013) Identification of seven loci affect-
ing mean telomere length and their association with disease. Nature Genetics 45: 422-427.
 30. Usher R, McLean F (1969) Intrauterine growth of live-born Caucasian infants at sea level: stan-
dards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of 
gestation. J Pediatr 74: 901-910.
 31. Fredriks AM, Van Buuren S, Burgmeijer RJF, Meulmeester JF, Beuker RJ, et al. (2000) Continuing 
positive secular growth change in the Netherlands 1955-1997. Pediatric Research 47: 316-323.
 32. Oikawa S, Kawanishi S (1999) Site-specific DNA damage at GGG sequence by oxidative stress may 
accelerate telomere shortening. Febs Letters 453: 365-368.
 33. von Zglinicki T (2002) Oxidative stress shortens telomeres. Trends Biochem Sci 27: 339-344.
 34. Entringer S, Epel ES, Kumsta R, Lin J, Hellhammer DH, et al. (2011) Stress exposure in intrauterine 
life is associated with shorter telomere length in young adulthood. Proc Natl Acad Sci U S A 108: 
E513-518.
 35. Entringer S, Epel ES, Lin J, Buss C, Shahbaba B, et al. (2013) Maternal psychosocial stress during 
pregnancy is associated with newborn leukocyte telomere length. Am J Obstet Gynecol 208: 134 
e131-137.
 36. Menon R, Yu J, Basanta-Henry P, Brou L, Berga SL, et al. (2012) Short Fetal Leukocyte Telomere 
Length and Preterm Prelabor Rupture of the Membranes. PLoS One 7.
 37. Marseglia L, D’Angelo G, Manti S, Arrigo T, Barberi I, et al. (2014) Oxidative Stress-Mediated Aging 
during the Fetal and Perinatal Periods. Oxidative Medicine and Cellular Longevity.
 38. Samani NJ, van der Harst P (2008) Biological ageing and cardiovascular disease. Heart 94: 537-
539.
 39. Laganovic M, Bendix L, Rubelj I, Kirhmajer MV, Slade N, et al. (2014) Reduced telomere length is 
not associated with early signs of vascular aging in young men born after intrauterine growth 
restriction: a paradox? Journal of Hypertension 32: 1613-1620.
98 Chapter 5
 40. Mukherjee M, Brouilette S, Stevens S, Shetty KR, Samani NJ (2009) Association of shorter telo-
meres with coronary artery disease in Indian subjects. Heart 95: 669-U106.
 41. Brouilette SW, Moore JS, D McMahon A, Thompson JR, Ford I, et al. (2007) Telomere length, risk of 
coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a 
nested case-control study. Lancet 369: 107-114.
 42. Brouilette SW, Whittaker A, Stevens SE, van der Harst P, Goodall AH, et al. (2008) Telomere length is 
shorter in healthy offspring of individuals with coronary artery disease: support for the telomere 
hypothesis. Heart 94: A58-A58.
 43. Frenck RW, Blackburn EH, Shannon KM (1998) The rate of telomere sequence loss in human 
leukocytes varies with age. Proceedings of the National Academy of Sciences of the United States 
of America 95: 5607-5610.
 44. Lansdorp PM (2008) Telomeres, stem cells, and hematology. Blood 111: 1759-1766.
 45. Zeichner SL, Palumbo P, Feng YR, Xiao XD, Gee D, et al. (1999) Rapid telomere shortening in 
children. Blood 93: 2824-2830.

 Chapter 6
Eﬀ ects of Size at Birth, 
Childhood Growth Patterns 
and Growth Hormone 
Treatment on Leukocyte 
Telomere Length
C.C.J. Smeets
V. Codd
M. Denniff 
N.J. Samani
A.C.S. Hokken-Koelega
PLoS One. 2017 Feb 8;12(2):e0171825
102 Chapter 6
ABStRACt
Background: Small size at birth and rapid growth in early life are associated with increased 
risk of cardiovascular disease in later life. Short children born small for gestational age 
(SGA) are treated with growth hormone (GH), inducing catch-up in length. Leukocyte 
telomere length (LTL) is a marker of biological age and shorter LTL is associated with 
increased risk of cardiovascular disease.
Objectives: To investigate whether LTL is influenced by birth size, childhood growth and 
long-term GH treatment.
Methods: We analyzed LTL in 545 young adults with differences in birth size and child-
hood growth patterns. Previously GH-treated young adults born SGA (SGA-GH) were 
compared to untreated short SGA (SGA-S), SGA with spontaneous catch-up to a normal 
body size (SGA-CU), and appropriate for gestational age with a normal body size (AGA-
NS). LTL was measured using a quantitative PCR assay.
Results: We found a positive association between birth length and LTL (p=0.04), and a 
trend toward a positive association between birth weight and LTL (p=0.08), after adjust-
ments for gender, age, gestational age and adult body size. Weight gain during infancy 
and childhood and fat mass percentage were not associated with LTL. Female gender 
and gestational age were positively associated with LTL, and smoking negatively. After 
adjustments for gender, age and gestational age, SGA-GH had a similar LTL as SGA-S 
(p=0.11), SGA-CU (p=0.80), and AGA-NS (p=0.30).
Conclusions: Larger size at birth is positively associated with LTL in young adulthood. 
Growth patterns during infancy and childhood are not associated with LTL. Previously 
GH-treated young adults born SGA have similar LTL as untreated short SGA, SGA with 
spontaneous catch-up and AGA born controls, indicating no adverse effects of GH-
induced catch-up in height on LTL.
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intRoduCtion
Small size at birth and catch-up in weight for length in early life are associated with an 
increased risk for cardiovascular disease (CVD) in later life (1-3). The mechanisms under-
lying these associations are not fully understood, but it appears that early life growth 
trajectories have programming effects on later health outcomes (4,5). Ten percent of 
all children born small for gestational age (SGA) show insufficient catch-up growth and 
remain short (6). These children can nowadays be treated with growth hormone (GH) 
from the age of four years, resulting in a significant catch-up in length (7). GH treatment 
has several positive effects on metabolic health, but the long-term effects on later life 
health are less known (8). Previous studies have suggested that shorter, smaller bodies 
have advantages in terms of health and longevity (9,10).
Telomeres are noncoding repeating DNA sequences at the end of each chromosome. 
Their primary function is to maintain genomic stability (11,12). Telomeres shorten with 
each cell division due to the inability of DNA polymerase to fully replicate the end of the 
chromosome. When telomeres are reduced to a critical length, the cell enters a state of 
arrest (13). Since leukocyte telomere length (LTL) declines with increasing age, it can 
serve as an index for biological ageing. LTL is influenced by oxidative and replicative 
stress, and shorter LTL is associated with increased risk for CVD (14,15).
In this study, we investigated whether size at birth, growth patterns during infancy 
and childhood, and GH treatment influence LTL of young adults. We hypothesized that 
small size at birth and accelerated weight gain during infancy lead to shorter LTL. We 
also hypothesized that the gradual catch-up in length caused by GH treatment does 
not lead to increased attrition of telomeres and thus does not influence LTL. To address 
the fact that those born SGA have an already increased risk for CVD, we compared the 
data of previously GH-treated young adults born SGA with untreated short young adults 
born SGA. To study whether GH-induced catch-up growth has a similar effect on LTL as 
spontaneous catch-up after SGA birth, we also compared the GH-treated group to a 
group of young adults born SGA with spontaneous catch-up (SGA-CU).
methodS
Subjects
The total population consisted of 545 participants: 470 healthy participants from the 
PROGRAM and PREMS study cohorts (2,16), and 75 age-matched participants who had 
participated in a GH trial (8,17). The 470 healthy participants fulfilled the same inclusion 
criteria: 1) age 17-24 yr; 2) born singleton; 3) Caucasian; 4) uncomplicated neonatal pe-
riod without severe asphyxia (defined as an Apgar score below three after five minutes), 
sepsis, or long-term complications of respiratory ventilation and/or oxygen supply. 
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Participants were randomly selected from hospitals in the Netherlands, where they had 
been registered because of their small size at birth (birth length <-2 standard deviation 
score (SDS)), short stature (adult height <-2 SDS) or being born preterm (gestational 
age <36 weeks). Young adults born appropriate for gestational age (AGA) were asked to 
participate via advertisements at schools with different educational levels. For the last 
analysis, we additionally included the 75 GH-treated subjects. All subjects were born SGA 
(birth weight and/or birth length <-2 SDS) and received GH treatment during childhood 
because of their short stature, for ≥7 years. All participants received biosynthetic GH at a 
dose of 1 mg/m2/day (0.035 mg/kg/d), sc at bedtime. Every three months, GH dose was 
adjusted to the calculated body surface area. The data of the GH group were compared 
to those of three subgroups based on their size at birth and their adult stature: untreated 
young adults born SGA (birth length <-2 SDS) with persistent short stature (adult height 
<-2 SDS) (SGA-S, n=48); young adults born SGA (birth length <-2 SDS) with spontane-
ous catch-up growth resulting in a normal adult height (>-1 SDS) (SGA-CU, n=89); and 
young adults born appropriate for gestational age with a normal adult height (>-1 SDS) 
(AGA-NS, n=135). In order to increase the statistical power for subgroup comparison, the 
cut-off values for small birth size and short adult height were set at <-2 SDS, and the 
cut-off-values for normal birth size and normal adult height were set at >-1 SDS.
This study was conducted according to the Helsinki Declaration. The Medical Ethics 
Committee of Erasmus Medical Centre approved the study. Written informed consent 
was obtained from all participants and/or their parents.
measurements
Birth data were obtained from hospital records, primary health care records and gen-
eral practitioner records. Height was measured to the nearest 0.1 cm by a Harpenden 
stadiometer, weight to the nearest 0.1 kg by a scale (Servo Balance KA-20-150S). All 
anthropometric measurements were performed by a trained investigator, according to 
standardized methods. The measurements were performed twice, the mean value was 
used for analyses. Fat mass, fat mass percentage and lean body mass were measured 
on one Dual-energy X-ray Absorptiometry (DXA) machine (Lunar Prodigy, GE Health-
care, Chalfont St Giles, England) (18). Quality control was performed daily. Information 
regarding socioeconomic status (SES) based on education level, and smoking of the 
participants was obtained using questionnaires (19).
LtL assessment
Genomic DNA was isolated from peripheral leukocytes using standard procedures. All 
LTL measurements were performed in the laboratory of the University of Leicester, using 
the quantitative PCR-based technique as previously described (20). Telomere sequence 
copy number (T) was compared with a single copy gene number in the genome 36B4 (S) 
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and telomere length expressed as a T/S ratio. All T and S values were calculated relative 
to a calibrator DNA (genomic DNA from the K562 cell line) that was included on every 
plate, minimizing the potential for inter-run variation. All samples were checked for 
concordance between duplicate values. Samples showing a difference of greater than 
0.2 cycles in the take-off value or amplifying outside of the linear range of the assay were 
excluded and re-run. Reproducibility of the assay was tested by re-running samples on 
separate days. The mean inter-run coefficient of variation for the T/S ratio was 3.33%.
Calculations and statistical analysis
Standard deviation scores (SDS) for birth length and birth weight were calculated in or-
der to correct for gender and gestational age, and SDS for adult height and weight were 
calculated to correct for gender and age (21), all using the growth analyzer software 
(http://www.growthanalyser.org). Fat mass percentage SDS was calculated according to 
age- and sex-matched Dutch reference values (22). Because lean body mass is strongly 
related to height, lean body mass was expressed as SDS for height and sex (22).
Means and SD were used to describe the distribution of continuous variables. Multiple 
linear regression analyses were performed to determine whether size at birth (i.e. birth 
length and birth weight) and childhood growth patterns (i.e. the degree of catch-up in 
length and weight from birth to adulthood) were significant predictors of LTL. Because 
of collinearity between birth weight and birth length, these variables were analyzed in 
separate models. Adjustments were made for age and gender, and additionally for ges-
tational age, body composition, smoking and SES. Because the study group had been 
selected on birth length and adult height, the interaction term birth length SDS*adult 
height SDS was added to the analysis, in order to ensure that the effect of these variables 
was modeled correctly.
Quartiles of weight gain during the first 12 months of life were determined in the total 
group, except for the GH-treated subjects and for men and women separately. ANCOVA 
was used to determine differences in LTL between the lowest and highest quartile, cor-
rected for age and gestational age. Lastly, we analyzed whether there were differences 
in LTL between the SGA-GH subgroup and the SGA-S, SGA-CU and AGA subgroups. In 
this analysis, we additionally adjusted for age, gender and gestational age. Results were 
considered statistically significant if the p-value was <0.05. Statistical package SPSS ver-
sion 21.0 (SPSS, Inc., Chicago, IL) was used for all analyses.
ReSuLtS
Clinical characteristics of the total study population (n=470), and for men and women 
separately are shown in Table 1. Mean (SD) age of the total population was 20.9 (1.7) 
years. Mean (SD) lean body mass SDS was higher in men than in women (-0.12 (1.1) 
106 Chapter 6
versus -0.62 (1.3), resp.; p<0.001). The other clinical characteristics were similar in men 
and women. Mean (SD) LTL was shorter in men than in women (p=0.02).
factors associated with LtL in the total group
We analyzed the effects of size at birth and postnatal growth on LTL in a multiple regres-
sion analysis. First, birth length was analyzed (Table 2). As expected, female gender was 
positively associated with LTL (p=0.004). Age was not a significant confounder of LTL 
in our analyses, probably because of the fact that most subjects in our study popula-
tion had approximately the same age. In Model A, birth length SDS did not predict LTL 
(p=0.36). In Model B, we added gestational age to the model, which proved to be a 
significant predictor of LTL (β=0.02, p=0.002). In Model C, we added adult height and the 
interaction term birth length SDS*adult height SDS to the model. In this model, there 
was a trend toward a positive relation between birth length and LTL (β=0.03, p=0.06). 
Adult height was not associated with LTL, and since birth length was included in the 
model, this shows us that gain in height from birth to adulthood does not predict LTL. 
Then, parameters of body composition were added to the model (Model D), showing a 
trend toward a positive relation between LBM SDS and LTL (β=0.04, p=0.06). The relation 
between birth length and LTL was still close to significant in this model (p=0.08). Finally, 
we included the possible confounders smoking and SES in the model (Model E), show-
table 1. Clinical characteristics
  total group
(n=470)
men
(n=204)
women
(n=266)
p-value
Age (yrs) 20.9 (1.7) 21.0 (1.7) 20.8 (1.7) 0.29
Gestational age (wks) 36.7 (3.9) 36.3 (4.0) 37.0 (3.7) 0.06
Birth weight SDS -0.97 (1.6) -0.83 (1.7) -1.07 (1.5) 0.10
Birth length SDS -1.43 (1.6) -1.33 (1.6) -1.52 (1.6) 0.22
Adult height SDS -0.85 (1.3) -0.86 (1.2) -0.85 (1.3) 0.94
Adult weight SDS -0.52 (1.4) -0.57 (1.3) -0.49 (1.4) 0.55
BMI 22.5 (3.7) 22.3 (3.2) 22.6 (4.0) 0.36
Fat mass % SDS 0.62 (0.9) 0.63 (0.9) 0.62 (0.9) 0.89
Lean body mass SDS -0.41 (1.2) -0.12 (1.1) -0.62 (1.3) <0.001
Smoking (%) 27.5 29.5 25.9 0.39
SES (%) 1 12.4 13.5 11.7  
       2 26.6 27.5 26.0 0.78
       3 60.9 59.1 62.3  
LTL 3.20 (0.5) 3.14 (0.4) 3.24 (0.5) 0.02
Values are given as means (SD). P-values <0.05 are shown in bold. BMI = body mass index; LTL = Leukocyte 
Telomere Length (in T/S ratio); SES = socioeconomic status
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ing an inverse association between smoking and LTL (ß -0.12, p=0.03). In this last model, 
gender, gestational age and birth length SDS were all positive predictors of LTL.
The same models were used to analyze the relation between birth weight and LTL 
(Table 3). Instead of height SDS, we included weight SDS to the model, to analyze the 
influence of weight gain from birth to adulthood. Regarding the variables gender, age, 
gestational age, LBM and smoking, this analysis showed similar results, except that 
LBM was a significant predictor of LTL. There was a (trend toward a) significant positive 
relation between birth weight and LTL in all models. Weight SDS was not a significant 
predictor of LTL. Since birth weight was included in this model, this shows us that weight 
gain from birth to adulthood does not predict LTL. Due to the high collinearity between 
weight and FM%, weight was excluded in Model D. In the final model, there was still a 
trend toward a positive relation between birth weight SDS and LTL (ß=0.02, p=0.08).
effects of weight gain and fat mass accumulation during infancy on LtL
We analyzed the effect of weight gain and fat mass accumulation during the first 12 
months of life on LTL. We found no significant correlation between weight gain in the 
first 12 months of life and LTL (r= -0.08, p=0.15). Subsequently, we stratified the popula-
tion into quartiles based on weight gain in kg and Δweight (kg)/Δlength (cm) during 
the first 12 months of life. Figure 1 shows LTL of the total group and men and women 
separately, adjusted for age and gestational age.
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figure 1. weight gain and fat mass accumulation during infancy and LtL. Values are given as esti-
mated means ± SEM, adjusted for age and gestational age.
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The weight gain analyses showed no difference in LTL between the lowest and highest 
quartile of weight gain during the first 12 months of life in the total population (p=0.51), 
in men (p=0.91) and women (p=0.97). The analyses for Δweight/Δlength during the first 
12 months of life neither showed significant differences in LTL between the lowest and 
highest quartile in the total population (p=0.31) and in men (p=0.99), and there was a 
trend toward longer LTL in women with the highest Δweight/Δlength (p=0.06), indicat-
ing no negative effect of fat mass accumulation during the first 12 months of life on LTL 
in early adulthood.
effects of growth hormone treatment on LtL
The effect of long-term GH treatment on LTL was analyzed by comparing LTL between 
subjects born SGA and treated with GH (SGA-GH) versus age-matched untreated short 
subjects born SGA (SGA-S), subjects born SGA with spontaneous catch-up during child-
hood (SGA-CU), and AGA born controls with a normal adult stature (AGA-NS). Clinical 
table 4. Clinical characteristics of the subgroups
  SGA-Gh 
(n=75)
SGA-S
(n=48)
SGA-Cu
(n=89)
AGA-nS
(n=135)
Male/female 42/331,2 16/32 35/54 64/71
Age (yrs) 20.2 (2.4)2 20.8 (1.8) 20.9 (1.6) 20.8 (1.7)
Gestational age (wks) 36.2 (4.0)1 38.2 (3.1) 36.3 (3.2) 36.3 (4.0)
Birth weight SDS -2.44 (1.2)3 -2.07 (0.9) -2.31 (0.8) 0.29 (1.3)
Birth length SDS -3.42 (1.5)2,3 -3.05 (0.9) -2.93 (0.8) 0.22 (0.8)
Adult height SDS -1.42 (0.8)1,2,3 -2.55 (0.5) -0.17 (0.6) 0.18 (0.8)
Adult weight SDS -1.01 (1.3)2,3 -1.44 (1.5) 0.08 (1.2) 0.09 (1.0)
BMI 20.5 (2.7)1,2,3 23.3 (4.4) 22.8 (4.3) 22.3 (3.1)
Fat mass % SDS 0.88 (0.9)1 1.60 (0.8) 1.19 (0.8) 0.97 (0.8)
Lean body mass SDS -0.68 (1.3)1 0.09 (1.6) -0.72 (1.1) -0.63 (1.0)
Smoking (%) 28.6 25.0 29.4 24.1
SES (%) 1 9.1 20.9 16.4 3.4
       2 63.63 30.2 31.5 17.8
       3 27.3 48.8 52.1 78.8
LTL 3.12 (0.5) 3.30 (0.4) 3.07 (0.4) 3.20 (0.5)
Values are given as means (SD).
1= p<0.05 compared to SGA-S.
2= p<0.05 compared to SGA-CU.
3= p<0.05 compared to AGA-NS.
BMI = body mass index; LTL = Leukocyte Telomere Length (in T/S ratio); SES = socioeconomic status; SGA-
GH = birth length <-2 SDS, treated with growth hormone; SGA-S = birth length <-2 SDS, adult height <-2 
SDS; SGA-CU = birth length <-2 SDS, with spontaneous catch-up to adult height >-1 SDS; AGA-NS = birth 
length >-1 SDS, adult height >-1 SDS
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characteristics of the subgroups are shown in Table 4. There were significant differences 
in gender, age, gestational age, birth length SDS, birth weight SDS, adult height SDS, 
weight SDS, BMI, body composition and distribution of SES between the groups.
Figure 2 shows estimated mean (SE) LTL of the subgroups, adjusted for gender, age and 
gestational age. The SGA-GH subgroup had a similar LTL as the SGA-S group (p=0.11), 
the SGA-CU group (p=0.80) and the AGA-NS group (p=0.30).
diSCuSSion
We found a positive association between birth length and LTL, and a trend toward a 
positive association between birth weight and LTL. No associations were found between 
gain in weight for length during infancy and childhood and adult body size, and no 
influence of GH-induced catch-up growth on LTL.
We performed a multiple regression analysis in the total group to analyze the effects 
of size at birth, adult body size and weight gain during childhood on LTL. Birth length 
was positively associated with LTL, and there was a trend toward a positive association 
between birth weight and LTL. These associations were adjusted for possible confound-
ers, such as gender and gestational age, indicating an independent effect of size at birth 
on LTL. Since previous reports have shown that small size at birth is associated with risk 
for CVD in later life, it could be that LTL is one of the links between birth size and later life 
CVD-risk. Our results are in concordance with a recent study of de Zegher et al., showing 
that telomere lengths are shorter in SGA newborns than in AGA newborns (23). On the 
other hand, a study of Kajantie et al. found no correlation between size at birth and LTL 
(24). Future studies should aim at exploring the possible underlying mechanisms of the 
association between size at birth and LTL, such as increased oxidative stress in those 
born after intra-uterine growth restriction.
figure 2. Comparison of LtL in the subgroups. 
Values are given as estimated means ± SEM, ad-
justed for gender, age and gestational age. SGA-GH 
= birth length <-2 SDS, treated with growth hor-
mone; SGA-S = birth length <-2 SDS, adult height 
<-2 SDS; SGA-CU = birth length <-2 SDS, with spon-
taneous catch-up to adult height >-1 SDS; AGA-NS 
= birth length >-1 SDS, adult height >-1 SDS
112 Chapter 6
We found a positive association between gestational age and LTL. In a previous report 
we have shown that those born preterm have shorter LTL than those born at term (25), 
which could be due to increased oxidative stress in those born preterm. Our findings 
that female gender is positively associated with LTL, and smoking negatively, also corre-
spond to previous studies (26,27), although it is striking that smoking already influences 
LTL at such a young age.
In our study, extensive data on adult body composition were available: next to weight 
SDS and BMI, we also measured fat mass and lean body mass using DXA. We found no 
relation between fat mass percentage and LTL. This result is in contrast with previous 
studies, showing that obesity is associated with shorter LTL in both children and adults, 
probably due to the fact that obesity causes increased oxidative stress, which exacer-
bates telomere attrition (28,29). The main difference with our study is that these studies 
compared groups with a high BMI to groups with a normal BMI, while we modelled 
the effect of the continuous variables weight SDS, fat mass and lean body mass in a 
multiple regression analysis. It could be that the relation between obesity and shorter 
LTL is subtle, and therefore not present in our group of healthy young adults, with a low 
percentage of obese participants.
Gain in weight, gain in height and fat mass accumulation from birth to adulthood 
were not associated with LTL in our study. We previously showed that growth patterns 
during infancy have programming effects on health in later life (2,30). We, therefore, 
additionally analyzed whether catch-up in weight and fat mass accumulation during 
the first year of life were associated with LTL. This analysis showed no difference in LTL 
between those in the lowest and highest quartile of weight gain and fat mass accumula-
tion during the first year of life. Our results are in contrast with a recent study, that also 
measured LTL by quantitative PCR, and found an inverse association between weight 
gain in the first 12 months and LTL at the age of 70 (31). This association was only found 
in women. Based on these results, the investigators suggested that rapid growth during 
the perinatal period accelerates cellular ageing in late adulthood. The main differences 
with our study are that the effects of Δweight/Δlength as a proxy of fat mass accumula-
tion were not tested in that study and the fact that the participants were much older. 
It would, therefore, be interesting to analyze whether the association between weight 
gain during infancy and LTL becomes significant at a later age, when age-associated 
diseases also become more apparent.
To our knowledge, we are the first to evaluate whether GH treatment has an effect on 
LTL. Young adults born SGA who were treated with GH during childhood had similar LTL 
as age-matched untreated short subjects born SGA, subjects born SGA with spontane-
ous catch-up and controls born AGA with a normal stature. Thus, GH-induced catch-up 
in length does not lead to shorter LTL in young adults born SGA. It seems that a gradual 
catch-up in length, after the age of four years (when GH therapy is usually started), does 
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not lead to increased replicative stress. Since data on age-associated diseases, such as 
CVD, long after cessation of GH treatment are scarce, this result is reassuring (32). Our 
results support previous data, showing that there are no adverse effects of long-term GH 
treatment on CVD-risk and that adults who were treated with GH during childhood do 
not have increased mortality rates (33-35).
Although the multiple regression analyses resulted in significant associations between 
multiple variables and LTL, it should be noted that the R2 was small in all analyses, indi-
cating that there are other determinants of LTL, that were not included in our analyses.
Telomere lengths measured in different tissues of the same patient are highly cor-
related (36,37). Therefore, LTL not only mirrors the ageing process in circulating immune 
cells, but in other tissues as well. This way, LTL might reflect the vulnerability of our cells 
to exogenous stress factors in general. The mechanisms underlying telomere shortening 
are complex. It is known that, next to genetic factors, oxidative and replicative stress 
are main determinants of LTL. However, the generalizability of shorter telomere length 
due to replicative stress to other cells is not well studied. For future studies, it would be 
interesting to measure telomere length in other tissues as well, to see whether low birth 
weight and subsequent catch-up growth influence telomere length in other tissues that 
might be more prone to replicative stress (for example bone and muscle tissue).
One of the main strengths of the present study is the large group of young adults 
that was included, with a great variation in size at birth and childhood growth patterns. 
Because we oversampled subjects with extreme variants of normal growth, such as 
subjects born SGA with and without catch-up growth, we created greater contrast in the 
study population, which contributed to more statistical power.
In conclusion, we found that size at birth, gestational age and female gender are 
positively associated with LTL and smoking negatively, while adult fat mass and gain in 
weight and height from birth to adulthood and during infancy were not associated with 
LTL. Young SGA adults who received GH treatment during childhood have similar LTL as 
age-matched untreated short SGA, SGA with spontaneous catch-up and controls born 
AGA, indicating no adverse effects of GH treatment on LTL, which is reassuring.
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ABStRACt
Context: Short children born small for gestational age (SGA) have a bone mineral density 
(BMD) below average. Growth hormone (GH) treatment improves height and BMD in 
short SGA children. Longitudinal data on BMD in adults born SGA after cessation of GH 
treatment are lacking.
Objectives: To determine BMD in young adults born SGA during 5yrs after GH cessation.
Methods: In 173 GH-treated adults born SGA (SGA-GH), BMD of total body (BMDTB) and 
bone mineral apparent density of lumbar spine (BMADLS) were measured longitudinally 
at adult height (GH-stop), and 6 months, 2yrs and 5yrs thereafter. At 5yrs after GH-stop 
(age 21yrs), data were compared with 45 untreated short SGA adults (SGA-S), 59 SGA 
adults with spontaneous catch-up (SGA-CU), and 81 adults born appropriate for gesta-
tional age (AGA).
Results: At GH-stop (mean age 16.4yrs), estimated mean (SE) BMDTB standard deviation 
score (SDS) was -0.40 (0.1) in males and -0.51 (0.1) in females followed by a trend to-
ward a decrease of BMDTB in males to -0.59 (0.1) at 5yrs after GH-stop (p=0.06), while it 
remained stable in females (-0.57 (0.1), p=0.33). At GH-stop, BMADLS SDS was -0.01 (0.1) 
in males and -0.29 (0.1) in females, followed by a decrease in males and females to -0.38 
and -0.55 at 5yrs after GH-stop, resp. (p<0.001). At 5yrs after GH-stop, BMDTB and BMADLS 
in SGA-GH were similar compared to SGA-S, SGA-CU and AGA.
Conclusion: After cessation of GH treatment, there is a gradual decline of BMADLS, but at 
the age of 21yrs, BMDTB and BMADLS are similar as in untreated short SGA adults.
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intRoduCtion
Short stature persists in approximately 10% of children born small for gestational age 
(SGA) (1). The mechanisms underlying this lack of catch-up growth are largely unknown, 
but could be related to disturbances in the growth hormone(GH)-insulin like growth 
factor-I(IGF-I)-axis, which are present in approximately 60 percent of short SGA children 
(2).
Osteoporosis is a worldwide problem with high morbidity and increased mortality 
(3,4). Bone mineral density of the total body (BMDTB) and bone mineral apparent density 
of the lumbar spine (BMADLS) are important determinants of fracture risk and osteopo-
rosis in later life (5,6). BMDTB and BMADLS increase during childhood and peak bone mass 
is normally attained between the age of 18-20 years in girls and 18-23 years in boys (7). 
Bone strength in later life largely depends on this attained peak bone mass (8).
GH and IGF-I have a well-recognized role not only in bone elongation and skeletal 
maturation, but are also important factors in the regulation of BMD (9-11). This could 
be the reason why a low BMDTB and BMADLS have been found in children with GH de-
ficiency, idiopathic short stature, and Prader-Willi syndrome (12-14). Previous studies 
have shown that short SGA children have a lower than average BMDTB and BMADLS, even 
after correction for their short stature (15-17).
Short children born SGA can nowadays be treated with GH during childhood to 
improve adult height (AH). GH treatment also improves BMDTB and BMADLS on the short-
term. One study reported an increase of BMDTB from -0.9 standard deviation score (SDS) 
to 0.2 SDS and an increase of BMADLS from -0.6 SDS to 0.3 SDS during three years of GH 
treatment (15). A second study reported an increase of BMADLS with 0.5 SDS during six 
years of treatment (16). However, long-term studies on BMDTB and BMADLS in GH-treated 
short SGA patients are lacking, and the effects after cessation of treatment are unknown.
In this study, we longitudinally investigated BMDTB and BMADLS in young adults born 
SGA who were treated with GH during childhood, and had attained an age of 21 years, 
so that peak bone mass could be evaluated. We hypothesized that BMDTB and BMADLS 
had improved during long-term GH treatment and would not be significantly different 
from 0 SDS at attainment of AH. We also hypothesized that BMDTB and BMADLS decline 
in the first months after cessation of GH treatment due to the loss of pharmacologic 
effects of GH. We compared the data at five years after cessation of GH treatment to 
young adults born SGA with persistent short stature who were never treated with GH, 
hypothesizing that BMDTB and BMADLS of GH-treated SGA adults would return to levels 
of untreated short young adults born SGA. Additionally, we compared the data at five 
years after cessation of GH treatment to those of healthy young adults born appropriate 
for gestational age (AGA).
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methodS
Subjects
The total study group comprised 358 young adults of which 173 young adults born SGA 
had participated in a GH trial (18-20). These participants started GH when prepubertal, 
had a birth length and height below -2.5 SDS and had no growth failure caused by other 
disorders. Subjects with a GH deficiency (defined as a serum GH peak response of <20 
mU/l during a GH stimulation test) were excluded. Once daily, 1 mg/m2 biosynthetic GH 
(Norditropin; Novo Nordisk A/S, Denmark) was given subcutaneously at bedtime. Every 
three months, the GH dose was adjusted to the calculated body surface area.
At attainment of AH (i.e. when height velocity dropped below 0.5 cm in six months 
and bone age was ≥15 years for girls and ≥16.5 years for boys), GH treatment was dis-
continued. Patients were invited to participate in the current longitudinal study evaluat-
ing BMD at four time points: at AH (GH cessation), at six months, two years and five years 
after GH cessation. Additionally, data at five years after GH cessation were compared 
with three clinically relevant groups of age-matched healthy young adults (21,22): 45 
untreated young adults born SGA (birth weight and/or birth length <-2 SDS) with per-
sistent short stature (AH <-2 SDS) (SGA-short, SGA-S), 59 young adults born SGA (birth 
weight and/or birth length <-2 SDS) with catch-up growth resulting in a normal AH (>-1 
SDS) (SGA-catch-up, SGA-CU) and 81 young adults born appropriate for gestational age 
(birth length >-1 SDS) with a normal stature (AH >-1 SDS) (AGA).
This study was performed according to the Helsinki declaration. The Medical Ethics 
Committee of the Erasmus University Medical Centre approved this study. Written in-
formed consent was obtained from all participants and/or their parents.
measurements
Height was measured to the nearest 0.1 cm (Harpenden stadiometer), weight to the 
nearest 0.1 kg (Servo Balance KA-20-150S). Anthropometric measurements were per-
formed twice according to standardized methods, after which the mean was calculated. 
Information regarding oral contraceptive use was obtained using questionnaires.
In all participants, BMDTB and BMD of the lumbar spine (BMDLS), bone mineral content, 
lean body mass (LBM) and fat mass percentage (FM%) were measured by dual-energy 
x-ray absorptiometry (DXA) (Lunar Prodigy, GE Healthcare, Chalfont St. Giles, UK). BMDTB 
measurements included the head. All measurements of both the GH-treated subjects 
and the control groups were performed on one machine, and quality assurance was 
performed daily. All measurements were performed between 2003 and 2016, by the 
same personnel of the same department. The coefficients of variation were 0.64% for 
BMDTB and 1.04% for BMDLS (23).
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Serum IGF-I levels were expressed as SDS adjusted for age and gender, using reference 
values for healthy children with normal stature, determined in the same laboratory (24).
Calculations
Height and weight were expressed as SDS adjusted for age and gender according to 
Dutch reference data (25) and calculated using the Growth Analyzer software (http://
www.growthanalyser.org).
In all subjects with short stature, true BMDLS is underestimated by the areal presenta-
tion and should be corrected for bone size by calculating the bone mineral apparent 
density (BMADLS) (26). BMADLS was calculated as follows: BMADLS = BMDLS * [4/(π * width)], 
with the width as the mean width of the second to fourth lumbar vertebral body.
Because BMDTB, BMADLS, and FM% are dependent on age and gender, SDS were calcu-
lated based on age- and gender-matched reference values from the Dutch population 
(27,28). Because LBM is strongly related to height, LBM was expressed as SDS for height 
and gender (27).
Statistical analysis
Distribution of variables was determined by Shapiro-Wilk tests and normal Q-Q plots. 
Data were compared to zero using one sample t-tests. Longitudinal changes after ces-
sation of GH treatment were analyzed using repeated measurements analyses with an 
unstructured covariance type, adjusting for missing data. Multiple linear regression 
analyses were performed to determine the associations between GH treatment and 
BMDTB and BMADLS, with corrections for the possible confounders age, gender, birth 
weight, height, LBM, FM%, and, in girls, oral contraceptive use. An analysis of covariance 
(ANCOVA) was used to compare the four groups, corrected for the confounders identi-
fied in the multiple regression analyses.
Results were considered statistically significant if the p-value was <0.05. All analyses 
were performed with SPSS version 21.0.
ReSuLtS
Clinical characteristics
Table 1 shows the clinical characteristics of the 173 GH-treated SGA adults (82 males; 
91 females), at start of GH treatment and at AH, when GH treatment was discontinued 
and the follow-up study started. Mean (SD) age at start of GH treatment was 6.2 (2.0) 
years and height -3.00 (0.6) SDS. After a mean (SD) treatment duration of 10.2 (2.1) years, 
subjects attained an AH of -1.69 (0.8) SDS.
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Longitudinal changes in BmdtB and BmAdLS after Gh cessation
Figure 1 shows the longitudinal changes in BMDTB and BMADLS SDS in males and fe-
males, until five years after GH cessation. At GH cessation, estimated mean (SE) BMDTB 
SDS was -0.40 (0.1) in males, and -0.51 (0.1) in females. This was both within the normal 
range but significantly lower than 0 SDS (p<0.001). Both males and females had a sig-
nificantly higher BMDTB at cessation of GH treatment compared to at onset of treatment 
(p<0.001 and p=0.002 resp.). In the six months after GH cessation, BMDTB SDS increased 
significantly in males to -0.30 (0.1) (p=0.008), followed by a decrease from then onwards 
(p=0.004). At five years after GH cessation, estimated mean (SE) BMDTB SDS was -0.59 
(0.1) in males (p=0.06 compared to BMDTB at GH cessation and p<0.001 compared to 
0 SDS). In females, BMDTB SDS remained stable after cessation of GH-treatment: BMDTB 
SDS was -0.57 (0.1) at five years after GH cessation (p=0.33 compared to BMDTB at GH 
cessation and p<0.001 compared to 0 SDS).
At GH cessation, estimated mean (SE) BMADLS SDS was -0.01 (0.1) in males (p=0.76 
compared to 0 SDS), and -0.29 (0.1) in females (p=0.003 compared to 0 SDS). Both males 
and females had a significantly higher BMADLS at cessation of GH treatment compared 
to at onset of treatment (p=0.006 and p=0.002 resp.). In both males and females, BMADLS 
SDS did not change in the six months after GH cessation, but started to decrease in 
the 18 months thereafter in males (p<0.001), and between two and five years after GH 
cessation in females (p<0.001). At five years after GH cessation, estimated mean (SE) 
BMADLS SDS was -0.38 (0.1) in males (p<0.001 compared to BMADLS at GH cessation and 
p=0.02 compared to 0 SDS), and -0.55 (0.1) in females (p<0.001 compared to BMADLS at 
GH cessation and 0 SDS).
table 1. Clinical characteristics of the GH-treated SGA subjects at start of GH and at GH cessation
At start of Gh At Gh cessation
total males females total males females
N 173 82 91 173 82 91
Age (years) 6.2 (2.0) 6.3 (2.1) 6.1 (1.8) 16.4 (1.3) 17.2 (1.1) 15.6 (0.9)
Height SDS -3.00 (0.6) -3.08 (0.6) -2.93 (0.6) -1.69 (0.8) -1.66 (0.9) -1.72 (0.8)
Weight for height SDS -1.22 (1.2) -1.22 (1.1) -1.22 (1.4) 0.58 (0.8) 0.65 (0.6) 0.52 (1.0)
BMI SDS -1.21 (1.1) -1.17 (1.0) -1.24 (1.2) -0.04 (0.9) -0.05 (0.8) -0.04 (1.1)
BMDTB SDS -1.00 (1.0)a -1.32 (1.2) -0.73 (1.0) -0.44 (0.9) -0.43 (1.1) -0.45 (0.9)
BMADLS SDS -0.48 (0.8)a -0.33 (0.6) -0.61 (0.9) -0.14 (1.1) 0.04 (1.2) -0.30 (0.9)
BMC SDS -2.43 (0.9)a -2.92 (1.0) -2.03 (0.4) -1.23 (0.7) -1.25 (0.8) -1.21 (0.7)
IGF-I SDS -0.53 (1.1) -0.42 (1.1) -0.63 (1.3) 1.22 (0.8) 1.28 (0.8) 1.17 (0.8)
GH duration (years) NA NA NA 10.2 (2.1) 10.9 (2.2) 9.5 (1.7)
Data are expressed as mean (SD).
GH = Growth hormone; NA = Not applicable; SDS = standard deviation score
a at start of GH treatment only available of 31 participants
BMD after cessation of GH in SGA 123
In order to compare the individual BMDTB and BMADLS of the SGA-GH patients to the 
healthy population, BMDTB and BMADLS data points at GH cessation and two and five 
years thereafter were plotted against the reference curve of the healthy Dutch popula-
tion (Figure 2). At GH cessation, 5.2% of the study population (males and females) had a 
BMDTB ≤-2 SDS, which was a higher proportion than the expected 2.3% in the reference 
population (p=0.019). At five years after GH cessation, only 1.3% of the study group had 
a BMDTB ≤-2 SDS, which was similar to the expected proportion in the reference popula-
tion (p=0.48). At GH cessation, 3.5% had a BMADLS ≤-2 SDS (p=0.21 compared to 2.3%). 
Also at five years after GH cessation, the proportion of patients with a BMADLS ≤-2 SDS 
was not significantly different from the expected 2.3% (p=0.66).
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figure 1. Longitudinal changes in BmdtB and BmAdLS in in Gh-treated males and females, until 5 
years after Gh cessation
Data expressed as estimated marginal means ± SEM. * = p<0.05; ** = p<0.001
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factors influencing the change in BmdtB and BmAdLS during the 5 years after 
Gh cessation
From GH cessation until five years thereafter, there was a decrease in LBM of 0.39 SDS, 
and an increase in FM% of 0.56 SDS. We analyzed whether there was a correlation be-
tween these changes in body composition and the deterioration in BMDTB and BMADLS 
SDS during the five years after GH cessation. There was no correlation between ΔLBM 
SDS and ΔBMDTB SDS (r=0.17, p=0.24), nor between ΔFM% SDS and ΔBMDTB SDS (r=0.05, 
p=0.75).There was also no correlation between ΔLBM SDS and ΔBMADLS SDS (r=0.17, 
p=0.24), nor between ΔFM% SDS and BMADLS (r=0.18, p=0.22).
From GH cessation until five years thereafter, serum IGF-I levels decreased with 1.66 
SDS. There was no correlation between ΔIGF-I SDS and ΔBMDTB SDS (r=0.40, p=0.20). 
However, there was a trend toward a significant correlation between the decrease in 
IGF-I SDS and the decrease in BMADLS SDS (r=0.57, p=0.05).

    





  
  
  




 




    





  
  
  




 



    





  
  
  




 



    





  
  
  




 



                
figure 2. BmdtB and BmAdLS in Gh-treated males and females, plotted against the reference curve 
of the healthy dutch population
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BmdtB and BmAdLS at five years after Gh cessation, compared to SGA-S, SGA-Cu 
and AGA
Table 2 shows the clinical characteristics of the SGA-GH young adults at five years after 
GH cessation, compared to the SGA-S, SGA-CU and AGA young adults. The percentage 
of males/females was similar in the four groups. Mean age was around 21 years in all 
groups. Due to the selection criteria, there were significant differences in birth length 
SDS, birth weight SDS, height SDS, weight for age SDS and body composition. The per-
centage of smokers and of girls who used oral contraceptives was similar in all groups.
We analyzed which variables contributed to BMDTB and BMADLS in the total group 
consisting of SGA-GH, SGA-S, SGA-CU and AGA at 21 years, in a multiple regression 
analysis (Table 3). In the first model with BMDTB as dependent variable, we included the 
variables gender, age, birth weight SDS, height SDS, LBM SDS (corrected for height and 
gender) and FM% SDS (corrected for age and gender). Male gender, height SDS, LBM 
SDS and FM% SDS were all positively associated with BMDTB (p<0.001 for gender, height 
and LBM, and p=0.01 for FM%). Age and birth weight SDS were not associated with 
BMDTB. This model accounted for 38% of the variance in BMDTB. In the second model, 
we evaluated the effect of oral contraceptive use in girls, which was not a significant 
table 2. Clinical characteristics of the total study group at age 21 years
  SGA-Gh SGA-S SGA-Cu AGA
N 89 45 59 81
Male/female 38/51 15/30 22/37 30/51
Gestational age (wks) 36.3 (3.6)1 39.5 (1.5)4 38.3 (1.5)6 39.4 (1.7)
Birth length SDS -3.21 (1.7)6 -3.01 (1.1)6 -2.90 (0.8)6 0.07 (0.7)
Birth weight SDS -2.39 (1.2)3,6 -1.92 (0.9)5,6 -2.37 (0.8)6 -0.10 (1.3)
Age 21.4 (1.5)3,7 20.7 (1.7) 21.1 (1.5) 20.8 (1.7)
Height SDS -1.56 (0.9)1 -2.62 (0.6)4,6 -0.14 (0.8)7 0.24 (0.9)
BMI SDS -0.36 (1.7) 0.13 (1.1) 0.11 (1.3) -0.06 (1.0)
Lean body mass SDS -0.94 (1.3)2,7 0.04 (1.5)5,7 -0.67 (1.3) -0.54 (1.1)
Fat mass % SDS 0.85 (0.9) 0.79 (0.8) 0.90 (0.8) 0.78 (0.8)
OC-use (% of females) 89.5 78.3 80.0 71.1
IGF-I SDS -0.46 (1.0) -0.29 (0.8) -0.26 (0.7) -0.26 (0.8)
Data are expressed as mean (SD).
1 P<0.001 compared to the other groups; 2 P<0.001 compared to SGA-S; 3 P<0.05 compared to SGA-S;
4 P<0.001 compared to SGA-CU; 5 P<0.05 compared to SGA-CU; 6 P<0.001 compared to AGA; 7 P<0.05 com-
pared to AGA
SGA-GH = growth hormone treated subjects born SGA, 5 years after GH cessation; SGA-S = untreated sub-
jects born SGA with short stature; SGA-CU = subjects born SGA with spontaneous catch-up growth; AGA = 
subjects born appropriate for gestational age
Lean body mass was corrected for height and gender; fat mass percentage was corrected for age and gen-
der; OC-use = oral contraceptive use
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predictor of BMDTB (p=0.27). In Model 3, we included the subjects who were GH-treated 
during childhood as a dummy variable, showing that GH treatment was not a significant 
predictor of BMDTB at five years after GH cessation (p=0.63).
The same variables were then included in the model with BMADLS as dependent vari-
able. Male gender was negatively associated with BMADLS (p<0.001). Height SDS was 
not significantly associated with BMADLS, which was expected since BMADLS is already 
corrected for bone size. LBM SDS and FM% SDS were positively associated with BMADLS 
(p=0.04 and p=0.001 resp.). This model accounted for 18% of the variance in BMADLS. 
In the second model, we evaluated the effect of oral contraceptive use in girls. This 
model showed that oral contraceptive use did not influence BMADLS (p=0.28). Finally, 
the dummy GH treatment was included in the model, showing that this was neither a 
predictor of BMADLS (p=0.14).
Figure 3 shows the comparisons of BMDTB and BMADLS between the SGA-GH young 
adults at five years after GH cessation, and the SGA-S, SGA-CU and AGA young adults. 
Adjustments were made based on the significant predictors in the multiple regression 
analysis. BMDTB in SGA-GH, adjusted for gender, height SDS, LBM SDS and FM% SDS, was 
not different from BMDTB in SGA-S and SGA-CU (p=0.22 and p=0.76, resp.). There was a 
trend toward a lower BMDTB in SGA-GH than in AGA (p=0.09). SGA-S and SGA-CU had a 
similar BMDTB, but both lower than AGA (p=0.03). BMADLS SDS, adjusted for gender, LBM 
SDS and FM% SDS, was similar in SGA-GH and SGA-S, SGA-CU and AGA (p=0.63, p=0.72 
and p=0.26, resp.).




             




 
 








             




 







             




 
 








             




 



figure 3. BmdtB and BmAdLS at 5 years after Gh cessation, compared to SGA-S, SGA-Cu and AGA
Data expressed as estimated means (SEM). BMDTB was additionally adjusted for gender, height SDS, LBM 
SDS and FM% SDS and BMADLS for gender, LBM SDS and FM% SDS
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diSCuSSion
This study presents five-year longitudinal data on BMDTB and BMADLS after cessation 
of GH treatment in young adults born SGA. We show that cessation of GH treatment is 
accompanied with a trend toward a decline of BMDTB in males and a gradual decline of 
BMADLS in males and females. However, at five years after cessation of treatment, previ-
ously GH-treated SGA young adults had a similar BMDTB and BMADLS as young adults 
who remained untreated and as controls born AGA with a normal stature.
To our knowledge, this is the first study describing BMDTB and BMADLS after cessation 
of GH treatment in a large group of young adults born SGA. Until now, there were limited 
data available. Our research group reported on BMDTB and BMADLS in children born SGA 
during GH treatment (15,16). These studies were performed during respectively three 
and six years of treatment, and reported a BMDTB SDS of -0.9 and a BMADLS SDS of -0.6 at 
onset of treatment. Although we found that BMDTB was lower than average at cessation 
of GH treatment, both BMDTB and BMADLS were higher than the baseline BMDs reported 
in previous studies. The same studies showed that during the first years of GH treatment 
there was an increase of BMDTB and BMADLS, which was maintained at the same level up 
to six years after the start of treatment. We can now conclude that these positive effects 
are maintained until adult height attainment.
During the five years after cessation of GH treatment, there was a gradual decline of 
BMADLS, and a trend toward a decline of BMDTB in males, probably due to the loss of 
pharmacological effects of GH treatment. The correlation between the decline in IGF-I 
SDS levels and the deterioration in BMADLS in the five years after GH cessation provides 
support for this explanation. In contrast to other metabolic changes after GH cessation 
(29), the decrease in BMDTB and BMADLS did not commence directly after cessation. In 
males, there was even an increase of BMDTB in the first six months after GH cessation. It 
could be that GH treatment has relatively longer-lasting effects on bone metabolism 
than on body mass and fat mass, and that, therefore, there is not an immediate effect of 
GH cessation on BMD. Despite the deteriorations in the years after GH cessation, average 
BMDTB and BMADLS at five years after GH cessation were above -1 SDS, and only a very 
small percentage of all subjects had a BMDTB or BMADLS below -2 SDS, which is reas-
suring. Most of the skeletal mass in the total body and lumbar spine is attained in the 
first years of the third decade (28,30,31). This attained peak bone mass is an important 
determinant of osteoporosis in later life (8). The higher BMDTB and BMADLS at young adult 
age, the lower the risk of osteoporosis in later life. Thus, although BMDTB and BMADLS in 
formerly GH-treated subjects were within the normal range, it is unfortunate that the 
beneficial effects of GH treatment disappear after cessation of treatment. Future studies 
should aim at investigating how BMDTB and BMADLS progress when GH-treated subjects 
born SGA get older, and what the long-term clinical implications will be.
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Our multiple regression analysis could explain a relatively large part of the total vari-
ance in BMDTB and BMADLS. Gender, height, LBM and FM% were significant determinants 
of BMDTB, and gender, LBM and FM% of BMADLS. The combination of LBM and FM% can 
also be seen as a measure of physical fitness, which is an important determinant of 
BMDTB and BMADLS (32,33). Although GH-treated subjects had BMDTB and BMADLS below 
average at five years after GH cessation, this did not significantly influence BMDTB and 
BMADLS of the total group at the age of 21 years. We found no effect of oral contraceptive 
use in females on BMDTB and BMADLS, although the fact that there were relatively few 
females who did not use oral contraceptives makes it difficult to draw definite conclu-
sions. Another factor influencing BMDTB and BMADLS in adolescence is pubertal stage, 
but since all participants were postpubertal in our cohort, this was already accounted 
for. Although the most important determinants of BMDTB and BMADLS in a healthy young 
population were assessed in this study, there are of course other determining factors, 
such as calcium and vitamin D status. Unfortunately, there were no data on these factors 
available.
At five years after cessation of GH treatment, we additionally compared the data of 
the GH-treated subjects to age-matched clinically relevant subgroups of young adults 
born SGA with persistent short stature who were never treated with GH, young adults 
born SGA who showed spontaneous catch-up growth, and AGA born controls with a 
normal stature. After correction for the significant determinants of BMDTB and BMADLS, 
we found no differences between the GH-treated and untreated young adults born SGA 
who remained short. There was a trend toward a lower BMDTB in the GH-treated sub-
jects than in the AGA born controls. Interestingly, subjects born SGA with spontaneous 
catch-up growth had also a lower BMDTB than the AGA born subjects, suggesting that 
BMDTB in subjects born SGA is not only reduced due to short stature, but that there are 
other determining factors of BMDTB that are disturbed in subjects born SGA. BMADLS was, 
however, similar in all groups.
In conclusion, this study shows that GH treatment improves BMDTB and BMADLS in 
subjects born SGA. However, after cessation of GH, BMADLS gradually deteriorates after 
GH cessation and there is a trend toward a deterioration of BMDTB in males. At the age of 
21 years, BMDTB and BMADLS are, however, similar in GH-treated and untreated subjects 
born SGA. Although this study describes the largest and longest follow-up thus far on 
BMDTB and BMADLS measured by DXA in young adults born SGA who were treated with 
GH during their childhood, for definite conclusions a longer follow-up is required to see 
how these parameters develop as subjects progress further into adulthood.
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GeneRAL diSCuSSion
In 1991, our research group initiated the first Dutch study on growth hormone (GH) 
treatment in children born small for gestation age (SGA). Since then, several clinical 
trials have proved that GH treatment is safe and effective to improve adult height (AH) 
in these children (1-3). In the studies presented in this thesis, we focused on important 
knowledge gaps that remained in the research about short children born SGA.
In the first part of this thesis we present studies about Silver-Russell syndrome (SRS), 
which is one of the causes of short SGA. Issues that we addressed were long-term effects 
of GH treatment on growth and metabolic health (Chapter 2 and 3) and pubertal devel-
opment and gonadal function (Chapter 4). In the second part of this thesis, we explored 
a possible underlying mechanism behind the increased risk for cardiovascular diseases 
(CVD) in those born with a low birth weight. To do so, we used the ageing parameter 
telomere length, which we measured in young adults who were born preterm (Chapter 
5), and in young adults with differences in size at birth and postnatal growth patterns, 
including GH-induced catch-up growth (Chapter 6). Finally, we longitudinally assessed 
bone mineral density (BMD) and peak bone mass in young adults born SGA, during five 
years after cessation of GH treatment due to AH attainment (Chapter 7).
This chapter offers a general discussion of the results from the studies presented in 
this thesis. The clinical implications of these data are addressed, as well as future direc-
tions for the field.
SiLveR-RuSSeLL SyndRome
SRS is one of the causes of short SGA and children with SRS can be treated with GH 
under the indication short SGA. However, whether children with SRS benefit the same 
from GH treatment as non-SRS subjects born SGA had never been investigated. Since 
the majority of individuals with SRS are not routinely followed up, there was very little 
information in the literature regarding the long-term natural history of SRS. It is well 
known that children born SGA have an increased risk for metabolic health issues in 
adulthood (4-6), but this had never been investigated in SRS patients. Moreover, while 
it had been shown that GH treatment has several metabolic effects in those born SGA 
(7-10), the long-term effects of GH treatment on metabolic health in SRS were unknown. 
Another issue that had not been evaluated in SRS patients was their pubertal progres-
sion and gonadal function.
Gh treatment in Silver-Russell syndrome
In Chapter 2, we evaluated whether children with SRS benefit the same from GH treat-
ment as non-syndromic subjects born SGA, and compared growth response from start 
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of GH treatment until AH attainment among the SRS subtypes. We demonstrated that 
SRS patients are significantly shorter than non-SRS patients at start of GH treatment, but 
gain more height in the first years of treatment, resulting in a similar height SDS at onset 
of puberty in SRS and non-SRS. However, there was a steeper decline in height SDS from 
onset of puberty until AH attainment in SRS compared to non-SRS, resulting in an AH of 
-2.17 SDS in SRS, versus -1.65 SDS in non-SRS. Although SRS subjects did not attain the 
same AH, total height gain was similar in SRS and non-SRS subjects born SGA and we 
therefore conclude that GH treatment is similarly effective in SRS and non-SRS subjects 
born SGA. Studies examining the long-term effects of GH treatment on growth in SRS 
patients are sparse, with only two studies describing AH after GH therapy (11, 12). In 
both studies, total height gain was similar as in our cohort.
The finding that SRS subjects did not attain the same AH as non-SRS subjects born 
SGA could be due to the fact that patients were shorter at start of GH treatment and the 
fact that puberty started earlier in SRS patients, leading to earlier closure of the growth 
plates. This implies that SRS patients have a shorter time window in which height gain 
can be achieved. Expanding this window might be beneficial for SRS patients. This was 
also suggested by Binder et al., since their study group found that duration of GH treat-
ment was strongly positively correlated with both AH and overall height gain (11). We 
therefore suggest that GH treatment should be started at a young age in SRS patients, 
and SRS patients who start puberty at a young age could be additionally treated with a 
gonadotropin-releasing hormone analogue (GnRHa) to postpone puberty.
We additionally compared growth data from onset of GH treatment until AH attain-
ment among the different SRS subtypes and found a trend toward a better response to 
GH treatment in SRS patients with mUPD7 and clinical SRS, compared to patients with 
11p15 LOM. A previous study on genotype-phenotype correlations in SRS concluded 
that patients with 11p15 LOM show the more ‘classic’ SRS phenotype (13). Based on our 
results, we conclude that this is also the case for their growth and response to GH treat-
ment. Since those with 11p15 LOM still gained almost 1 SDS in height during treatment, 
we do consider GH treatment beneficial for SRS patients with 11p15 LOM. 
Due to the rarity of SRS, it remains difficult to conduct studies on the differences 
among the SRS subtypes with sufficient statistical power. Expertise centres that provide 
optimal care for SRS patients and initiating international collaborations with other study 
groups, could aid in obtaining larger cohorts of SRS patients.
metabolic health in Silver-Russell syndrome
In addition to positive effects on linear growth, GH treatment has also several metabolic 
effects in children born SGA, namely an increase in lean body mass, a decline in fat mass, 
a decrease in blood pressure, and a more favourable lipid profile, but also a lower insulin 
sensitivity (Si) (7, 8, 10). After cessation of GH treatment, some of these effects are lost, 
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due to the loss of pharmacologic effects of GH (9). The long-term safety of GH treatment 
and metabolic effects after cessation of treatment after AH attainment had never been 
investigated in SRS patients. Up until now, there were only case reports of adults with 
SRS, in which an adverse metabolic health profile was described (14, 15). In Chapter 
3, we therefore assessed longitudinal changes in metabolic health (i.e. blood pressure, 
fasting lipid levels, body composition, Si and occurrence of diabetes mellitus type 2 
(DM2) and metabolic syndrome) in 29 SRS patients, from start of treatment until two 
years after cessation of GH due to AH attainment. We compared these data to those of 
171 GH-treated non-SRS subjects born SGA.
We found that SRS and non-SRS patients have a similar metabolic health profile at start 
of treatment and that, apart from minor variations, SRS and non-SRS patients respond 
similarly to GH treatment regarding their metabolic health profile. In the months after 
cessation of GH, we found several changes related to the loss of pharmacologic effects 
of GH in SRS patients, such as a decrease in lean body mass and an increase in fat mass 
percentage, but this was similar as in non-SRS patients. Si and ß-cell function improved 
after cessation of GH. Most importantly, at two years after cessation of GH, at a mean age 
of approximately 18 years, there were no significant differences between the groups, 
and none of the SRS patients had developed DM2 or metabolic syndrome.
In general practice, the majority of the SRS patients are not routinely followed up after 
AH attainment, which is the reason why there is very little information on the long-term 
history of SRS. There are only two case reports addressing metabolic health in SRS (14, 
15). The first described three SRS patients (all with 11p15 LOM, two having received GH 
treatment for several years during childhood) who developed adult diseases such as 
obesity, hypertension, and DM2 in their early twenties. The second described the oldest 
SRS patient reported so far, who has DM2, osteopenia, and hypercholesterolemia at the 
age of 69 years. These studies did, however, not compare the data of SRS patients to those 
of non-SRS subjects born SGA. Our study is the first study describing metabolic health 
data in a cohort of GH-treated SRS patients that was followed from childhood into early 
adulthood. We used gold standard tests such as dual-energy x-ray absorptiometry (DXA) 
to measure body composition, and frequently sampled intravenous glucose tolerance 
test with Tolbutamide to assess Si and ß-cell function, which makes our data unique.
Although our results are reassuring, larger cohorts are needed to be able to draw 
definite conclusions. Due to the rarity of the syndrome, this remains a challenging issue. 
Moreover, patients in our study were young adults, and although we used appropriate 
tests with which we were able to establish the subtlest changes in metabolic health, 
it could be that they develop metabolic health related issues at an older age. Thus, a 
longer follow-up of SRS patients is needed to establish whether the fact that there are 
no metabolic differences between SRS and non-SRS subjects born SGA before, during 
and after GH treatment will be maintained over the years when patients progress further 
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into their adulthood. It is therefore important that SRS patients are not lost to follow-up 
once they reach AH and GH treatment is discontinued.
Pubertal development and gonadal function in Silver-Russell syndrome
There was very little information in the literature regarding pubertal development and 
possible reproductive issues in SRS patients. It is known that boys with SRS have an 
increased risk for genital abnormalities such as cryptorchidism and hypospadias (13, 16, 
17). In girls with SRS, an association has been described with Mayer-Rokitansky-Kuster-
Hauser syndrome, a disorder characterized by hypoplasia of the uterus and upper part 
of the vagina (18, 19). In Chapter 4, we longitudinally assessed pubertal development 
and gonadal function in 31 SRS patients. We compared these data to those of a control 
group of 123 GH-treated subjects born SGA without SRS and healthy references.
We found that age at onset of puberty was similar in SRS and non-SRS subjects born 
SGA. Puberty progressed similarly in SRS and non-SRS, and all SRS patients attained an 
adult Tanner stage. Thus, our study shows that there is neither concern for a precocious 
nor for a delayed puberty in SRS patients.
In the consensus statement it was stated that onset of puberty in SRS is usually within 
the normal range, although mostly in the younger age of the spectrum (20), which has 
disadvantages for eventual AH. We found that SRS patients have the same benefit from 
two years of additional GnRHa treatment as the non-SRS patients when they are still 
short at onset of puberty, improving their growth from onset of puberty until AH (21). 
We, therefore, suggest considering two years of GnRHa treatment in addition to GH 
treatment in SRS patients with an expected AH below -2.5 SDS at onset of puberty.
We longitudinally assessed gonadal function in the SRS patients. Since all females 
with SRS had LH, FSH and AMH levels within the reference range, the follicle pool and 
gonadal function do not seem to be impaired in SRS females, although there was one 
female with clinical SRS with a normal pubertal progression but primary amenorrhea 
due to Müllerian agenesis. Previous case-reports have shown an association between 
SRS and Mayer-Rokitansky-Küster-Hauser syndrome (18, 19), but the etiology of this 
association and whether it is more common in certain SRS subtypes remains to be elu-
cidated. We found that more than a quarter of the SRS males had a postpubertal inhibin 
B level below the 5th percentile for healthy references, and two males also had an FSH 
level above the 95th percentile. These results imply that Sertoli cell dysfunction is more 
common in SRS patients. This might at least be partly caused by the increased risk for 
cryptorchidism in SRS males. Larger cohorts with a longer follow-up period are needed 
to confirm these findings and to study the etiology of possible reproductive issues in 
SRS males. Evaluating Sertoli cell function at an early age might lead to earlier identifica-
tion of a dysfunction and better opportunities for successful conception in later life. 
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We therefore recommend assessing gonadal function in SRS males, also in those with 
normal pubertal progression.
methodological considerations in studies regarding SRS
In the studies presented in this thesis, we adhered to strict guidelines to diagnose SRS 
and performed extensive genetic testing to confirm the molecular diagnosis. Neverthe-
less, approximately 40% of the SRS patients remain without a molecular diagnosis, and 
there is no adequate way to establish whether these patients are not falsely diagnosed 
with SRS while another syndrome underlies their symptoms. Testing for mUPD7 has 
been possible for a long time, but this aberration is only present in 5-10% of all SRS 
patients. More recently, it was discovered that over half of the SRS patients have an 
aberration in the 11p15 region (22, 23). All studies on SRS that were conducted before 
2005 thus describe cohorts of SRS patients that are only based on a clinical diagnosis or 
mUPD7. Due to the highly variable phenotype of SRS, and the fact that symptoms tend 
to become less severe with age, it can be very difficult to diagnose SRS based on clinical 
findings. The recently developed Netchine-Harbison clinical scoring system is a practi-
cal scoring system for clinicians, since four of the six criteria are objective (23). It has a 
sensitivity of 98% and negative predictive value of 89%, which gives a high degree of 
confidence that patients who have less than four of the six clinical criteria for diagnosis 
are truly unaffected by SRS. On the other hand, the specificity of this scoring system 
is low, which could result in false positive results when the diagnosis is only based on 
clinical findings. Lately, a lot of research has focused on unravelling the mechanism(s) 
underlying clinical SRS. Although new mechanisms have been discovered, such as the 
CDKN1C and IGF2 mutation (24-26), these mutations do not seem to explain a large part 
of the SRS patients (27, 28). Thus, future studies are needed to elucidate the underlying 
mechanisms of clinical SRS. Not only would this be an important step for the patients 
who now remain without an established diagnosis, but it will also help in attaining SRS 
cohorts that are not biased by other syndromes, which might improve the results of 
future studies and their applicability for clinical practice.
Conclusions and clinical implications regarding Silver-Russell syndrome
From our studies, we conclude that GH treatment is safe and effective in patients with 
SRS. This is true for each SRS subtype, although those with 11p15 LOM might attain 
a lower AH. Starting GH treatment at a young age and postponing puberty by means 
of two years of GnRHa treatment might enlarge the window in which height gain can 
be achieved. Future research should aim at elucidating this. Until the age of 18 years, 
there is no difference in metabolic health between those with SRS and those born SGA 
without SRS. Although this is reassuring, a longer follow-up is needed to see whether 
this is maintained over the years as subjects reach their thirties and forties. Since Sertoli 
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cell dysfunction is more common in SRS, we recommend assessing gonadal function in 
SRS patients, particularly in males. Finally, we emphasize the need for expertise centres 
that provide the most experienced care for SRS patients and will in the future be able to 
obtain larger cohorts of SRS patients.
teLomeRe LenGth in younG AduLtS BoRn PReteRm And/oR SGA
Low birth weight, whether due to preterm birth or SGA, followed by accelerated weight 
gain during infancy is associated with an increased risk for adult diseases such as CVD 
and DM2 in later life (4, 5, 29). The mechanisms underlying these associations are largely 
unknown, but it appears that growth trajectories in early life have programming effects 
on later health outcomes. Rapid weight gain during infancy is also associated with an 
advanced bone age and early menarche in girls (30, 31), suggesting that a faster early 
growth trajectory represents a more rapid development, and might also predict earlier 
cellular ageing (32).
Telomere length is a marker of biological age and a shorter telomere length is associ-
ated with increased CVD risk (33-35). Telomere length can be measured in leukocytes 
(i.e. leukocyte telomere length (LTL)) using a quantitative PCR assay (36). Next to biologi-
cal age, attrition of LTL is influenced by genetic factors and exogenous stressors (37, 38).
In Chapter 5 and 6, we postulated that accelerated biological ageing might be one 
of the underlying mechanisms behind the increased risk for CVD in those born with a 
low birth weight due to premature or SGA birth. We used LTL as a marker of biological 
age to test this hypothesis. Since both preterm birth and poor fetal growth can lead to 
small size at birth, we studied these effects separately. Moreover, we assessed LTL in 
young adults with different infant growth trajectories, to assess whether rapid weight 
gain influences LTL. Finally, we measured LTL in a group of GH-treated young adults born 
SGA to investigate whether GH-induced catch-up growth influences LTL.
telomere length in young adults born preterm
In Chapter 5, we assessed LTL in 470 young adults, of which 186 were born preterm. 
We found a positive association between gestational age and LTL. Young adults born 
preterm had shorter LTL than young adults born at term. This difference remained sig-
nificant after correction for size at birth, indicating an independent effect of gestational 
age on LTL.
Previous studies have highlighted oxidative stress as an important determinant of 
LTL (37, 38) and have shown that intrauterine stress causes shorter LTL (39-41). Since 
pregnancies resulting in preterm birth are often accompanied by increased stress ex-
posure (42) and preterm infants are more frequently exposed to stressful events, we 
think it is plausible that oxidative stress is one of the explanations for the difference in 
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LTL between young adults born preterm and those born at term. A future study that 
longitudinally measures LTL and oxidative stress biomarkers in early postnatal life and 
late adulthood, would be a good way to evaluate if increased perinatal oxidative stress 
is indeed the mechanism behind shorter LTL in those born preterm.
We found no correlations between LTL and putative risk factors for CVD in these 
young adults. Future studies should aim to explore whether LTL may contribute to CVD 
and other adult onset diseases at a later age in those born preterm.
effects of size at birth, childhood growth patterns and Gh treatment on 
telomere length
In Chapter 6, we assessed LTL in 470 participants with different sizes at birth and infant 
growth trajectories. Additionally, we measured LTL in 75 young adults born SGA who 
were treated with GH during childhood. We found a positive association between birth 
length and LTL, and a trend toward a positive association between birth weight and LTL, 
indicating shorter LTL in young adults who were born with a low birth weight and/or 
length. These associations were found after adjustments for possible confounders, such 
as gender and gestational age, indicating an independent effect of size at birth on LTL. 
Our results imply that LTL could play a role in the association between small size at birth 
and later life CVD risk. The underlying mechanism for this association could be increased 
oxidative stress, similarly as in those born preterm. Future studies should aim at further 
exploring these mechanisms.
We found no association between weight gain during early infancy and LTL. Our results 
are in contrast to those of a previous study, that found an inverse association between 
weight gain in the first 12 months and LTL at the age of 70 (32). That association was, 
however, only found in women. The main difference with our study is the fact that the 
participants in that study were much older. For future studies, it would be interesting to 
analyze whether the association between weight gain during infancy and LTL becomes 
significant at a later age, when age-associated diseases become more apparent.
Our study was the first study to evaluate whether GH treatment is associated with LTL. 
Young adults born SGA who were treated with GH during childhood had similar LTL as 
age-matched untreated short subjects born SGA, subjects born SGA with spontaneous 
catch-up and controls born appropriate for gestational age (AGA) with a normal stature. 
We thus concluded that GH-induced catch-up in length does not lead to shorter LTL in 
young adults born SGA.
Conclusions and clinical implications regarding LtL in subjects born preterm 
and/or SGA
Our findings indicate that preterm birth and small size at birth have adverse effects on 
telomere length in later life, at least in early adulthood. Since telomere length is a marker 
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of biological age, we conclude that young adults born preterm and/or with a low birth 
weight, have an older biological age compared to young adults born at term with a 
normal birth weight. The fact that this association was already present at a young adult 
age, when manifestations of age-associated diseases are not present yet, is particularly 
intriguing. We postulate that pregnancies leading to preterm or SGA birth are associ-
ated with increased oxidative stress, which causes faster attrition of telomere length. 
However, before statements on clinical implications can be made, more (longitudinal) 
research is required. Since the prevalence and survival rate of preterm birth and low 
birth weight for gestational age are increasing (43, 44), our results are relevant for an 
increasing number of subjects.
Bone mineRAL denSity in younG AduLtS BoRn SGA AfteR Gh CeSSAtion
Short SGA children have a lower than average BMD, even after correction for their short 
stature (10, 45). A lower BMD and subsequent lower peak bone mass are risk factors for 
osteoporosis and bone fractures in later life (46, 47). BMD can be assessed by measuring 
BMD of the total body (BMDTB), and of the lumbar spine by means of DXA. Since BMD 
of the lumbar spine in short individuals is underestimated by the areal presentation, 
it should be corrected for bone size by calculating the bone mineral apparent density 
(BMADLS). Previous studies in short SGA patients have shown that GH treatment improves 
BMDTB and BMADLS on the short-term (10, 45), but long-term studies were lacking. More-
over, the effects of cessation of GH treatment after AH attainment on BMDTB and BMADLS 
were unknown. In Chapter 7, we investigated BMDTB and BMADLS longitudinally during 
five years after GH cessation in young adults born SGA who were treated with GH during 
childhood until AH, and who had attained an age of 21 years. In addition, we compared 
BMDTB and BMADLS at five years after cessation of GH treatment to young adults born 
SGA with persistent short stature who were never treated with GH, and to AGA born 
controls with a normal stature.
We demonstrate that both BMDTB and BMADLS at AH are higher than the baseline BMDs 
reported in previous studies (10, 45). We can thus conclude that the positive effects of 
GH treatment are maintained until AH attainment. In the five years after GH cessation, we 
observed a trend toward a decline of BMDTB in males, and a gradual decline of BMADLS in 
males and females, probably due to the loss of pharmacological effects of GH treatment. 
The higher BMDTB and BMADLS at young adult age, the lower the risk of osteoporosis in 
later life. Thus, although BMDTB and BMADLS in formerly GH-treated subjects were within 
the normal range, it is unfortunate that the beneficial effects of GH treatment are partly 
lost after cessation of treatment.
Despite the deteriorations in the years after GH cessation, average BMDTB and BMADLS 
at five years after GH cessation were above -1 SDS, and only a very small percentage of 
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all subjects had a BMDTB or BMADLS below -2 SDS. Moreover, at five years after cessation 
of treatment, previously GH-treated young SGA adults had a similar BMDTB and BMADLS 
as young SGA adults who remained untreated and as controls born AGA with a normal 
stature, which is reassuring.
Conclusions and clinical implications regarding Bmd in young adults born SGA
We demonstrated that GH treatment improves BMDTB and BMADLS in subjects born 
SGA. After cessation of GH, BMADLS gradually deteriorates and there is a trend toward 
a deterioration of BMDTB in males. However, BMDTB and BMADLS at five years after GH 
cessation were above -1 SDS, and only a very small percentage of all subjects had a 
BMDTB or BMADLS below -2 SDS. At the age of 21 years, BMDTB and BMADLS are similar in 
GH-treated and untreated subjects born SGA. Future studies should aim at investigating 
how BMDTB and BMADLS progress when formerly GH-treated adults born SGA get older, 
and what the long-term clinical implications will be.
GeneRAL ConCLuSionS
SRS is one of the causes of short SGA and children with SRS can be treated with GH un-
der the indication short SGA. However, whether SRS patients benefit the same from GH 
treatment as non-SRS patients born SGA was unknown. Moreover, metabolic health in 
SRS patients had never been evaluated before, and there were no data on the long-term 
natural history of SRS regarding pubertal development and gonadal function. These 
issues are addressed in this thesis. From our studies we conclude that GH treatment is 
safe and effective in patients with SRS. This is true for each SRS subtype, although those 
with 11p15 LOM might attain a lower AH. Furthermore, we conclude that at least until 
the age of 18 years, there is no difference in metabolic health between SRS patients and 
non-SRS patients born SGA. Finally, we conclude that puberty progresses similarly in SRS 
and non-SRS patients born SGA, but that Sertoli cell dysfunction is more common in SRS 
males. In females with SRS, gonadal function does not seem to be impaired, but there 
seems to be an increased risk of Müllerian agenesis.
In the second part of this thesis, we measured the ageing biomarker LTL in young 
adults who were born preterm and in young adults with differences in size at birth 
and postnatal growth patterns, including GH-induced catch-up growth. Our findings 
indicate that preterm birth and small size at birth have adverse effects on telomere 
length in early adulthood. GH-induced catch-up in length does not lead to shorter LTL in 
young adults born SGA. To draw definite conclusions on the clinical implications of these 
results, more longitudinal research is needed.
Finally, we longitudinally assessed BMDTB and BMADLS in young adults born SGA, dur-
ing five years after GH cessation due to AH attainment. We found that BMDTB and BMADLS 
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improve during GH treatment, but that there is a gradual deterioration of BMADLS and a 
trend toward a deterioration of BMDTB after cessation of GH in males. At five years after 
GH cessation, at the age of 21 years, BMDTB and BMADLS are similar in GH-treated and 
untreated subjects born SGA.
CLiniCAL imPLiCAtionS of thiS theSiS
– SRS patients benefit from GH treatment and should start GH therapy at a young age, 
to enlarge the window during which height gain can be achieved.
– SRS patients with an expected AH below -2.5 SDS at onset of puberty benefit from 
the addition of two years of GnRHa treatment to postpone puberty.
– Although metabolic health is similar in SRS and non-SRS SGA at the age of 18 years, 
it is important that SRS patients are not lost to follow-up once they have attained AH 
and GH treatment is discontinued, so that the long-term natural history of SRS can 
be monitored.
– It is recommended to assess gonadal function in SRS patients once they attain an 
adult pubertal stage. This is particularly the case for SRS males, since Sertoli cell 
dysfunction is common. Although gonadal function does not seem to be impaired 
in females with SRS, it is important to be aware of the increased risk for Müllerian 
agenesis, so that a timely diagnosis can be made.
– There is a need for expertise centres which combine research with optimal care for 
SRS patients.
– Subjects born preterm and/or SGA have shorter telomere length, but more longitu-
dinal research is required before statements on clinical implications can be made.
diReCtionS foR futuRe ReSeARCh
– Elucidating the underlying (epi)genetic mechanisms of clinical SRS is important to 
improve the care for clinical SRS patients that now remain with an unknown genetic 
diagnosis.
– It is important to participate in international collaborations with other study groups, 
to obtain larger cohorts of SRS patients.
– Setting up studies with a long follow-up to assess metabolic health in adults with 
SRS, beyond the age of 18 years, will help in learning more about the long-term 
natural history of SRS.
– Longitudinally measuring oxidative stress biomarkers in early postnatal life, child-
hood and late adulthood, will help to elucidate whether increased perinatal oxida-
tive stress is one of the mechanisms underlying the association between small size 
at birth, shorter LTL and adult onset diseases.
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– Since previous studies found an association between rapid weight gain during 
infancy and CVD risk later in life, it is important to analyze whether there is an asso-
ciation between accelerated weight gain during infancy, shorter LTL and adult onset 
diseases.
– Since we found a deterioration of BMADLS after cessation of GH treatment in subjects 
born SGA, it is important to investigate how BMDTB and BMADLS progress on the very 
long-term after cessation of GH treatment in subjects born SGA.
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SummARy
Chapter 1
In Chapter 1 we provide an overview of the definition, prevalence and causes of small 
for gestational age (SGA) birth. We describe the etiology and clinical aspects of Silver-
Russell syndrome (SRS) and give an update about the effects of growth hormone (GH) 
treatment in children with and without SRS who were born SGA. We also provide an 
introduction on parameters addressed in this thesis, namely gonadal function, leuko-
cyte telomere length and bone mineral density (BMD). Finally, we present the aims and 
outline of this thesis.
Chapter 2
In Chapter 2, we compared response to GH treatment between 62 SRS patients and 227 
short, non-syndromic subjects born SGA (non-SRS). We show that SRS patients respond 
well to GH treatment and that total height gain is similar in SRS and non-SRS subjects 
born SGA. There was a trend toward a better response to GH treatment in SRS patients 
with mUPD7 and idiopathic SRS compared to patients with 11p15 LOM, but GH treat-
ment proved also beneficial for those with 11p15 LOM. Since no adverse events occurred 
over a long treatment period, there is no safety concern about GH in SRS patients.
Chapter 3
In Chapter 3, we compared long-term data on metabolic health and safety of GH treat-
ment between SRS and non-SRS patients. We found that SRS and non-SRS patients have 
a very similar metabolic health profile at start of treatment, and that, apart from minor 
variations, the metabolic health profile of SRS and non-SRS patients responds similarly 
to GH treatment. Two years after cessation of GH treatment, at the age of 18 years, there 
was no difference in risk for metabolic syndrome between SRS and non-SRS, and none 
of the patients had developed diabetes mellitus type 2.
Chapter 4
In Chapter 4, we assessed onset and progression of puberty and gonadal function in 32 
SRS patients. We compared these data to a control group of subjects born SGA without 
SRS, and to age-appropriate reference data of healthy Dutch adolescents. We found that 
SRS patients have a similar age at onset of puberty and a similar pubertal progression 
as non-SRS subjects born SGA. Although gonadal function was on average similar in 
SRS and non-SRS subjects born SGA, disturbances in Sertoli cell function were more 
common in SRS males. Gonadal function does not seem to be impaired in SRS females 
with a normal pubertal progression.
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Chapter 5
In Chapter 5, we analyzed the association between gestational age and leukocyte 
telomere length (LTL) in 470 young adults born preterm and at term. We found that 
gestational age is positively associated with LTL and that young adults born preterm 
have shorter LTL than age-matched subjects born at term. This difference remained 
significant after correction for birth length and birth weight, indicating an independent 
positive effect of gestational age on LTL, not confounded by birth size. These results 
could reflect pre- and postnatal oxidative stress and could partly explain the associa-
tion between preterm birth and risk for cardiovascular disease (CVD) in later life. At this 
young age, we found no relation between LTL and other putative risk factors for CVD.
Chapter 6
In Chapter 6, we investigated whether size at birth, childhood growth patterns and adult 
body size influence LTL. We also analyzed the effect of GH treatment on LTL by com-
paring LTL between previously GH-treated young adults born SGA with age-matched 
untreated short subjects born SGA, SGA born subjects with spontaneous catch-up to a 
normal height and controls born appropriate for gestational age (AGA) with a normal 
stature. We found that size at birth, gestational age and female gender were positively 
associated with LTL and smoking negatively, while adult fat mass and gain in weight 
and height during infancy and from birth to adulthood were not associated with LTL. 
Since the subjects who received GH treatment during childhood had similar LTL as age-
matched untreated short SGA subjects, subjects born SGA with spontaneous catch-up 
and controls born AGA, we concluded that there are no adverse effects of GH treatment 
on LTL.
Chapter 7
In Chapter 7, we present longitudinal data on BMD of the total body (BMDTB) and bone 
mineral apparent density of the lumbar spine (BMADLS) in young adults born SGA, during 
the five years after cessation of GH treatment due to adult height attainment. We found 
that GH treatment improves BMDTB and BMADLS in subjects born SGA. After cessation of 
GH, BMADLS gradually deteriorates and there is a trend toward a deterioration of BMDTB 
in males, although BMD remained within the normal range and almost all participants 
had a BMD above -2 SDS. At the age of 21 years, BMDTB and BMADLS were similar in 
GH-treated and untreated subjects born SGA.
Chapter 8
In the General Discussion, we discuss the most important findings of our studies in a 
broader context. We emphasize the clinical implications and give directions for future 
research.
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SAmenvAttinG
hoofdstuk 1
In hoofdstuk 1 beschrijven we de definitie, prevalentie, en oorzaken van een kleine 
lengte en/of laag geboortegewicht voor de zwangerschapsduur (small for gestational 
age (SGA)). Ook bespreken we de etiologie en de klinische aspecten van Silver-Russell 
syndroom (SRS), evenals de effecten van groeihormoon (GH) behandeling bij SGA ge-
boren kinderen met en zonder SRS. We geven een introductie over parameters die we 
beschrijven in dit proefschrift, zoals telomeerlengte (leukocyte telomere length (LTL)) en 
botdichtheid. Ten slotte bespreken we de doelstellingen van de studies.
hoofdstuk 2
In Hoofdstuk 2 onderzochten we de effecten van GH behandeling op de groei bij 62 
patiënten met SRS. We vergeleken deze data met die van 227 kleine, niet-syndromale 
kinderen die SGA geboren waren (non-SRS). We laten zien dat SRS patiënten goed rea-
geren op GH en dat de totale lengtewinst vergelijkbaar is tussen SRS en non-SRS. Er was 
een trend naar een betere respons bij SRS patiënten met mUPD7 of idiopathische SRS in 
vergelijking met patiënten met 11p15 LOM, maar GH behandeling heeft ook gunstige 
effecten bij de patiënten met 11p15 LOM. Aangezien er geen bijwerkingen werden 
gevonden gedurende een lange behandelduur, zijn er geen zorgen over de veiligheid 
van GH behandeling bij SRS patiënten.
hoofdstuk 3
In Hoofdstuk 3 laten we lange-termijn data zien betreffende het gezondheidsprofiel en 
de veiligheid van GH behandeling bij SRS patiënten in vergelijking met non-SRS. We 
laten zien dat SRS en non-SRS patiënten een zeer vergelijkbaar gezondheidsprofiel 
hebben bij start van de behandeling. Los van kleine verschillen reageerden SRS en 
non-SRS patiënten vergelijkbaar op GH behandeling. Op de leeftijd van 18 jaar was er 
geen verschil in risico op metabool syndroom tussen SRS en non-SRS, en waren er geen 
patiënten met diabetes type 2.
hoofdstuk 4
In Hoofdstuk 4 onderzochten we het verloop van de puberteit en gonadale functie 
bij SRS patiënten. We vergeleken deze data met een groep van SGA geboren jongvol-
wassenen en met een groep gezonde jongvolwassenen. SRS patiënten hadden een 
vergelijkbare leeftijd bij start van de puberteit, en een vergelijkbare progressie van 
puberteitsstadia als non-SRS patiënten. Hoewel de gonadale functie over het algemeen 
vergelijkbaar was tussen SRS en non-SRS, kwam dysfunctie van de Sertoli cellen meer 
voor bij mannen met SRS. Bij vrouwen met SRS lijkt de gonadale functie niet verstoord.
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hoofdstuk 5
In Hoofdstuk 5 analyseerden we de associatie tussen zwangerschapsduur en LTL bij 
470 jongvolwassenen. We vonden dat zwangerschapsduur positief geassocieerd is 
met LTL en dat prematuur geboren jongvolwassenen kortere telomeren hebben dan 
a term geboren jongvolwassenen. Dit verschil bleef significant na correctie voor ge-
boortelengte en geboortegewicht, wat indiceert dat er een onafhankelijk effect is van 
zwangerschapsduur op LTL. Dit zou het gevolg kunnen zijn van perinatale oxidatieve 
stress en zou één van de verklaringen kunnen zijn van de associatie tussen prematuriteit 
en het risico op hart- en vaatziekten op latere leeftijd. We vonden op deze jonge leeftijd 
geen relatie tussen LTL en determinanten van hart- en vaatziekten.
hoofdstuk 6
In Hoofdstuk 6 onderzochten we de invloed van geboortelengte en –gewicht, groei in 
het eerste levensjaar, en volwassen lichaamssamenstelling op LTL. Ook onderzochten 
we het effect van GH behandeling op LTL bij SGA geborenen. Geboortegewicht en –
lengte, zwangerschapsduur en vrouwelijk geslacht waren positief geassocieerd met LTL, 
en roken negatief. Toename in gewicht en lengte gedurende het eerste levensjaar en 
van geboorte tot aan de jongvolwassen leeftijd waren niet geassocieerd met LTL. GH 
behandelde SGA geboren jongvolwassenen hadden een vergelijkbare LTL als onbehan-
delde SGA geboren jongvolwassenen, SGA geboren jongvolwassenen met spontane 
inhaalgroei en controles met een normaal geboortegewicht en –lengte.
hoofdstuk 7
In Hoofdstuk 7 presenteren we longitudinale data over botdichtheid van het totale 
lichaam en de lumbale wervelkolom tot vijf jaar na het staken GH behandeling bij SGA 
geboren jongvolwassenen. We lieten zien dat GH behandeling de botdichtheid verbe-
tert. Na het staken van GH neemt de botdichtheid van de lumbale wervelkolom af en er 
is een trend naar een afname van de botdichtheid van het totale lichaam bij mannen, 
hoewel deze binnen de normale range blijft en vrijwel alle deelnemers een botdicht-
heid boven de -2 SDS hadden. Op de leeftijd van 21 jaar hadden GH behandelde en 
onbehandelde SGA geboren jongvolwassenen een vergelijkbare botdichtheid.
hoofdstuk 8
In dit hoofdstuk bespreken we de belangrijkste resultaten van onze studies in een bre-
dere context, evenals de klinische implicaties en suggesties voor toekomstig onderzoek.
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LiSt of ABBReviAtionS
11p15 LOM loss of methylation in the 11p15 region
AGA appropriate for gestational age
AH adult height
AIR acute insulin response
AIRg acute insulin response to glucose
AMH anti-Müllerian hormone
ANCOVA analysis of covariance
ATP-III adult treatment panel III
BL birth length
BMAD bone mineral apparent density
BMADLS bone mineral apparent density of the lumbar spine
BMD bone mineral density
BMDTB bone mineral density of the total body
BMI body mass index
BP blood pressure
BW birth weight
CI confidence interval
CVD cardiovascular disease
DBP diastolic blood pressure
DI disposition index
DM2 diabetes mellitus type 2
DXA dual energy X-ray absorptiometry
FM fat mass
FM% fat mass percentage
FSH follicle stimulating hormone
FSIGT-test frequently sampled intravenous glucose tolerance test
GA gestational age
GFR glomerular filtration rate
GH growth hormone
GnRH gonadotropin-releasing hormone
GnRHa gonadotropin-releasing hormone analogue
HDLc high-density lipoprotein cholesterol
hsCRP high sensitivity C-reactive protein
ICR imprinting control region
IGF-I insulin-like growth factor-I
IGFBP-3 insulin-like growth factor binding protein-3
IUGR intrauterine growth retardation
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IQR interquartile range
LBM lean body mass
LDLc low-density lipoprotein cholesterol
LH luteinizing hormone
LTL leukocyte telomere length
M2 breast development stage II according to Tanner
MR multiple regression
MRKH Mayer-Rokitansky-Küster-Hauser syndrome
MS-MLPA methylation-specific multiplex ligation-mediated probe amplification
mUPD7 maternal uniparental disomy of chromosome 7
OC oral contraceptive
PCR polymerase chain reaction
SBP systolic blood pressure
SCFE slipped capital femoral epiphysis
SD standard deviation
SDS standard deviation score
SES socio-economic status
Sg glucose effectiveness
SGA small for gestational age
SGA-CU born small for gestational age with spontaneous catch-up growth
SGA-GH previously GH-treated subjects born small for gestational age
SGA-S born small for gestational age with short adult stature
Si insulin sensitivity
SRS Silver-Russell syndrome
T/S ratio telomere to single-gene copy ratio
TC total cholesterol
Tg triglyceride
TH target height
TV testicular volume
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For over 25 years, our research group and others have been investigating children 
born small for gestational age (SGA) with 
persistent short stature, and the efficacy 
and safety of biosynthetic growth hormone 
treatment (GH) in these children.
One of the causes of short SGA is Silver-
Russell syndrome (SRS). This doctoral 
thesis presents the response to, and safety 
of GH treatment, and describes pubertal 
progression and metabolic health in 
patients with SRS.
Because being born with a lower birth 
weight leads to an increased risk for age-
associated diseases, health in later life has 
been a concern in patients born SGA. In 
the second part of this thesis, we present 
data on parameters associated with health 
in later life, such as telomere length and 
bone mineral density, and the effects of GH 
treatment on these parameters.
